UC Pathogenesis: Interconnected Oxidative Stress, Dysregulated Immune Responses, Epithelial Barrier Dysfunction, and Gut Microbiota Dysbiosis
UC 发病机制的系统综述与"氧化应激—免疫失调—屏障损伤—菌群失衡"多因素整合框架
均为综述/框架性论文,从整体视角梳理 UC 免疫异常、上皮屏障缺陷、菌群失调与细胞因子/分子网络之间的交互关系,并整合现有分子靶向与精准医学思路,为后续各机制专题与干预专题提供统一的理论背景与概念框架。
- Unraveling the complexity of ulcerative colitis: insights into cytokine dysregulation and targeted therapies(Yuta Shimomori, Y. Yokoyama, Hiroki Kurumi, Kotaro Akita, Tomoe Kazama, Yuki Hayashi, K. Mizukami, H. Nakase, 2025, EXCLI Journal : Experimental and Clinical Sciences)
- Intestinal Barrier Dysfunction in Ulcerative Colitis: Mechanisms and Therapeutic Perspectives(Jing-Duan Yang, Hai-Fa Qiao, 2026, Medicine Insights)
- Immune dysregulation in ulcerative colitis: pathogenic mechanisms and therapeutic strategies of traditional Chinese medicine(Xu-Dong Tang, Yilin Huang, Ying Zhu, Yin Xu, 2025, Frontiers in Cell and Developmental Biology)
- Gut microbiota and intestinal immunity interaction in ulcerative colitis and its application in treatment(Fan Bu, Kai-Yuan Chen, Si-Che Chen, Yi Jiang, 2025, Frontiers in Cellular and Infection Microbiology)
- Gut microbiota, microbial metabolites, and mucosal barrier dysfunction in benign anorectal disorders and ulcerative colitis: shared mechanisms, clinical links, and precision interventions(He-Xue Yuan, Mao-Fang Zhao, Yun-Fen Wang, Chen-Jie Shen, De-Long Liu, Chun-Xiao Wang, Jian Liu, 2026, Frontiers in Medicine)
- Targeting Molecular Dysregulation in Ulcerative Colitis: A Paired Cellular Perspective on CD4+, CD8+, and IL-6 Immunohistochemistry(R. Mirică, A. Coman, M. State, C. Popp, 2025, International Journal of Molecular Sciences)
氧化应激机制:ROS 过量生成、内源性抗氧化防御失衡与 NLRP3 炎症小体的上游激活
共同聚焦 ROS 产生与清除失衡这一上游环节:DUOX2/DUOXA2 来源的 ROS、ORMDL3 调控线粒体动力学激活 NLRP3、MMP9 对 ROS/DNA 损伤的调节、非编码 RNA 与 ROS 相关性综述,以及萝卜硫素、依鲁替尼通过降低氧化应激抑制炎症通路的证据,共同刻画"氧化应激驱动炎症小体活化"的分子链条。
- Recent updates on correlation between reactive oxygen species and synbiotics for effective management of ulcerative colitis(S. Ashique, N. Mishra, A. Garg, Belay Zeleke Sibuh, P. Taneja, G. Rai, S. Djearamane, Ling-Shing Wong, Noura Al-Dayan, Shatabhisha Roychoudhury, K. Kesari, P. Sláma, S. Roychoudhury, Piyush Kumar Gupta, 2023, Frontiers in Nutrition)
- Matrix metalloproteinase 9 (MMP9) limits reactive oxygen species (ROS) accumulation and DNA damage in colitis-associated cancer(Lewins Walter, Brandon S. B. Canup, A. Pujada, Tien Anh Bui, Behafarin Arbasi, H. Laroui, D. Merlin, P. Garg, 2020, Cell Death and Disease)
- Ibrutinib attenuated DSS-induced ulcerative colitis, oxidative stress, and the inflammatory cascade by modulating the PI3K/Akt and JNK/NF-κB pathways(Liang-Liang Hao, Lina Alkry, Abdullah Alattar, M. Faheem, Reem Alshaman, F. Shah, Shu-Peng Li, 2022, Archives of Medical Science : AMS)
- Advances in Studies on NLRP3 Inflammasome in Inflammatory Bowel Disease(Zuo Xiul, 2011, No journal)
- DUOX2 and DUOXA2 Form the Predominant Enzyme System Capable of Producing the Reactive Oxygen Species H2O2 in Active Ulcerative Colitis and are Modulated by 5-Aminosalicylic Acid(Tammie S. MacFie, R. Poulsom, Alexandra Parker, G. Warnes, T. Boitsova, A. Nijhuis, N. Suraweera, Angela Poehlmann, J. Szary, R. Feakins, Rosemary Jeffery, Richart W. Harper, A. Jubb, J. Lindsay, A. Silver, 2014, Inflammatory Bowel Diseases)
- ORMDL3 regulates NLRP3 inflammasome activation by maintaining ER-mitochondria contacts in human macrophages and dictates ulcerative colitis patient outcome(Jyotsna Sharma, Shaziya Khan, N. C. Singh, S. Sahu, Desh Raj, Shakti Prakash, Pamela Bandyopadhyay, Kabita Sarkar, V. Bhosale, Tulika Chandra, J. Kumaravelu, M. Barthwal, S. Gupta, M. Srivastava, R. Guha, Veena Ammanathan, U. Ghoshal, Kalyan Mitra, Amit Lahiri, 2024, Journal of Biological Chemistry)
- Sulforaphane decreases oxidative stress and inhibits NLRP3 inflammasome activation in a mouse model of ulcerative colitis.(Zi-juan Zhou, Jian-Yi Dong, Yang Qiu, Guo-Lin Zhang, Kun Wei, Liheng He, Yi-ning Sun, Hao Jiang, Shuang-shuang Zhang, Xinrui Guo, Jingying Wang, Da-Peng Chen, 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie)
NLRP3 炎症小体组装、IL-1β 成熟与细胞焦亡的免疫机制及靶向评价
围绕天然免疫核心轴展开:ASC–NLRP3 互作与 caspase-1/GSDMD 焦亡、NLRP3 依赖与非依赖的 IL-1β 加工、HSF2/Nrf2 对炎症小体的负向调控、DLG2 表达下调导致炎症小体失控,并纳入 NLRP3 双重作用(保护性一面)的争议与小分子/杂合药物(美沙拉嗪-NSAID 杂合物)的炎症小体靶向评价。
- Metrnl ameliorates ulcerative colitis by inhibiting NLRP3 inflammasome activation via ASC(Rui-Long Kou, Yueming Xia, Wenqin Wei, Yu Chen, Jin-Zhou Wang, Zhi-Wei Qin, Guang-Wei Zhu, Liang-Sheng Lin, Dingming Zheng, Jian-Xin Ye, Bin Lan, 2026, Scientific Reports)
- NLRP3-Dependent and -Independent Processing of Interleukin (IL)-1β in Active Ulcerative Colitis(N. Ranson, M. Veldhuis, B. Mitchell, Scott B. Fanning, A. Cook, Dale A. Kunde, R. Eri, 2018, International Journal of Molecular Sciences)
- Heat shock transcription factor 2 reduces the secretion of IL-1β by inhibiting NLRP3 inflammasome activation in ulcerative colitis.(Feng-Rui Zhang, Wei Zhao, Jiaoli Zhou, Wen Wang, Juan Luo, Yuran Feng, Jing Wu, Mao-Juan Li, Kun-Hua Wang, Jun-Kun Niu, Ying-Lei Miao, 2020, Gene)
- Trans-10-hydroxy-2-decenoic acid alleviates dextran sulfate sodium-induced colitis in mice via regulating the inflammasome-mediated pyroptotic pathway and enhancing colonic barrier function.(Shan-Shan Huang, Ran-Ran Tao, Jie-Fei Zhou, Lin-Xi Qian, Jiang Wu, 2022, Molecular Nutrition & Food Research)
- Design and biological evaluation of mesalamine–NSAID hybrids targeting the NLRP3 inflammasome: a multi-target strategy for ulcerative colitis therapy(M. Yahya, J. Safaei-Ghomi, A. Haghir Ebrahimabadi, Hanieh Jalali, Hossein Mojtabazadeh, 2025, Scientific Reports)
- Sulforaphane Attenuates Ulcerative Colitis by Activating Nrf2 and Suppressing the NLRP3/IL-1β Inflammasome Axis.(H. Dong, Ling Wang, Xiao-Rui Ding, 2026, Current molecular medicine)
- NLRP3 inflammasome has a protective effect against oxazolone-induced colitis: a possible role in ulcerative colitis(Shigehiro Itani, T. Watanabe, Y. Nadatani, Naoki Sugimura, S. Shimada, Shogo Takeda, K. Otani, S. Hosomi, Y. Nagami, F. Tanaka, N. Kamata, Hirokazu Yamagami, T. Tanigawa, M. Shiba, K. Tominaga, Y. Fujiwara, T. Arakawa, 2016, Scientific Reports)
- Inflammation suppresses DLG2 expression decreasing inflammasome formation(S. Keane, M. Herring, P. Rolny, Y. Wettergren, K. Ejeskär, 2022, Journal of Cancer Research and Clinical Oncology)
- NLRP3 Inhibitors as Potential Therapeutic Agents for Treatment of Inflammatory Bowel Disease.(Agampodi Promoda Perera, Dale A. Kunde, R. Eri, 2017, Current pharmaceutical design)
程序性细胞死亡(焦亡、铁死亡、PANoptosis、凋亡)与肠上皮完整性丧失
聚焦肠上皮细胞多种死亡方式对屏障的破坏:程序性死亡与上皮屏障的系统综述、天然产物调控焦亡的综述、PANoptosis 相关基因的免疫浸润分析、精胺经 NCOA4–铁蛋白轴抑制铁死亡,以及具核梭杆菌经铁死亡破坏肠屏障的微生物—死亡通路交叉机制。
- Dysregulated programmed cell death of intestinal epithelial cells in ulcerative colitis: Molecular mechanisms and novel therapeutic interventions (Review)(Bi-Hua Wu, Shuang-Yan Su, Yu-Wei Li, Le Guo, 2025, International Journal of Molecular Medicine)
- Regulation of pyroptosis by natural products in ulcerative colitis: mechanisms and therapeutic potential(Xiao-Bei Lu, Yapeng Sun, Zhao-Yi Zhang, Zhigang Sun, Shao-Hui Wang, Er-Ping Xu, 2025, Frontiers in Pharmacology)
- PANoptosis‐related genes: Molecular insights into immune dysregulation in ulcerative colitis(Yu-Xiao Ji, Peng-Chong Li, Ting-Ting Ning, Deyi Yang, Hai-Yun Shi, Xueyu Dong, Shengtao Zhu, Peng Li, Shu-Tian Zhang, 2024, Journal of Gastroenterology and Hepatology)
- Ferroptosis Inhibition by Spermidine via the NCOA4/Ferritin Axis and Polyamine-Microbiota Dysbiosis in Ulcerative Colitis.(Mengjie Zhang, Ziyue Dou, Langlang Yang, Hongqian Wang, Beibei Tian, Shao-Cheng Hong, Qi Yang, Jian Lu, Xi Chen, 2025, Journal of Nutritional Biochemistry)
- Periodontitis-associated Fusobacterium nucleatum promotes ulcerative colitis by ferroptosis-mediated gut barrier disruption(Xiao-Yu Zhang, Shou-Zheng Cheng, Shu-Ze Chen, Qiu-Hao Wang, Jeiyu Zhou, Hui Wang, Lei Cheng, Lei Zhao, 2025, npj Biofilms and Microbiomes)
- Machine learning-based characterization of PANoptosis-related biomarkers and immune infiltration in ulcerative colitis: A comprehensive bioinformatics analysis and experimental validation.(Changshan Wan, Qiuyan Wu, Ya-Li Wang, Y. Sun, Tao Ji, Yu Gu, Liwei Wang, Qiu-Yu Chen, Zhen Yang, Yao-W. Wang, Bang-Mao Wang, Wei-Long Zhong, 2025, International Immunopharmacology)
肠上皮屏障缺陷的结构与分子病理生理:紧密连接/黏附连接、离子转运与"渗漏型"屏障
不针对单一化合物疗效,而研究屏障本身的病理机制:非线性多模态成像直接可视化 UC 患者上皮裂隙与顶端连接复合体改变、结肠离子转运缺陷与连接蛋白分布异常导致"渗漏"、mTOR/PBLD/AMOT 轴调控 TJ 修复、NUDT1 经氧化应激—Nrf2/ERK 加重屏障损伤,以及 STEAP4 等分子对屏障功能的调控。
- Intestinal epithelial barrier integrity investigated by label-free techniques in ulcerative colitis patients(Elsie Quansah, E. Gardey, A. Ramoji, Tobias Meyer-Zedler, Bianca Goehrig, A. Heutelbeck, S. Hoeppener, Michael Schmitt, M. Waldner, A. Stallmach, J. Popp, 2023, Scientific Reports)
- Ion transport and epithelial barrier dysfunction in experimental models of ulcerative colitis(G. Sandle, Vazhaikkurichi M. Rajendran, 2025, American Journal of Physiology - Gastrointestinal and Liver Physiology)
- Rapamycin promotes the intestinal barrier repair in ulcerative colitis via the mTOR/PBLD/AMOT signaling pathway.(Yan Xu, Jinyuan Ou, Chu-Hong Zhang, Jia-Yu Chen, Junsheng Chen, Ai-Min Li, Bing Huang, Xin-Mei Zhao, 2024, Biochimica et Biophysica Acta - Molecular Basis of Disease)
- NUDT1 aggravates intestinal epithelial barrier injury through oxidative stress in ulcerative colitis.(Gui-Yuan Jin, Xi-Zhuang Gao, Feng-Xian Dai, Hai-Rong Zhang, Ting-Ting Lu, De-huai Jing, Yong-Hong Yang, Feng-Qin Zhu, Guang-Xi Zhou, 2025, International Immunopharmacology)
- STEAP4 Modulates Intestinal Barrier Dysfunction and Inflammatory Signaling Pathways in Ulcerative Colitis.(Shimeng Xu, Peixiang Chen, Xiang Shi, Min Li, Zhao-Xiu Liu, Cuihua Lu, Yu Sheng, 2026, Shock)
- Restoration of dysregulated intestinal barrier and in�ammatory regulation through synergistically ameliorating hypoxia and scavenging reactive oxygen species using ceria nanozymes in ulcerative colitis(No journal)
免疫失调的细胞与分子机制:NK 细胞抑制性受体、巨噬细胞极化、血小板活化与 DNA 感应—Ⅰ型干扰素通路
集中于免疫细胞与固有免疫信号层面的失调机制:NKG2A 上调导致 CD4+T 细胞清除障碍、极化的巨噬细胞来源微囊泡差异调控肠上皮、DNA 感应器驱动的Ⅰ型干扰素反应,以及活化血小板增强炎症细胞互作,共同解释 UC 免疫稳态失衡的细胞学基础。
- P0163 NKG2A upregulation on natural killer cells contributes to immune dysregulation in Ulcerative Colitis(Y. Zhang, H. Guo, 2026, Journal of Crohn's & Colitis)
- Polarized macrophage-derived microvesicles differentially modulate intestinal barrier dysfunction and endoplasmic reticulum stress in ulcerative colitis(Chao-Yue Liang, Qasim Khan, Yan-Ling Wei, Sha Wang, Han Wei, Yu-Yang Jia, Yan-Qiu Xu, Cui-Hua Qi, 2026, Biology Direct)
- DNA sensor associated type I Interferon signalling is increased in ulcerative colitis and induces JAK-dependent inflammatory cell death in colonic organoids.(P. Flood, A. Fanning, Jerzy A. Woznicki, Tadhg Crowley, A. Christopher, Alessandra Vaccaro, A. Houston, S. McSweeney, Sarah A. Ross, A. Hogan, E. Brint, Agnieszka Skowyra, Milán Bustamante, Monica Ambrose, G. Moloney, John Macsharry, M. Hammarström, Margot Hurley, Christine Fitzgibbons, E. Quigley, F. Shanahan, S. Zulquernain, J. McCarthy, G. S. Dodson, K. Dabbagh, B. Mcrae, S. Melgar, K. Nally, 2022, American Journal of Physiology - Gastrointestinal and Liver Physiology)
- Activated Platelets in Ulcerative Colitis Enhance the Production of Reactive Oxygen Species by Polymorphonuclear Leukocytes(Kenta Suzuki, K. Sugimura, K. Hasegawa, K. Yoshida, A. Suzuki, K. Ishizuka, K. Ohtsuka, T. Honma, R. Narisawa, H. Asakura, 2001, Scandinavian Journal of Gastroenterology)
肠道菌群失调的病理作用与临床证据:多样性下降、致病菌富集、病毒组、SCFA 与口腔—肠轴
以微生态失衡的"病理证据"为主线:菌群与 UC 关系综述、回肠末端与波兰人群菌群谱、具核梭杆菌等致病共生菌的促炎机制、肠道病毒组(Orthohepadnavirus/HBx)关联、PPI 诱发菌群紊乱、丁酸等 SCFA 水平下降,以及牙周炎经口腔—肠轴加重菌群失调,论证菌群失调与 UC 的因果关联。
- Unraveling the microbial mysteries: gut microbiota’s role in ulcerative colitis(Ke-Yu Ren, Chunming Yong, Yanchun Jin, Shanwei Rong, Kui-Jin Xue, Bin Cao, Hong-Yun Wei, 2025, Frontiers in Nutrition)
- Bacterial Dysbiosis Observed in the Terminal Ileum of Ulcerative Colitis(J. Mar, A. Nguyen, A. Scherl, M. Wittke, M. Doona, C. Lamb, M. Keir, 2025, Inflammatory Bowel Diseases)
- P1220 Dysbiosis of the gut microbiota and decreased fecal levels of short-chain fatty acid in patients with Ulcerative Colitis: a hospital-based case-control study(R. Yamamura, T. Katsurada, 2024, Journal of Crohn's & Colitis)
- Gut microbiota dysbiosis in the pathogenesis of ulcerative colitis and the therapeutic efficacy of fecal microbiota transplantation: a meta-analysis(Chao Zhu, Meng-Yuan Wang, Ling-Fei Meng, Zi-Xuan Zhao, Hai-Tao Han, Ying-Yun Chang, Shuang-Xi Zhang, Yun Yang, 2026, BMC Gastroenterology)
- Dysbiosis of gut microbiota in Polish patients with ulcerative colitis: a pilot study(Oliwia Zakerska-Banaszak, H. Tomczak, M. Gabryel, A. Baturo, L. Wolko, M. Michalak, Natalia Malińska, D. Mańkowska-Wierzbicka, P. Eder, A. Dobrowolska, R. Słomski, M. Skrzypczak-Zielińska, 2021, Scientific Reports)
- Fusobacterium nucleatum aggravates ulcerative colitis through promoting gut microbiota dysbiosis and dysmetabolism.(Shulan Lin, Xiaoyue Zhang, Xuan-Zhi Zhu, Junwei Jiao, YafeiWu Li, Yan Li, Lei Zhao, 2022, The Journal of Periodontology)
- Gut virome-colonising Orthohepadnavirus genus is associated with ulcerative colitis pathogenesis and induces intestinal inflammation in vivo(L. Massimino, O. Palmieri, A. Facoetti, D. Fuggetta, S. Spanò, L. Lamparelli, S. D'Alessio, S. Cagliani, F. Furfaro, F. D'Amico, A. Zilli, G. Fiorino, T. Parigi, D. Noviello, A. Latiano, F. Bossa, T. Latiano, A. Pirola, L. Mologni, R. Piazza, D. Abbati, F. Perri, C. Bonini, L. Peyrin-biroulet, A. Malesci, V. Jairath, S. Danese, F. Ungaro, 2023, Gut)
- Proton pump inhibitors and gut microbiota dysbiosis: insights into the pathogenesis of ulcerative colitis(Feng Cao, Zhen-Xing Liu, Shuo Liu, Yan-Wei Liu, Y. Qi, Yunsheng Cheng, Yong Wang, Yan-Yan Xu, 2025, Frontiers in Microbiology)
- Effects of Short Chain Fatty Acid-Butyrate Supplementation on the Disease Severity, Inflammation, and Psychological Factors in Patients With Active Ulcerative Colitis: A Double-Blind Randomized Controlled Trial(D. Firoozi, S. Masoumi, Seyed Mohammad-Kazem Hosseini Asl, M. Fararouei, S. Jamshidi, 2025, Journal of Nutrition and Metabolism)
- Oral-gut axis in inflammation: periodontitis exacerbates ulcerative colitis via microbial dysbiosis and barrier disruption(Jin-Ping Yu, J. Lyu, Tongxin Zhu, Yang Li, Hanping Xia, Qing Liu, Li-Li Li, Bin Chen, 2025, BMC Oral Health)
天然产物/中药单体靶向紧密连接与黏附连接蛋白(TJ/AJ)的屏障修复干预
均以 TJ/AJ 蛋白表达与分布(ZO-1、occludin、claudin、E-cadherin)及跨上皮电阻为主要终点:经 MLCK/NF-κB、RhoA/ROCK/MLC 细胞骨架重塑、SLC26A3、TGR5-PERK-eIF2α 等通路恢复连接复合体,还包括穴位埋线等非药物疗法对 TJ 的调节,形成"连接蛋白修复"这一独立干预板块。
- Sophocarpine Alleviates Inflammation-induced Colonic Epithelial Barrier Dysfunction in Ulcerative Colitis(Yanmin Zhang, Tianzhi Liu, Zhi-Gang Zuo, 2025, Pharmacognosy Magazine)
- Oxymatrine ameliorates ulcerative colitis via improving epithelial barrier function through targeting DSG2.(Pengyan Li, Xin Jin, Yi Li, Yunjiao Shen, Jiangpeng Wu, N. Kang, Xin-Chi Feng, F. Qiu, 2025, Phytomedicine)
- Anemoside B4 alleviates ulcerative colitis by attenuating intestinal oxidative stress and NLRP3 inflammasome via activating aryl hydrocarbon receptor through remodeling the gut microbiome and metabolites(Hao Wu, Yao-lei Li, Yu Wang, Yu-Ge Wang, Jia-hui Hong, Mi-mi Pang, Pan-Miao Liu, Jian-Jun Yang, 2025, Redox Biology)
- [Effect of acupoint thread-embedding on tight junction of intestinal mucosa epithelium in rats with ulcerative colitis].(Huan Wang, Ying Zhu, 2021, Zhongguo zhen jiu = Chinese acupuncture & moxibustion)
- Dragon’s blood attenuates LPS-induced intestinal epithelial barrier dysfunction via upregulation of FAK-DOCK180-Rac1-WAVE2-Arp3 and downregulation of TLR4/NF-κB signaling pathways(Huayan Liu, Ranran Yan, Yong-Zhi Li, Jia-Ping Wang, YuLin Deng, Yu-Juan Li, 2024, Journal of Natural Medicines)
- Phillygenin ameliorates tight junction proteins reduction, fibrosis, and apoptosis in mice with chronic colitis via TGR5-mediated PERK-eIF2α-Ca2+ pathway(Huanhuan Xue, Peijie Li, Jing Guo, Ting-Gui Chen, Shi-Fei Li, Liwei Zhang, 2024, Journal of Pharmaceutical Analysis)
- Atractylenolide-1 Alleviates Ulcerative Colitis via Restraining RhoA/ROCK/MLC Pathway-Mediated Intestinal Barrier Dysfunction.(Zengxiang Gao, Xuecheng Yu, Wen-Long Su, Peng Huang, Zhen-Hui Li, Yunya Lin, Lin-Lin Chen, Yan Cao, Yan-Ju Liu, Jianbei Chen, De-Sen Yang, Guo-Sheng Cao, 2025, Journal of Agricultural and Food Chemistry)
- p-hydroxy benzaldehyde attenuates intestinal epithelial barrier dysfunction caused by colitis via activating the HNF-1β/SLC26A3 pathway(Meng Liu, Yu-Hui Wang, Xiao-Tian Xu, Guoqiang Guan, Shu Zhang, Sheng-Nan Zhu, Yang Liu, Yi-Zhun Zhu, Xiao-Qun Duan, 2024, Frontiers in Pharmacology)
- Palmatine ameliorates intestinal epithelial barrier injury in ulcerative colitis via targeting enolase 3.(Yong Zhang, Zi-Xuan Lai, Xiao-Xia Hu, Ming-Hui Wu, Shanshan Chen, Lin-Jie Su, Shaoxia Xie, Mihong Ren, Bowen Yang, Juan Wang, Weimu Huang, Ziren Su, Zhuoming Li, Youliang Xie, 2025, International Immunopharmacology)
- Formononetin ameliorates dextran sulfate sodium-induced colitis via enhancing antioxidant capacity, promoting tight junction protein expression and reshaping M1/M2 macrophage polarization balance.(Qiu-Ping Xiao, Jiaqi Huang, Xiyan Zhu, Min Shi, Li-Ling Chen, Lai Chen, Xuan Liu, Rong-Hua Liu, Youbao Zhong, 2024, International Immunopharmacology)
促进黏膜愈合的机制与干预:杯状细胞/黏蛋白、AhR 通路、黏膜微循环与 PI3K-AKT 信号
区别于单纯连接蛋白修复,本组以"黏膜愈合"为共同终点:鸭胆子苦醇经 IL-22/STAT3 恢复杯状细胞与黏蛋白、黄连碱激活 AhR/CYP1A1、獐牙菜苷改善黏膜微循环、黄芪甲苷抑制 PI3K/AKT 修复屏障、青蒿琥酯促进上皮修复、白术提取物与龙血竭改善上皮损伤,并含黏膜屏障修复的系统综述。
- Repairing the intestinal mucosal barrier of traditional Chinese medicine for ulcerative colitis: a review(Yi-Chen Zong, Jie Meng, Tang-You Mao, Q. Han, Peng Zhang, Lei Shi, 2023, Frontiers in Pharmacology)
- Brusatol ameliorates intestinal mucosal injury in ulcerative colitis via activating IL-22/STAT3 pathway.(Ying Xu, Li Chen, Xiao-Xia Hu, Zi-Xuan Lai, Baoyi Chen, Ming-Hui Wu, Li-Ting Mai, Zi-Ren Su, Jian-Nan Chen, Zheng-Quan Lai, Weipeng Ai, Jian-Hui Xie, Huijun Liao, Youliang Xie, 2025, International Immunopharmacology)
- Coptisine activates aryl hydrocarbon receptor to regulate colonic epithelial homeostasis in DSS induced ulcerative colitis and TNF-α challenged intestinal organoids.(Bingyan Tan, Jing-Yan Zhang, An Kang, Li Zhang, Dan Fang, Hong Wu, Tai Han, Rong-Li Qiu, Hui Li, Dongdong Sun, 2025, Phytomedicine)
- Sweroside ameliorates intestinal mucosal microcirculatory disturbances in ulcerative colitis mice by modulating the VEGF and Hippo signaling pathways.(Dantong Li, Jian Chen, Jiaqi An, Ying Gu, Zhikuo Dong, Xing-Xing Gao, Xiaoying Zhang, Yi-Xin Zhang, 2025, International Immunopharmacology)
- Blockade of PI3K/AKT signaling pathway by Astragaloside IV attenuates ulcerative colitis via improving the intestinal epithelial barrier(Xinhui Zhang, Fan Zhang, Yan Li, N. Fan, Ke-Xue Zhao, A. Zhang, Jie-Fang Kang, Yan Lin, Xiao-Chang Xue, Xun Jiang, 2024, Journal of Translational Medicine)
- Artesunate promotes intestinal epithelial barrier repair by facilitating HMGCS2-dependent ketogenesis in experimental ulcerative colitis model mice.(Guan Wang, Li-Zhuang Han, Hai-Mei Sun, Ting-Yi Sun, Bo Wu, Xu Cheng, Shu Yang, De-Shan Zhou, 2025, International Immunopharmacology)
- Ethanolic Extract of Atractylodis Rhizoma Ameliorates DSS-Induced Ulcerative Colitis via Improving Intestinal Barrier Function Through the Rho-Associated Kinase/Myosin Light Chain Pathway(Zengxiang Gao, Peng Huang, Xuecheng Yu, Ruo-Tong Dong, Yunya Lin, Ji-Yuan Tu, Lin-Lin Chen, Yan Cao, Yan-Ju Liu, De-Sen Yang, Guo-Sheng Cao, 2025, Journal of Medicinal Food)
免疫调节型干预:巨噬细胞极化重编程、miRNA 调控与免疫细胞功能纠正
共同点为"以免疫细胞为直接靶点"的干预研究:青蒿琥酯纠正巨噬细胞极化、灵芝提取物与 SGLT2 抑制剂改善免疫浸润、小分子 miR-124 诱导剂与真菌β-葡聚糖—miR-32-5p—Dectin-1 轴调控巨噬细胞表型,属于免疫机制导向而非单纯抗炎或屏障修复的治疗策略。
- Artesunate alleviated murine ulcerative colitis by regulating immune response through inhibiting endoplasmic reticulum stress(S. Yin, Liu-Hui Li, Xiaolan Chen, Jing Wang, Yu-Juan Mao, Jing-Xuan Wang, Xiao-Yan Xie, Jin-Gui Li, Hai-Feng Yang, 2025, Frontiers in Immunology)
- Protective effects of Amauroderma rugosum on dextran sulfate sodium-induced ulcerative colitis through the regulation of macrophage polarization and suppression of oxidative stress.(Jing-Jing Li, Xi Luo, Polly Ho-Ting Shiu, Yan-Fen Cheng, Xin Nie, P. Rangsinth, B. W. Lau, Cheng-Wen Zheng, Xuebo Li, Ren-Kai Li, Simon Ming‐Yuen Lee, Chao-Mei Fu, S. Seto, Jin-Ming Zhang, G. Leung, 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie)
- Ertugliflozin ameliorates experimentally-induced colitis in rats by regulating the interplay between M1/M2 macrophage polarization, tight junction proteins, and MicroRNA 155 expression.(Marina R Fouad, M. Rabie, H. F. Zaki, Rania M. Salama, 2025, International Immunopharmacology)
- Novel Small-Molecule miR-124 Inducer Acts as "a Physiological Brake" of Inflammation in Ulcerative Colitis by Targeting the PIK3R2/PI3K/Akt Axis.(Tian-Tian Wang, Yan Xu, Song Li, Ruo-Bing Du, Jing Shi, Chunhuan Jiang, Rong Wang, Yongqiang Zhu, 2025, Journal of Medicinal Chemistry)
- Fungal β-glucan instructed miR-32-5p modulates Dectin-1 signaling mediated inflammation, reactive oxygen species and apoptosis through polarization of “M2a-like” macrophage in Candida colitis(Liu Yang, Chengcheng Liu, Han-Yu Zhu, Zixu Wang, Qinai Luo, Yu-Zhe Huang, Hao Wang, Min Hu, Jing Shao, 2025, Virulence)
多酚、黄酮、香豆素类天然产物的抗氧化—抗炎多靶点干预
该组化合物药理重心在清除 ROS、提升 SOD/GSH/GPx 等抗氧化指标并抑制 NF-κB、MAPK、JAK2/STAT3 促炎通路:姜黄、苹果多酚、黄芩素(线虫与小鼠模型两篇)、芍药苷、委陵菜黄酮、芦丁、菊花亚微米颗粒、没食子酸之外的多酚/香豆素类成分,机制描述集中于氧化—炎症环节而非特定屏障或菌群靶点。
- Dietary Turmeric Consumption Alleviates Ulcerative Colitis via Restoring Tryptophan Metabolism and Alleviating Gut Microbiota Dysbiosis in Mice.(Chengcheng Yang, Yao Du, Aiqing Zhao, Lei Liu, Dao-Yuan Ren, Peng-Fei Niu, Xiang-Nan Zhang, Yu Wang, Yan Zhao, Xing-Bin Yang, 2022, Journal of Agricultural and Food Chemistry)
- Biochanin A mitigates colitis by inhibiting ferroptosis-mediated intestinal barrier dysfunction, oxidative stress, and inflammation via the JAK2/STAT3 signaling pathway.(Beiying Deng, Kunpeng Wang, Hao-Dong He, Miao Xu, Jiao Li, Pengzhan He, Yinghui Liu, Jingjing Ma, Ji-Xiang Zhang, Wei-Guo Dong, 2025, Phytomedicine)
- Psoralen alleviates ulcerative colitis by suppressing inflammation, modulating oxidative stress, and regulating ferroptosis.(Liu Cao, Xiaoqing Tang, Xi-Min Wang, Yiting Wang, Wei-Bo Dai, 2025, European Journal of Pharmacology)
- 7-hydroxycoumarin ameliorates ulcerative colitis in mice by inhibiting the MAPK pathway and alleviating gut microbiota dysbiosis(Mengqi Liu, Hua-Ru Sun, Hao Fu, Ling-Ping Fu, Xiao Zheng, Yu Chen, 2024, BMC Gastroenterology)
- Apple polyphenols extract alleviated dextran sulfate sodium‐induced ulcerative colitis in C57BL/6 male mice by restoring bile acid metabolism disorder and gut microbiota dysbiosis(Fang Liu, Xinjing Wang, De-Ming Li, Yuan Cui, Xin-Li Li, 2020, Phytotherapy Research)
- An Apple a Day Keeps the Doctor Away: The Effect of a Low-Fat, High-Fiber Diet on Quality of Life, Inflammation, and Dysbiosis in Patients with Ulcerative Colitis.(S. Gold, S. Cohen-Mekelburg, 2021, Gastroenterology)
- Baicalein from Scutellaria baicalensis mitigates oxidative stress through the IIS pathway in a C. elegans model of ulcerative colitis(Wei Wang, Xiao-Yu Fu, Jia-Ning Xu, Weiguang Lv, Sheng-Nan Han, Yi Wang, Yu Xia, Jing Han, Ke Li, Cheng-Gang Zhang, 2025, Frontiers in Pharmacology)
- Baicalein ameliorates ulcerative colitis by improving intestinal epithelial barrier via AhR/IL-22 pathway in ILC3s(Yan-yang Li, Xiao-jing Wang, Yulin Su, Qing Wang, Shao-Wei Huang, Zeng-Feng Pan, Yan-ping Chen, Jun-Jie Liang, Mei-Ling Zhang, Xue-Qian Xie, Zhi-Yun Wu, Jin-Yan Chen, Lian Zhou, Xia Luo, 2021, Acta Pharmacologica Sinica)
- Paeoniflorin alleviates DSS-induced ulcerative colitis by suppressing inflammation, oxidative stress, and apoptosis via regulating serum metabolites and inhibiting CDC42/JNK signaling pathway.(Qi-Chao Hu, Jin Xie, Tao Jiang, Pan Gao, Yuan Chen, Wen-Wen Zhang, Jin Yan, Jin-Hao Zeng, Xiao Ma, Yan-Ling Zhao, 2024, International Immunopharmacology)
- Potentilla anserina L. flavonoids ameliorate ulcerative colitis by modulating oxidative stress, intestinal microbiota dysbiosis, and inflammatory responses(Ya-Xin Guo, Ao Shen, Kexin Han, Rong-Rong Wang, Qian Wang, Jian-Teng Wei, Shuxian Wang, Ming Liu, 2025, 3 Biotech)
- Rutin Ameliorates Inflammation and Oxidative Stress in Ulcerative Colitis by Inhibiting NLRP3 Inflammasome Signaling Pathway(Xiang-Ju Zhao, Xiao-Chao Chen, Chao-Chi Yue, 2024, Cell Biochemistry and Biophysics)
- Submicroparticle in chrysanthemum infusion inhibit oxidative stress, inflammation, and intestinal epithelial barrier dysfunction: a new alternative for intervention of ulcerative colitis(Lezhen Dong, An Peng, Mou-Ming Zhao, Lian-Zhu Lin, 2026, Food Bioscience)
靶向 NLRP3/TLR4/NF-κB 炎症信号的天然单体、中药复方与小分子药物
本组文献以明确的通路靶点作为共同特征:没食子酸、东莨菪内酯、atranorin 抑制 NLRP3 并降低 IL-1β/IL-18,干姜黄芩黄连人参汤调控 TLR4/NF-κB/NLRP3,连翘苷抑制 TLR4/Src-NF-κB,余甘子与齐墩果酸苷多通路作用,姜黄素联合色氨酸、乌梅及 SGLT2 抑制剂达格列净的药理干预,体现"通路导向"的单体/复方/化学药研究范式。
- Gallic acid ameliorates dextran sulfate sodium-induced ulcerative colitis in mice via inhibiting NLRP3 inflammasome(Tian-Ming Yu, Yi-Ming Feng, Wei-Song Kong, Shan-Ni Li, Xueqiang Sun, Guidan Zhou, Rui-Fang Xie, Xin Zhou, 2023, Frontiers in Pharmacology)
- Exploring Scopoletin's Therapeutic Efficacy in DSS-Induced Ulcerative Colitis: Insights into Inflammatory Pathways, Immune Modulation, and Microbial Dynamics(A. Alqudah, E. Qnais, O. Gammoh, Y. Bseiso, M. Wedyan, Mohammad A. Alqudah, A. Aljabali, M. Tambuwala, 2024, Inflammation)
- Atranorin inhibits NLRP3 inflammasome activation by targeting ASC and protects NLRP3 inflammasome-driven diseases(Hao-Yu Wang, Xi Lin, Guan-gen Huang, Rong Zhou, Shu-yue Lei, Jing Ren, Kai-Rong Zhang, Chun-Lan Feng, Yan-Wei Wu, Wei Tang, 2023, Acta Pharmacologica Sinica)
- Ganjiang Huangqin Huanglian Renshen Decoction protects against ulcerative colitis by modulating inflammation, oxidative stress, and gut microbiota.(Ce Zhou, Bo Peng, Ming-Xue Zhang, Yang Yang, Zelin Yi, Yinghua Wu, 2024, Phytomedicine)
- Dapagliflozin, an SGLT2 inhibitor, ameliorates acetic acid-induced colitis in rats by targeting NFκB/AMPK/NLRP3 axis(Magdy Abou El-Rous, S. Saber, Eman M. Raafat, Amany A. E. Ahmed, 2021, InflammoPharmacology)
- Phillygenin Attenuated Colon Inflammation and Improved Intestinal Mucosal Barrier in DSS-induced Colitis Mice via TLR4/Src Mediated MAPK and NF-κB Signaling Pathways(Huanhuan Xue, Jing-Jing Li, Shi-Fei Li, Jing Guo, Rui Yan, Tingdeng Chen, Xiang Shi, Jin-Dong Wang, Li-Wei Zhang, 2023, International Journal of Molecular Sciences)
- Aegle marmelos effectively attenuates DSS-induced colitis by restoring intestinal mucosal barrier and alleviating inflammation through modulation of gut microbiota in mice.(Mridula Sahu, Amit Kaushik, Aashcharya U. Mishra, P. Rout, V. Sundaresan, K. Shanker, D. Mani, Ashutosh K. Shukla, 2025, Phytomedicine)
- Oleanolic acid 28-O-β-D-glucopyranoside: A novel therapeutic agent against ulcerative colitis via anti-inflammatory, barrier-preservation, and gut microbiota-modulation.(Cai-Xia Wang, Hanlin Liu, Zhuoqiao Li, Qing-Yao Yang, Qian-Yu Wang, Ting Yang, Daohao Tang, Cui-Zhu Wang, Jin-Ping Liu, 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie)
- Curcumin Combined with Tryptophan Ameliorates DSS-Induced Ulcerative Colitis via Reducing Inflammation and Oxidative Stress and Regulation of Gut Microbiota(Hedong Jiang, Gong-Long Li, Liu-Ming Xie, Nan-Hai Zhang, Yi Huang, Xin-Li Liang, Fanghua Guo, Qieying Jiang, Zhenggen Liao, 2025, Nutrients)
- Fructus Mume (Wu Mei) Attenuates Acetic Acid-Induced Ulcerative Colitis by Regulating Inflammatory Cytokine, Reactive Oxygen Species, and Neuropeptide Levels in Model Rats(Zong-Ying Xu, Xue-Li Zhang, Wen-Ya Wang, Di Zhang, Yan Ma, Dong-Mei Zhang, Meng Chen, 2022, Journal of Medicinal Food)
经重塑肠道菌群及其代谢物间接发挥疗效的天然提取物
共同特点是采用 16S rRNA 测序与代谢组作为核心机制证据,证明疗效主要由菌群结构与 SCFA/氨基酸/糖代谢改善介导:Limonium bicolor 乙醇提取物、美洲大蠊水提物及不同分子量组分、党参炔苷、二氢杨梅素(菌群—NLRP3 轴),属"菌群介导型"天然产物研究,与直接抗炎/修屏障的单体研究相区别。
- Ethanol Extract of Limonium bicolor Improves Dextran Sulfate Sodium-Induced Ulcerative Colitis by Alleviating Inflammation and Restoring Gut Microbiota Dysbiosis in Mice(W. Jia, Siyu Yu, Xi Liu, Qing-Qing Le, Xiwen He, Lu-Tao Yu, Jian-Lin He, Longhe Yang, Hui-Yuan Gao, 2024, Marine Drugs)
- Active ingredients isolated from Periplaneta americana L. inhibit the inflammation of the colonic mucosa and regulate the gut microbiota in DSS-induced ulcerative colitis in mice(Yanhuan Wang, Fan Ni, Gen-Rui Wu, Huai Xiao, Zhi-Bin Yang, Cheng-Gui Zhang, Hai-Rong Zhao, Heng Liu, 2025, Frontiers in Pharmacology)
- Lobetyolin ameliorates DSS-induced ulcerative colitis in mice by alleviating inflammation, restoring barrier function, and modulating gut microbiota–metabolite interactions(Min Chang, Feng-Ping Liu, Junhui Lu, Qing Wang, Jing-Wei Liu, Xing Chen, 2025, Frontiers in Microbiology)
- Dihydromyricetin Improves Ulcerative Colitis by Suppressing NLRP3 Inflammasome Activation Caused by Dysbiosis of Gut Microbiota(Jun Chen, Shengchen Ding, Hua-Bing Yang, Yi Dai, Zhi-Gang Zhang, Tianxiang Zhu, Lu-Cheng Cao, Bai-Fei Hu, Hong-Tao Liu, 2025, Journal of Inflammation Research)
功能性多糖与膳食纤维经"益生元—SCFA—黏液/紧密连接"轴的调控
以功能性多糖/膳食纤维为主体,强调其作为益生元选择性富集有益菌、提升 SCFA 与有益代谢物、修复黏液层与紧密连接屏障,并可与 5-ASA 协同;涵盖大麦麸阿拉伯木聚糖、D-塔格糖、薏苡仁多糖、淫羊藿多糖、浒苔可溶性膳食纤维、红花多糖、三叶青多糖及两种来源褐藻多糖(岩藻多糖)。
- Effect of chronic low-dose treatment with chitooligosaccharides on microbial dysbiosis and inflammation associated chronic ulcerative colitis in Balb/c mice(K. M. Rajesh, Manas Kinra, N. Ranadive, Goutam-Mohan Pawaskar, J. Mudgal, R. Raval, 2023, Naunyn-Schmiedeberg's Archives of Pharmacology)
- Arabinoxylan from barley bran alleviates ulcerative colitis in mice through enhancement of mucosal barrier function and modulation of gut microbiota.(Manchun Huang, Qing-Qing Yu, Yi-Ming Zhu, Jia-Yan Zhang, Yu-Feng He, Ying Zhu, Xiang Xiao, 2025, International Journal of Biological Macromolecules)
- D-Tagatose attenuates DSS-induced ulcerative colitis by inhibiting inflammation, reducing intestinal barrier damage and modulating the intestinal flora composition.(Le Wang, Houzhen Lu, Haitao Gui, Zi-Fu Ni, Zhong-Ke Sun, Zihua Wang, Zhi-Hua Wang, Xuanyan Liu, Qi-Peng Yuan, 2025, Food & Function)
- Coix Seed Polysaccharide Mitigates Ulcerative Colitis in Mice through the Modulation of Gut Microbiota and Improvement of Intestinal Metabolism Balance.(Zhong-Hao Ji, Wenyin Xie, Hong-Yu Wu, Bao Yuan, 2025, Journal of Agricultural and Food Chemistry)
- Epimedium polysaccharides ameliorate ulcerative colitis by inhibiting oxidative stress and regulating autophagy.(Linxian Zhao, Tao Jiang, Yuxin Zhang, Zhen Shen, 2024, The Journal of the Science of Food and Agriculture)
- Fucoidan as a therapeutic agent for ulcerative colitis: mechanisms of action and modulation of the gut microbiota(Ya-Ting Zhang, 2025, Frontiers in Cellular and Infection Microbiology)
- Enteromorpha prolifera soluble dietary fiber alleviates ulcerative colitis through restoration of mucosal barrier and gut microbiota homeostasis(Yuan Ding, Xin Tang, Yu Tian, Feng-Long Zhang, Xiang Ding, M. Qi, Wei Dong, Chen-Guang Liu, 2025, Frontiers in Nutrition)
- Safflower polysaccharide ameliorates acute ulcerative colitis by regulating STAT3/NF-κB signaling pathways and repairing intestinal barrier function.(Man Qi, Sheng-Hui Chu, Wenxuan Wang, Xianglei Fu, Chao Jiang, Liang Zhang, Md Hasan Ali, Yating Lu, Mengwei Jia, Dilraba Ubul, Hui Tang, Jian Li, Min Liu, 2024, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie)
- Tetrastigma hemsleyanum polysaccharide ameliorated ulcerative colitis by remodeling intestinal mucosal barrier function via regulating the SOCS1/JAK2/STAT3 pathway.(Xiao-Dan Bao, You-Ying Tang, Yishan Lv, Si-Yu Fu, Liu Yang, Yu-Chi Chen, Ming-Yuan Zhou, Bing-Qi Zhu, Zhi-Shan Ding, Fang-Mei Zhou, 2024, International Immunopharmacology)
- Fucoidan from Stichopus chloronotus relieved DSS induced ulcerative colitis through inhibiting intestinal barrier disruption and oxidative stress.(Rui Li, Jiaojiao Mou, Lei Zhao, Mengqiu Hu, Bin Wang, Yanying Sun, Jing Liu, Xiao-Hui Qi, Jie Yang, 2024, International Journal of Biological Macromolecules)
纳米酶与金属-多酚/无机纳米催化平台的抗氧化—抗炎多模块协同
均以纳米催化材料实现 ROS 清除为核心的级联调控:植物来源碳点纳米酶、肉桂醛负载普鲁士蓝中空介孔纳米酶、释 CO 的 MnOx@埃洛石纳米管、CaGA 纳米酶、透明质酸修饰聚多巴胺-硒纳米颗粒、金属-多酚网络酵母微囊、多巴胺介导的"一石三鸟"纳米平台及 hitchhiking 型 ROS 调节剂,兼顾抗炎、屏障修复与菌群重塑。
- Medicinal Plant-Derived Carbon Dots Nanozymes Ameliorate Ulcerative Colitis via Anti-inflammatory, Antioxidant, and Gut Barrier-Protective Effects.(Yi-Fan Li, Qian Li, Yuan-Yuan Zhu, Chen Huang, Huanyu Li, Zhi-Chao Deng, Chen-Xi Xu, Wen-Long Wang, Li-Yuan Chen, Shanli Zhang, M. Cui, Ming-Zhen Zhang, Ming-Xin Zhang, 2025, ACS Applied Materials and Interfaces)
- Cinnamaldehyde-hollow mesoporous Prussian blue nanozymes for ulcerative colitis via reactive oxygen and nitrogen species scavenging and gut microbiota-metabolism modulation(Min Feng, Chao-Yue Sun, Ting Yang, HuiPing Yin, Xiao Zhang, Ming Yang, Chang Peng, Zhao Fu, Hai-Yan Zhang, 2026, Journal of Drug Delivery Science and Technology)
- Manganese oxide nanozyme-loaded CO-releasing halloysite nanotubes for remodeling colonic immune, microbiota, and intestinal barrier homeostasis with concurrent pain relief in ulcerative colitis(He Zhang, Lin-Sa Zhou, Qiang Zhou, Huiyun Wen, Hong-Yang Lu, Jia-Yu Li, Li Yu, Hong-Yi Li, Yinci Zhu, Meng-Zhu Xu, Bin Lu, Cheng-Ge Shi, Yanmei Zhang, Xiao-Wen Hu, Q. T. Shubhra, Xiao-Song He, Xiao-Jun Cai, 2025, Bioactive Materials)
- CaGA nanozymes inhibit oxidative stress and protect mitochondrial function in ulcerative colitis therapy.(Liting Lin, Qing-Rong Li, Yan Yang, Cong Zhang, Wen-Qi Wang, Fan Ni, Xian-Wen Wang, 2025, Acta Biomaterialia)
- Microfluidics-enabled polydopamine-coated selenium nanoparticles in hyaluronic hydrogel microspheres for targeted antioxidant and immunomodulatory therapy of ulcerative colitis(Ying Fang, Hongwei Yu, Xiaochen Feng, Haike Xia, Yunze Xu, R. Kankala, Ai-Zheng Chen, Chaoping Fu, 2025, Materials Today Bio)
- Yeast microcapsules encapsulating metal-phenolic nanozymes alleviate ulcerative colitis by mitigating oxidative stress and modulating the gut microbiota(Mei-Hong Chai, Yuan-Yuan Zhu, Li-Yuan Chen, Shanli Zhang, Ya-Hui Huang, Ming-Zhen Zhang, Weiwei Jin, 2025, Materials Today Bio)
- Highly Effective Nobiletin-MPN in Yeast Microcapsules for Targeted Modulation of Oxidative Stress, NLRP3 Inflammasome Activation, and Immune Responses in Ulcerative Colitis.(Jing-Qi Yang, Xiao-Yu Xia, Ming Du, Shu-Zhen Cheng, Beiwei Zhu, Xian-Bing Xu, 2024, Journal of Agricultural and Food Chemistry)
- A “One-Stone-Three-Birds” Inspired Nanoplatform for Multitargeted Ulcerative Colitis Therapy via Combined Aryl Hydrocarbon Receptor Activation and Reactive Oxygen Species Scavenging(Kai Dong, Zelin Guan, Dan-Yang Wang, Jinyao Sun, Ying Zhang, Cui-Yu You, Yuanming Xing, 2026, Biomaterials Research)
- Robust reactive oxygen species modulator hitchhiking yeast microcapsules for colitis alleviation by trilogically intestinal microenvironment renovation(Jintao Li, Jian Song, Zhi-Chao Deng, Jian Yang, Xiao-Qin Wang, Bo-Wen Gao, Yuan-Yuan Zhu, Mei Yang, Ding-Pei Long, Xiaoqi Luo, Ming-Xin Zhang, Ming-Zhen Zhang, Runqing Li, 2024, Bioactive Materials)
ROS/刺激响应型聚合物胶束、纳米凝胶与微球的口服靶向递药系统
以"响应性载体设计"为共同点:ROS 响应型纳米胶束/聚醚胶束/聚合物前药/氯喹纳米凝胶、硫缩酮交联环糊精 MOF、苯硼酸修饰虾青素、结肠靶向羟乙基淀粉姜黄素微球与壳聚糖—非结合胆红素微球,实现炎症部位特异释放、富集与"抗氧化—抗炎—调菌群—免疫重编程"的协同增效。
- Reactive Oxygen Species-Responsive Nanocarrier Ameliorates Murine Colitis by Intervening Colonic Innate and Adaptive Immune Responses.(X. Yan, Ling-Zhang Meng, Xing-Zhe Zhang, Zhi-Chao Deng, Bo-Wen Gao, Yu-Jie Zhang, Mei Yang, Ya-Na Ma, Yuan Zhang, K. Tu, Ming-Zhen Zhang, Qiu-Ran Xu, 2023, Molecular Therapy)
- Reactive Oxygen Species-Responsive Polyether Micelle Nanomaterials for Targeted Treatment of Ulcerative Colitis.(Xinxin Zhao, Shanbo Ma, Jin-Peng Wen, Datao Hu, Jushan Gao, Qiao Peng, Yu-chen Zhang, Jin-qing Wang, Ke Wang, Xiao-peng Shi, 2022, Journal of Biomedical Nanotechnology)
- Reactive Oxygen Species-Responsive Polymer Drug Delivery System Targeted Oxidative Stressed Colon Cells to Ameliorate Colitis.(Wo-Qi Cai, Wanqi Liang, Dong Li, Wenli Dai, Zhishu Li, Xinlin Wei, Li-Zeng Cheng, Bo-Bo Zhang, Qiong-Qiong Yang, 2025, ACS Nano)
- Reactive Oxygen Species-Responsive Polymeric Chloroquine Nanogel for Targeted Oral Therapy of Ulcerative Colitis(Neha Kumari, Sudipta Panja, Balawant Kumar, Rizwan Ahmad, Sai Sundeep Kollala, K. Siddhanta, Farhana Islam, V. Joshi, G. Talmon, D. Murry, Amar B. Singh, D. Oupický, 2025, ACS Applied Materials and Interfaces)
- Reactive Oxygen Species Triggered Cleavage of Thioketal‐Containing Supramolecular Nanoparticles for Inflammation‐Targeted Oral Therapy in Ulcerative Colitis(Ting Xiong, Hui-Peng Xu, Qin Nie, Bing-Qian Jia, Haojie Bao, Han-Wen Zhang, Jing Li, Zeying Cao, Shunyao Wang, Li Wu, Ji-Wen Zhang, 2024, Advanced Functional Materials)
- Reactive oxygen species-responsive prodrug nanomicelle-functionalized Lactobacillus rhamnosus probiotics for amplified therapy of ulcerative colitis.(Xinyue Zhang, Shu-Yun Liu, Rui Xin, Wenxiu Hu, Qi-Qi Zhang, Qian Lu, Lu Han, 2025, Materials Horizons)
- Colon-targeted hydroxyethyl starch-curcumin microspheres with high loading capacity ameliorate ulcerative colitis via alleviating oxidative stress, regulating inflammation, and modulating gut microbiota.(Da Huang, Yong-Ming Wang, Chenlan Xu, Ming-Lang Zou, Yangcan Ming, Fang Luo, Zhenjin Xu, Ying-Lei Miao, Na Wang, Zhen Lin, Zu-Quan Weng, 2024, International Journal of Biological Macromolecules)
- Chitosan–Unconjugated Bilirubin Microspheres Alleviate Dysbiosis, Immune Dysregulation, and Intestinal Barrier Damage in Ulcerative Colitis(Xinyu Lyu, Xiao-Tong Xu, Meng-Qi Shi, Rui Wang, Xiao-Qing Yu, Yan Liu, Xiang-Yu Xue, Feng-Min Zhang, Xiu-Hong Wang, 2026, Biomolecules)
- Structural characteristics of phenylboronic acid-modified astaxanthin ester and its effect on DSS-induced ulcerative colitis by blocking reactive oxygen species and maintaining intestinal homeostasis(Xing Qiao, Hongyan Li, Qun Gao, Zhi-Gao Wang, Jie Xu, Lu Yang, Chang-Hu Xue, 2023, Food Science and Human Wellness)
仿生囊泡/外泌体与氢气等非聚合物型抗氧化递送与干预策略
共同点是采用非传统纳米载体或气体分子的新型抗氧化策略:姜黄来源纳米囊泡、苦瓜来源细胞外囊泡、缺氧间充质干细胞外泌体实现炎症靶向与免疫调节,氢气吸入/富氢水与氢气—氧化应激调控综述则从气体医学角度干预氧化损伤与屏障功能。
- Engineered Turmeric-Derived Nanovesicles for Ulcerative Colitis Therapy by Attenuating Oxidative Stress and Alleviating Inflammation.(Guihong Lu, Shan-Ming Lu, Haibing Dai, Fan Zhang, Xiaotian Wang, Wei-Qun Li, Lin Mei, Hui Tan, 2025, Molecular Pharmaceutics)
- Oral administration of Momordica charantia-derived extracellular vesicles alleviates ulcerative colitis through comprehensive renovation of the intestinal microenvironment(Bo-Wen Gao, Xiao-Ling Huang, Jun-Long Fu, Li-Yuan Chen, Zhi-Chao Deng, Shu-Hui Wang, Yuan-Yuan Zhu, Chen-Xi Xu, Yu-Jie Zhang, Ming-Xin Zhang, Li-Na Chen, M. Cui, Ming-Zhen Zhang, 2025, Journal of Nanobiotechnology)
- Hypoxic mesenchymal stem cell-derived exosomes alleviate ulcerative colitis injury by limiting intestinal epithelial cells reactive oxygen species accumulation and DNA damage through HIF-1α.(Feng Zhu, Chun-Zhu Wei, Hui Wu, B. Shuai, Ting Yu, Fei Gao, Yu-Yi Yuan, D. Zuo, Xing-Xing Liu, Li-Juan Zhang, Heng Fan, 2022, International Immunopharmacology)
- Regulation of hydrogen and oxidative stress in treating intestinal mucosa from ulcerative colitis(Na Yu, Jing-Wen Xu, Jie Fan, Huimin Gao, Ting Wu, Yun-Feng Zhu, Jing Xu, Xiaolin Li, Huae Xu, Xiao-Wei Lu, 2025, International Journal of Pharmaceutics: X)
- Hydrogen-rich water partially alleviate inflammation, oxidative stress and intestinal flora dysbiosis in DSS-induced chronic ulcerative colitis mice.(Lihua Song, Yao Zhang, Chuang Zhu, Xin-Wen Ding, Li Yang, Hongli Yan, 2021, Advances in Medical Sciences)
- Restoration of dysregulated intestinal barrier and inflammatory regulation through synergistically ameliorating hypoxia and scavenging reactive oxygen species using ceria nanozymes in ulcerative colitis(Ying Zhang, Hengyu Lei, Pengchong Wang, Qinyuan Zhou, Jie Yu, Xue Leng, Rui-Rui Ma, Danyang Wang, K. Dong, Jian-Feng Xing, Ya-Lin Dong, 2023, Biomaterials Research)
益生菌、后生元与膳食—菌群靶向干预
以"直接补充或调节菌群"为共同手段:副干酪乳杆菌 L21 及其后生元、植物乳杆菌 ZJ316、热处理 Akkermansia muciniphila、凝结芽孢杆菌与嗜酸乳杆菌抑制炎症小体、发酵—发芽谷子重塑菌群并降低 IL-6/claudin2,以及膳食植物化学指数与菌群/SCFA 的横断面关联,属临床与营养转化导向的菌群干预。
- Lacticaseibacillus paracasei L21 and Its Postbiotics Ameliorate Ulcerative Colitis Through Gut Microbiota Modulation, Intestinal Barrier Restoration, and HIF1α/AhR-IL-22 Axis Activation: Combined In Vitro and In Vivo Evidence(Jing-Ru Chen, Linfang Zhang, Yue-Hua Jiao, Xuan Lu, Ning Zhang, Xinyi Li, Suo Zheng, Bailiang Li, Fei Liu, Peng Zuo, 2025, Nutrients)
- Lactobacillus plantarum ZJ316 alleviates ulcerative colitis by inhibiting inflammation and regulating short-chain fatty acid levels and the gut microbiota in a mouse model.(Q. Gu, Chen-Lan Xia, N. Liu, Ziqi Chen, Qing-Qing Zhou, Ping Li, 2023, Food & Function)
- Pasteurized Akkermansia muciniphila Timepie001 ameliorates DSS-induced ulcerative colitis in mice by alleviating intestinal injury and modulating gut microbiota(Huan Han, Hui Xiong, Zenglin Liu, Xunzhi Liu, Hai-Lin Wang, Jiaxiang Kou, Dewei Yi, Ying Shi, Hao Wu, Jian-Jun Qiao, 2025, Frontiers in Microbiology)
- Probiotic Intervention With Bacillus coagulans and Lactobacillus acidophilus in Small Animals Experimental Ulcerative Colitis: Insights From a Small Animal Model(Fatemeh Shayesteh, Milad Shahini Shams Abadi, L. Rouhi, A. Doosti, Nader Bagheri, 2026, Veterinary Medicine and Science)
- Higher Dietary Phytochemical Index Is Associated With Lower Disease Activity, Inflammation, and Gut Dysbiosis in Patients With Ulcerative Colitis(Yue Zhu, Zhihui Lu, Jian Quan, Ling-Min Wu, 2025, Food Science & Nutrition)
- Fermented and Germinated Processing Improved the Protective Effects of Foxtail Millet Whole Grain Against Dextran Sulfate Sodium-Induced Acute Ulcerative Colitis and Gut Microbiota Dysbiosis in C57BL/6 Mice(Yu-heng Zhang, Wei Liu, Ding-Qi Zhang, Yan-Bin Yang, Xianshu Wang, Ling-Fei Li, 2021, Frontiers in Nutrition)
- Gut Microbiota and Inflammation Modulation in a Rat Model for Ulcerative Colitis after the Intraperitoneal Administration of Apigenin, Luteolin, and Xanthohumol(Patricia Magadán-Corpas, Álvaro Pérez-Valero, Su-Hui Ye, S. Sordon, E. Huszcza, J. Popłoński, C. J. Villar, F. Lombó, 2024, International Journal of Molecular Sciences)
饮食模式与营养因素(高脂饮食、低脂高纤饮食、进食行为与间歇性禁食)对 UC 的影响
从环境与生活方式维度探讨饮食对上皮屏障和菌群的塑造作用:膳食内容与进食行为(含间歇性禁食)的综述、高脂饮食诱导肠黏膜屏障损伤的实验证据,以及低脂高纤饮食降低炎症标志物并改善菌群失调的临床交叉试验,体现"饮食—屏障—菌群"轴的可干预性。
- Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective(Lingxi Qin, Wenliang Lv, 2025, Nutrix Journal)
- High-fat diet induces intestinal mucosal barrier dysfunction in ulcerative colitis: emerging mechanisms and dietary intervention perspective.(Shijing Jiang, Zhi-Wei Miao, 2023, American journal of translational research)
- Low-fat, High-fiber Diet Reduces Markers of Inflammation and Dysbiosis and Improves Quality of Life in Patients With Ulcerative Colitis.(Julia Fritsch, L. Garces, M. Quintero, J. Pignac-Kobinger, A. Santander, Irina Fernández, Yu-Guang J. Ban, D. Kwon, Matthew C. L. Phillips, Karina Knight, Qing-Qing Mao, R. Santaolalla, X. S. Chen, Mukil Maruthamuthu, N. Solis, O. Damas, D. Kerman, A. Deshpande, J. Lewis, Chi Chen, M. Abreu, 2020, Clinical Gastroenterology and Hepatology)
临床免疫学特征、诊断生物标志物与多组学分子分型
不侧重药物干预,而聚焦 UC 的临床/分子诊断与免疫特征刻画:NCF2 作为诊断标志物并与巨噬细胞浸润相关、DPP-4 与 IL-7/CRP 的联合诊断价值、循环 miRNA 谱与 T 细胞亚群及 IL-22/IFN-γ 的关联用于鉴别 CD 与 UC、直肠与结肠病变状态对疾病评估的意义,以及多组学衍生的核心基因分型。
- NCF2 as a Novel Diagnostic Biomarker in Ulcerative Colitis: Linking Macrophage Infiltration to Immune Dysregulation via Multi-Omics Analysis(Fang Zhang, Jian-Wei Zhu, Hai-Yan Liu, Jianlan Ye, Yuan-Yuan Li, Bing-Cheng Wang, 2025, Journal of Inflammation Research)
- Dipeptidyl peptidase-4 dysregulation and inflammatory cytokines as dual biomarkers in ulcerative colitis ‒ a case-control study(Hamza Hussein Hamid, Ban Mahmood Shaker, Ali Jaber Almamory, 2025, European Journal of Clinical and Experimental Medicine)
- Interplay Between Dysregulated Immune System and the Footprints of Blood-Borne miRNAs in Treatment Naive Crohn’s Disease and Ulcerative Colitis Patients(Emese Szilágyi-Tolnai, A. Szilagyi-Racz, O. Kadenczki, András Balajthy, Péter Dávid, G. Fidler, P. Fauszt, K. Gál, J. Remenyik, K. Palatka, G. Panyi, M. Paholcsek, G. Tajti, 2025, International Journal of Molecular Sciences)
- Importance of rectal over colon status in ulcerative colitis remission: the role of microinflammation and mucosal barrier dysfunction in relapse(Kei Nishioka, H. Ogino, E. Ihara, Takatoshi Chinen, Yusuke Kimura, M. Esaki, Xiao-Peng Bai, Yosuke Minoda, Yoshimasa Tanaka, Masafumi Wada, Y. Hata, Y. Ambrosini, Y. Ogawa, 2024, Journal of gastroenterology)
- Multi-omics derivation of a core gene signature for predicting therapeutic response and characterizing immune dysregulation in inflammatory bowel disease(Mingming Wang, Li-Ping Liang, Zibo Tang, Ji-Min Han, Lele Wu, Le Liu, Ye Chen, 2025, Frontiers in Immunology)
合并三套初始化分组后共形成 20 个并列一级分组、覆盖全部 145 篇文献,整体遵循"框架综述 → 机制解析 → 干预策略 → 临床转化"的递进逻辑。第一部分(1 组)以系统综述建立"氧化应激—免疫失调—上皮屏障障碍—菌群失衡"多因素整合框架。第二部分(6 组)深入机制:ROS 过量生成与抗氧化防御失衡及其对 NLRP3 的上游驱动、NLRP3–IL-1β–焦亡免疫轴、焦亡/铁死亡/PANoptosis/凋亡等程序性死亡、紧密连接—黏附连接—离子转运所致的"渗漏型"屏障结构缺陷、免疫细胞(NK、巨噬细胞极化、血小板、DNA 感应—IFN)失调、菌群失调的病理与临床证据(含病毒组、PPI、口腔—肠轴、SCFA)。第三部分(12 组)为干预研究,并按作用机制细分为互不交叉的板块:TJ/AJ 连接蛋白修复类天然产物、促黏膜愈合(杯状细胞/AhR/微循环/PI3K-AKT)、免疫细胞导向干预(极化重编程与 miRNA)、多酚黄酮香豆素的抗氧化—抗炎多靶点作用、靶向 NLRP3/TLR4/NF-κB 的单体复方与小分子药物、菌群介导型天然提取物、多糖与膳食纤维的益生元—SCFA 轴、纳米酶与纳米催化平台、ROS 响应型聚合物/微球递药、仿生囊泡与外泌体及氢气等新型策略、益生菌与后生元、饮食营养模式。第四部分(1 组)为临床生物标志物、免疫特征与多组学分子分型,呼应精准医学与个体化治疗。各分组主题边界清晰、文献不重复计入,形成"机制—靶点—干预—转化"完整知识链条。
均为综述/框架性论文,从整体视角梳理 UC 免疫异常、上皮屏障缺陷、菌群失调与细胞因子/分子网络之间的交互关系,并整合现有分子靶向与精准医学思路,为后续各机制专题与干预专题提供统一的理论背景与概念框架。相关文献:Yuta Shimomori et. al, 2025 等 6 篇文献
共同聚焦 ROS 产生与清除失衡这一上游环节:DUOX2/DUOXA2 来源的 ROS、ORMDL3 调控线粒体动力学激活 NLRP3、MMP9 对 ROS/DNA 损伤的调节、非编码 RNA 与 ROS 相关性综述,以及萝卜硫素、依鲁替尼通过降低氧化应激抑制炎症通路的证据,共同刻画"氧化应激驱动炎症小体活化"的分子链条。相关文献:S. Ashique et. al, 2023 等 7 篇文献
围绕天然免疫核心轴展开:ASC–NLRP3 互作与 caspase-1/GSDMD 焦亡、NLRP3 依赖与非依赖的 IL-1β 加工、HSF2/Nrf2 对炎症小体的负向调控、DLG2 表达下调导致炎症小体失控,并纳入 NLRP3 双重作用(保护性一面)的争议与小分子/杂合药物(美沙拉嗪-NSAID 杂合物)的炎症小体靶向评价。相关文献:Rui-Long Kou et. al, 2026 等 9 篇文献
聚焦肠上皮细胞多种死亡方式对屏障的破坏:程序性死亡与上皮屏障的系统综述、天然产物调控焦亡的综述、PANoptosis 相关基因的免疫浸润分析、精胺经 NCOA4–铁蛋白轴抑制铁死亡,以及具核梭杆菌经铁死亡破坏肠屏障的微生物—死亡通路交叉机制。相关文献:Bi-Hua Wu et. al, 2025 等 6 篇文献
不针对单一化合物疗效,而研究屏障本身的病理机制:非线性多模态成像直接可视化 UC 患者上皮裂隙与顶端连接复合体改变、结肠离子转运缺陷与连接蛋白分布异常导致"渗漏"、mTOR/PBLD/AMOT 轴调控 TJ 修复、NUDT1 经氧化应激—Nrf2/ERK 加重屏障损伤,以及 STEAP4 等分子对屏障功能的调控。相关文献:Elsie Quansah et. al, 2023 等 6 篇文献
集中于免疫细胞与固有免疫信号层面的失调机制:NKG2A 上调导致 CD4+T 细胞清除障碍、极化的巨噬细胞来源微囊泡差异调控肠上皮、DNA 感应器驱动的Ⅰ型干扰素反应,以及活化血小板增强炎症细胞互作,共同解释 UC 免疫稳态失衡的细胞学基础。相关文献:Y. Zhang et. al, 2026 等 4 篇文献
以微生态失衡的"病理证据"为主线:菌群与 UC 关系综述、回肠末端与波兰人群菌群谱、具核梭杆菌等致病共生菌的促炎机制、肠道病毒组(Orthohepadnavirus/HBx)关联、PPI 诱发菌群紊乱、丁酸等 SCFA 水平下降,以及牙周炎经口腔—肠轴加重菌群失调,论证菌群失调与 UC 的因果关联。相关文献:Ke-Yu Ren et. al, 2025 等 10 篇文献
均以 TJ/AJ 蛋白表达与分布(ZO-1、occludin、claudin、E-cadherin)及跨上皮电阻为主要终点:经 MLCK/NF-κB、RhoA/ROCK/MLC 细胞骨架重塑、SLC26A3、TGR5-PERK-eIF2α 等通路恢复连接复合体,还包括穴位埋线等非药物疗法对 TJ 的调节,形成"连接蛋白修复"这一独立干预板块。相关文献:Yanmin Zhang et. al, 2025 等 10 篇文献
区别于单纯连接蛋白修复,本组以"黏膜愈合"为共同终点:鸭胆子苦醇经 IL-22/STAT3 恢复杯状细胞与黏蛋白、黄连碱激活 AhR/CYP1A1、獐牙菜苷改善黏膜微循环、黄芪甲苷抑制 PI3K/AKT 修复屏障、青蒿琥酯促进上皮修复、白术提取物与龙血竭改善上皮损伤,并含黏膜屏障修复的系统综述。相关文献:Yi-Chen Zong et. al, 2023 等 7 篇文献
共同点为"以免疫细胞为直接靶点"的干预研究:青蒿琥酯纠正巨噬细胞极化、灵芝提取物与 SGLT2 抑制剂改善免疫浸润、小分子 miR-124 诱导剂与真菌β-葡聚糖—miR-32-5p—Dectin-1 轴调控巨噬细胞表型,属于免疫机制导向而非单纯抗炎或屏障修复的治疗策略。相关文献:S. Yin et. al, 2025 等 5 篇文献
该组化合物药理重心在清除 ROS、提升 SOD/GSH/GPx 等抗氧化指标并抑制 NF-κB、MAPK、JAK2/STAT3 促炎通路:姜黄、苹果多酚、黄芩素(线虫与小鼠模型两篇)、芍药苷、委陵菜黄酮、芦丁、菊花亚微米颗粒、没食子酸之外的多酚/香豆素类成分,机制描述集中于氧化—炎症环节而非特定屏障或菌群靶点。相关文献:Chengcheng Yang et. al, 2022 等 12 篇文献
本组文献以明确的通路靶点作为共同特征:没食子酸、东莨菪内酯、atranorin 抑制 NLRP3 并降低 IL-1β/IL-18,干姜黄芩黄连人参汤调控 TLR4/NF-κB/NLRP3,连翘苷抑制 TLR4/Src-NF-κB,余甘子与齐墩果酸苷多通路作用,姜黄素联合色氨酸、乌梅及 SGLT2 抑制剂达格列净的药理干预,体现"通路导向"的单体/复方/化学药研究范式。相关文献:Tian-Ming Yu et. al, 2023 等 10 篇文献
共同特点是采用 16S rRNA 测序与代谢组作为核心机制证据,证明疗效主要由菌群结构与 SCFA/氨基酸/糖代谢改善介导:Limonium bicolor 乙醇提取物、美洲大蠊水提物及不同分子量组分、党参炔苷、二氢杨梅素(菌群—NLRP3 轴),属"菌群介导型"天然产物研究,与直接抗炎/修屏障的单体研究相区别。相关文献:W. Jia et. al, 2024 等 4 篇文献
以功能性多糖/膳食纤维为主体,强调其作为益生元选择性富集有益菌、提升 SCFA 与有益代谢物、修复黏液层与紧密连接屏障,并可与 5-ASA 协同;涵盖大麦麸阿拉伯木聚糖、D-塔格糖、薏苡仁多糖、淫羊藿多糖、浒苔可溶性膳食纤维、红花多糖、三叶青多糖及两种来源褐藻多糖(岩藻多糖)。相关文献:K. M. Rajesh et. al, 2023 等 10 篇文献
均以纳米催化材料实现 ROS 清除为核心的级联调控:植物来源碳点纳米酶、肉桂醛负载普鲁士蓝中空介孔纳米酶、释 CO 的 MnOx@埃洛石纳米管、CaGA 纳米酶、透明质酸修饰聚多巴胺-硒纳米颗粒、金属-多酚网络酵母微囊、多巴胺介导的"一石三鸟"纳米平台及 hitchhiking 型 ROS 调节剂,兼顾抗炎、屏障修复与菌群重塑。相关文献:Yi-Fan Li et. al, 2025 等 9 篇文献
以"响应性载体设计"为共同点:ROS 响应型纳米胶束/聚醚胶束/聚合物前药/氯喹纳米凝胶、硫缩酮交联环糊精 MOF、苯硼酸修饰虾青素、结肠靶向羟乙基淀粉姜黄素微球与壳聚糖—非结合胆红素微球,实现炎症部位特异释放、富集与"抗氧化—抗炎—调菌群—免疫重编程"的协同增效。相关文献:X. Yan et. al, 2023 等 9 篇文献
共同点是采用非传统纳米载体或气体分子的新型抗氧化策略:姜黄来源纳米囊泡、苦瓜来源细胞外囊泡、缺氧间充质干细胞外泌体实现炎症靶向与免疫调节,氢气吸入/富氢水与氢气—氧化应激调控综述则从气体医学角度干预氧化损伤与屏障功能。相关文献:Guihong Lu et. al, 2025 等 6 篇文献
以"直接补充或调节菌群"为共同手段:副干酪乳杆菌 L21 及其后生元、植物乳杆菌 ZJ316、热处理 Akkermansia muciniphila、凝结芽孢杆菌与嗜酸乳杆菌抑制炎症小体、发酵—发芽谷子重塑菌群并降低 IL-6/claudin2,以及膳食植物化学指数与菌群/SCFA 的横断面关联,属临床与营养转化导向的菌群干预。相关文献:Jing-Ru Chen et. al, 2025 等 7 篇文献
从环境与生活方式维度探讨饮食对上皮屏障和菌群的塑造作用:膳食内容与进食行为(含间歇性禁食)的综述、高脂饮食诱导肠黏膜屏障损伤的实验证据,以及低脂高纤饮食降低炎症标志物并改善菌群失调的临床交叉试验,体现"饮食—屏障—菌群"轴的可干预性。相关文献:Lingxi Qin et. al, 2025 等 3 篇文献
不侧重药物干预,而聚焦 UC 的临床/分子诊断与免疫特征刻画:NCF2 作为诊断标志物并与巨噬细胞浸润相关、DPP-4 与 IL-7/CRP 的联合诊断价值、循环 miRNA 谱与 T 细胞亚群及 IL-22/IFN-γ 的关联用于鉴别 CD 与 UC、直肠与结肠病变状态对疾病评估的意义,以及多组学衍生的核心基因分型。相关文献:Fang Zhang et. al, 2025 等 5 篇文献
总计 145 篇相关文献
The mammalian gastrointestinal tract is continuously vulnerable to numerous bacteria and food additives as well as to environmental tox-ins that damage the epithelia of the gut [1]. Disturbance in intestinal
Ulcerative colitis (UC) is a chronic, non-specific inflammatory disease of the intestines with a significant increase in global incidence in recent years. Oxidative stress and inflammation are two hallmarks of UC pathogenesis. Anemoside B4 (AB4), a pentacyclic triterpenoid saponin, exhibits significant antioxidant and anti-inflammatory properties and shows potential for preventing UC. Here, an animal model induced by dextran sodium sulfate (DSS) was used to investigate the effect of AB4 on UC. The results demonstrated that AB4 significantly reduces intestinal oxidative stress and inflammation in UC mice, while also protecting intestinal barrier function. Furthermore, AB4 helps restore intestinal microbial balance primarily by modulating the abundance of Lactobacillus, which enhances the metabolism of short-chain fatty acids and upregulates the production of butyric acid (BA). Pseudogerm-free mice and fecal microbiota transplantation (FMT) demonstrated that AB4 significantly mitigated UC in a gut microbe-dependent manner. Both AB4 and BA markedly activate the aromatic hydrocarbon receptor (AhR). The intestinal organoid results suggest BA may activate the AhR to inhibit ROS production and activation of NLRP3 inflammasome, thereby protecting intestinal integrity. Administration of AhR antagonists abolished the protective effects, thus confirming the involvement of AhR in the underlying mechanism. Overall, these results indicate that AB4 is an effective agent against UC mainly by activating the AhR through gut microbial short-chain fatty acid metabolites to inhibit intestinal oxidative stress and inflammation.
Ulcerative colitis (UC) is defined as a chronic intestinal inflammation with an unknown cause. During its occurrence and development, oxidative stress and intestinal microbiota dysbiosis play important roles. Nevertheless, the treatment of UC continues to pose significant challenges due to the intricate nature of physiological barriers and the suboptimal targeting efficacy of traditional therapeutic strategies. To solve the dilemma facing UC treatment, in this study, we developed a metal-phenolic nanozyme, designated as DHM-Zn, which exhibits anti-inflammatory and antioxidant properties via metal coordination between dihydromyricetin (DHM) and Zn2+. Furthermore, we engineered yeast microcapsules (YM) encapsulating the metal-phenolic nanozymes (DZ@YM), leveraging the inherent biosafety and tolerability advantages offered by natural microorganisms. Following oral administration, the intestinal retention characteristics of YM facilitated the efficient aggregation of DHM-Zn nanozymes at the inflammation site, thereby extending their therapeutic efficacy. In addition to augmenting anti-inflammatory and antioxidant effects, DZ@YM contributed to the restoration of intestinal microbial balance by increasing the abundance of beneficial bacteria such as Parabacteroides and Muribaculaceae, while regulating potentially harmful bacteria like Clostridium-sensu-stricto and Escherichia-Shigella, thereby achieving a synergistic multi-pathway therapeutic approach. Collectively, with excellent biocompatibility, this novel therapeutic approach demonstrates extensive potential for clinical application in the treatment of UC and offers new directions and insights for UC therapy.
Ulcerative colitis (UC) is a long-term inflammatory bowel disease characterized by intense inflammation of the colorectal mucosa. Overproduction of reactive oxygen species exacerbates the progression of UC, which is linked to mitochondrial impairment and dysbiosis of the intestinal microbiota. CaGA nanozymes have demonstrated efficacy in the treatment of UC. The modulation of M1 and M2 polarization of macrophages by CaGA nanozymes has been demonstrated to be useful in reducing inflammation. Furthermore, CaGA nanozymes regulate the M1 and M2 polarization of macrophages, efficiently decreasing inflammation. The oral delivery of CaGA nanozymes resulted in their enrichment in inflamed areas of the colon and effectively reduced colonic damage in mice with DSS-induced colitis by improving the repair of the intestinal barrier. An investigation of 16S rDNA sequencing revealed that CaGA nanozymes regulate populations of both pathogenic and helpful bacteria and impact the progression of ulcerative colitis by influencing the tricarboxylic acid (TCA) cycle. Thus, CaGA nanozymes may be employed in the management of ulcerative colitis to control the intestinal milieu and improve the preservation of the intestinal barrier by decreasing the invasion of inflammatory cells and restoring mitochondrial activity. STATEMENT OF SIGNIFICANCE: CaGA nanozymes exhibit multifunctional enzymatic activity, effectively eliminating cellular RONS with robust antioxidant capacity. CaGA nanoenzymes promote macrophage M1 to M2 polarization and produce anti-inflammatory effects. CaGA nanozymes increase cell viability by restoring impaired mitochondrial function, reducing reactive oxygen species (ROS) production, and restoring the ability of mitochondria to produce ATP. CaGA nanozymes modulate intestinal flora diversity and composition, potentially influencing inflammatory pathways via aromatic compound metabolism. They participate in cellular energy and biosynthesis, regulating ulcerative colitis (UC)-related intestinal function through the tricarboxylic acid (TCA) and urea cycles. Calcium ions bind to GA nanomedicine and small particles are readily absorbed by inflammatory cells, preventing diarrhea from being rapidly excreted.
OBJECTIVE This study aimed to systematically evaluate the therapeutic effects of Psoralen (PSO) on ulcerative colitis (UC) and investigate its underlying mechanisms, with a particular focus on intestinal barrier function, gut microbiota, inflammation, oxidative stress, and ferroptosis. METHODS UC was induced in mice via 2.25 % dextran sulfate sodium (DSS). The therapeutic efficacy of PSO was assessed by monitoring body weight, disease activity index (DAI), colon length, and histopathological alterations. Intestinal barrier integrity was evaluated through tight junction protein expression and permeability assays. Changes in gut microbiota were analyzed by 16S rDNA sequencing. Inflammatory cytokines, oxidative stress markers, and ferroptosis-related proteins were quantified by ELISA and Western blot. RESULTS PSO significantly mitigated UC symptoms, demonstrated by reduced weight loss, decreased DAI scores, prolonged colon length, and improved histopathology. It reinforced intestinal barrier integrity by upregulating ZO-1, Claudin-1, and Occludin while reducing permeability. PSO modulated gut microbiota by promoting beneficial bacteria and inhibiting pathogenic species. Additionally, it suppressed the expression of IL-6, TNF-α, and IL-1β and inhibited the TLR4/MyD88/NF-κB and JAK2/STAT3 signaling pathways. PSO also alleviated oxidative stress, as evidenced by decreased ROS and MDA levels, and increased SOD and GSH. It inhibited ferroptosis by reducing Fe2+ accumulation and modulating ferroptosis-related proteins. CONCLUSION PSO exerts therapeutic effects on UC through a multi-target mechanism that enhances the intestinal barrier, modulates the gut microbiota, exerts anti-inflammatory actions, mitigates oxidative stress, and inhibits ferroptosis, highlighting its potential as a promising therapeutic candidate.
Inflammation and oxidative stress are important features of traumatic ulcerative colitis (UC). Turmeric has been used as a dietary and functional ingredient for its potent anti-inflammatory effects in UC therapy. However, its practical effectiveness is hindered by limited reactive oxygen species (ROS) elimination properties. To address this, we constructed a unique treatment agent by growing cerium oxide (CeO2) nanocrystals on the membranes of turmeric-derived nanovesicles (TNVs), named as TNV-Ce. The resulted TNV-Ce could suppress inflammation and exhibit exceptional ROS-scavenging activity, which was validated both in lipopolysaccharide-induced macrophages and dextran sulfate sodium salt-induced chronic colitis mouse model. Following oral administration, TNV-Ce significantly accumulated at inflamed sites, effectively eliminating ROS and inhibiting pro-inflammatory cytokines for synergistic action against UC.
Introduction Ulcerative colitis (UC) is a chronic, nonspecific inflammatory bowel disease with limited therapeutic options. Baicalein, a phenolic flavonoid extracted from Scutellaria baicalensis, has been traditionally used in Chinese medicine for its potent anti-inflammatory, anti-tumor, and antiviral properties. This plant, known as Huang-Qin, is indigenous to East Asia and has been widely used to treat various conditions such as fever, respiratory diseases, and inflammation. Aim of the Study This study aimed to establish a C. elegans model of UC induced by dextran sodium sulfate (DSS) and to investigate the protective effects of baicalein on intestinal injury. Materials and Methods DSS was used to induce acute intestinal injury in C. elegans. N2 and mutant strains (daf-2 and daf-16) were exposed to DSS at concentrations of 5% (w/v), which identified as optimal for inducing intestinal inflammation. The effects of 25 μM, 50 μM, and 100 μM of baicalein on intestinal barrier function, oxidative stress markers, and relevant gene expression were evaluated, including genes related to epithelial barrier integrity (clc-2, mtm-6, etc.), oxidative stress, and the IIS and p38 MAPK pathways. Results Baicalein significantly improved physiological condition and intestinal permeability in worm treated with 5% DSS. It restored the expression of epithelial barrier genes and reduced oxidative stress, as indicated by decreased ROS, enhancing SOD activity, daf-16 nuclear translocation etc. Baicalein’s protective effects were associated with the activation of the p38 MAPK and IIS pathways. In daf-2 and daf-16 mutant strains, baicalein demonstrated partial dependence on the IIS pathway for its protective effects. Conclusion This study established a DSS-induced UC model in C. elegans and demonstrated that baicalein exerts protective effects on intestinal barrier integrity and oxidative stress, through the IIS and MAPK pathways. These findings support the use of C. elegans as a model for UC research and provide valuable insights into baicalein’s therapeutic potential for inflammatory bowel diseases.
Background: Curcumin (Cur) and tryptophan (Trp) both show promise for treating ulcerative colitis (UC) alone, but their combination has not been explored. This study investigated the therapeutic advantage of the combination (Cur–Trp) for DSS-induced ulcerative colitis in mice. Methods: We established a mouse model of ulcerative colitis induced by dextran sulfate sodium (DSS). The mice were treated with Cur, Trp, or Cur–Trp, and to evaluate the therapeutic effects, we assessed clinical signs such as body weight, disease activity index (DAI), and colon length. We also examined intestinal barrier function through indicators including histopathological changes, inflammatory factors, oxidative stress levels, mucin secretion, and tight junction protein expression. Additionally, we analyzed the composition of gut microbiota and the content of its metabolites like short-chain fatty acids (SCFAs). Results: The Cur–Trp group produced the most significant improvement, exceeding that of Cur or Trp group. This was evidenced by a significant recovery of this sign, including slower weight loss, reduced colon shortening, and de-creased disease activity index. Compared with the model group, the weight loss of mice in the Cur–Trp group was reduced from 17.15% to 9.73%, which was better than that in the cur group (11.33%) and the Trp group (11.59%). The DAI decreased from the model group (3.6) to the Cur–Trp group (2.4), while the DAI in the Cur group and the Trp group only decreased to 2.9 and 2.8, respectively. The colon length in the Cur–Trp group (6.52 cm) was larger than that in the cur group (6.31 cm), the Trp group (6.23 cm) and the model group (5.5 cm). The Cur–Trp intervention effectively restored intestinal barrier function, as shown by reducing colon tissue dam-age, modulating inflammatory factors, restoring oxidative balance, increasing mucin secretion, and upregulating tight junction protein expression. Further studies showed that the combination uniquely modulated the gut microbiome, increased the Firmicutes/Bacteroidetes (F/B) ratio, decreased the genus of pro-inflammatory bacteria, and in-creased beneficial bacteria, while increasing SCFA levels to alleviate DSS-induced ulcerative colitis. Conclusions: Cur–Trp has shown great potential in alleviating colitis and promoting intestinal barrier function, suggesting that the combination of Cur and Trp has the potential to be developed as a therapeutic functional food or dietary supplement for UC. However, more studies are needed to validate this finding. Future research should focus on elucidating the precise molecular mechanisms, optimizing dosage and clinical trials in chronic models and humans to provide more targeted treatment options.
BACKGROUND Nudix hydrolase 1 (NUDT1) plays a crucial role in tumours, where it helps limit cellular damage caused by reactive oxygen species. However, the exact function of NUDT1 in ulcerative colitis (UC) is not well understood. METHODS NUDT1 expression in the intestinal mucosal tissues of patients with UC was analysed using quantitative reverse transcription polymerase chain reaction. A public database was used to analyse the expression of selected signature genes of interest in patients with UC with different NUDT1 expression levels. TH588, a potent NUDT1 inhibitor, was used to treat intestinal epithelial cells (IECs) in mice. The functions of the IECs were assessed using quantitative reverse transcription polymerase chain reaction, flow cytometry, western blotting, and fluorescence microscopy. A mouse model of dextran sodium sulphate-induced colitis was established. RESULTS We examined NUDT1 expression and found that it was significantly elevated in the colon tissues of patients with UC. A colitis model was established in wild-type mice treated with TH588, which significantly reduced intestinal mucosal inflammation and induced notable alterations in faecal microbiota composition. Moreover, TH588 helped preserve intestinal mucosal barrier function. Inhibition of NUDT1 expression in IECs enhanced antioxidant activity by increasing Nrf2 expression and reducing ERK phosphorylation, which, in turn, stabilised tight junctions in IECs exposed to oxidative stress. CONCLUSIONS Our research emphasises the role of NUDT1 in modulating the intestinal microbiota and intestinal mucosal barrier in UC, indicating that targeting NUDT1 during intestinal mucosal inflammation could serve as a promising therapeutic strategy for UC.
Ulcerative colitis (UC) is a diffuse chronic inflammation in the superficial intestine. Excessive accumulation of reactive oxygen species (ROS) leads to the of the colorectal damage. As the anti-inflammation therapy needs to be last for at least 3–5 years, the drugs demand less toxicity. However, current treatments in the clinic are often accompanied by unavoidable adverse side effects. Hydrogen is a nontoxic antioxidant reagent with excellent permeability of biomembranes, which shows the potential in treating UC. A novel simply designed hydrogen storage particle, Magnesium Hydride (MgH2) particle with an outer shell of passivated Magnesium oxide (MgO), was constructed in the current study to enable the safe and controlled release of hydrogen. This studies demonstrated that magnesium hydride particle (MgH2@MgO) was effective in scavenging excessive ROS, relieving the inflammation, and reversing the progression of UC through inhibiting the NF-κB signaling pathway, which provided the experimental evidence for the clinical prevention and therapy of UC.
Ulcerative colitis (UC) is an idiopathic inflammatory disease. We intend to explore the mechanism of Rutin in the therapy of UC. Disease activity index (DAI) and hematoxylin-eosin staining were employed to assess therapeutic effect of Rutin on dextran sulfate sodium-stimulated mice. The proliferation was detected by 3-(4, 5-dimethylthiazol-2-yl)-2, 5-diphenyl tetrazolium bromide assay. Oxidative stress (OS) was assessed by measuring reactive oxygen species (ROS), malondialdehyde (MDA), and superoxide dismutase (SOD). Inflammatory factors were detected using enzyme-linked immunosorbent assay and immunofluorescence staining. mRNA and protein expressions were detected by real-time quantitative polymerase chain reaction and immunoblotting assay. Rutin decreased DAI scores and ameliorated pathological damage in UC mice with decreased levels of inflammatory factors. Rutin recovered the inhibited proliferation of fetal human colon cells caused by lipopolysaccharide. Rutin inhibited OS by reducing ROS and MDA, while enhancing SOD activity in LPS-induced fetal human colon cells. Rutin inhibited NLRP3 inflammasome in UC mice and cell model. Silencing NLRP3 enhanced the inhibitory effect of Rutin on OS in lipopolysaccharide-induced fetal human colon cells. Conversely, NLRP3 overexpression reversed the restraining role of Rutin in OS. Rutin ameliorates UC by inhibiting inflammation and OS through suppressing NLRP3 inflammasome.
Inflammatory bowel disease (IBD) etiology is intricately linked to oxidative stress and inflammasome activation. Natural antioxidant nobiletin (NOB) contains excellent anti-inflammatory properties in alleviating intestinal injury. However, the insufficient water solubility and low bioavailability restrict its oral intervention for IBD. Herein, we constructed a highly efficient NOB-loaded yeast microcapsule (YM, NEFY) exhibiting marked therapeutic efficacy for dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) at a low oral dose of NOB (20 mg/kg). We utilized the metal polyphenol network (MPN) formed by self-assembly of epigallocatechin gallate (EGCG) and FeCl3 as the intermediate carrier to improve the encapsulation efficiency (EE) of NOB by 4.2 times. These microcapsules effectively alleviated the inflammatory reaction and oxidative stress of RAW264.7 macrophages induced by lipopolysaccharide (LPS). In vivo, NEFY with biocompatibility enabled the intestinal enrichment of NOB through controlled gastrointestinal release and macrophage targeting. In addition, NEFY could inhibit NLRP3 inflammasome and balance the macrophage polarization, which favors the complete intestinal mucosal barrier and recovery of colitis. Based on the oral targeted delivery platform of YM, this work proposes a novel strategy for developing and utilizing the natural flavone NOB to intervene in intestinal inflammation-related diseases.
BACKGROUND Ulcerative colitis (UC) is a disease that is difficult to treat and has been associated with high rates of recurrence. Moreover, the current medications for UC induce serious side effects following prolonged use. Ganjiang Huangqin Huanglian Renshen Decoction (GJHQHLRSD), has been traditionally used to treat UC. However, its protective mechanisms have not been fully studied. PURPOSE In this study the mechanisms by which GJHQHLRSD treats UC was investigated. METHODS The GJHQHLRSD and GJHQHLRSD drug-containing serum (GJHQHLRSD-DS) were characterized using LC-MS/MS. The therapeutic effect of GJHQHLRSD on dextran sodium sulfate (DSS)-induced UC was explored by assessing various parameters including intestinal flora 16S rRNA, intestinal barrier function, oxidative stress (OS) response, inflammatory cytokines, colonic histopathological injury, colon length, disease activity index (DAI) and body weight. RESULTS Treatment with GJHQHLRSD increased body weight, ameliorated colon length shortening and edema, reduced the DAI score, improved the pathological injury, down-regulated the levels of IL-1β, IL-6, IL-8, TNF-α, LPS, LDH, TLR4, and NLRP3, and up-regulated the ZO-1 and Occludin levels in UC mice. It also decreased intestinal oxidative stress in UC mice and improved mitogenic activity by modulating mitochondrial ultrastructure as well as the expression level of PINK1, LC3-II/Ⅰ, Beclin-1, p62, and Parkin proteins. In addition, we found that the effects of GJHQHLRSD on UC mice were inhibited by 3-MA.GJHQHLRSD treatment reduced the imbalance of intestinal flora in UC mice, by regulating the inflammation and oxidative stress. CONCLUSION These findings suggested that GJHQHLRSD effectively attenuated inflammatory responses, inhibited the TLR4/NF-κB/NLRP3 signalling, oxidative stress, and modulated the gut microbiota, and alleviated the DSS-induced UC symptoms, making it a promising and innovative therapeutic option for the treatment of UC.
Excessive oxidative stress and NLRP3 inflammasome activation are considered the main drivers of inflammatory bowel disease (IBD), and inhibition of inflammasomes ameliorates clinical symptoms and morphological manifestations of IBD. Herein, we examined the roles of NLRP3 activation in IBD and modulation of NLRP3 by sulforaphane (SFN), a compound with multiple pharmacological activities that is extracted from cruciferous plants. To simulate human IBD, we established a mouse colitis model by administering dextran sodium sulfate in the drinking water. SFN (25, 50 mg·kg-1·d-1, ig) or the positive control sulfasalazine (500 mg/kg, ig) was administered to colitis-affected mice for 7 days. Model mice displayed pathological alterations in colon tissue as well as classic symptoms of colitis beyond substantial tissue inflammation. Expression of NLRP3, ASC, and caspase-1 was significantly elevated in the colonic epithelium. The expression of NLRP3 inflammasomes led to activation of downstream proteins and increases in the cytokines IL-18 and IL-1β. SFN administration either fully or partially reversed these changes, thus restoring IL-18 and IL-1β, substantially inhibiting NLRP3 activation, and decreasing inflammation. SFN alleviated the inflammation induced by LPS and NLRP3 agonists in RAW264.7 cells by decreasing the levels of reactive oxygen species. In summary, our results revealed the pathological roles of oxidative stress and NLRP3 in colitis, and indicated that SFN might serve as a natural NLRP3 inhibitor, thereby providing a new strategy for alternative colitis treatment.
Ulcerative colitis (UC) poses a threat to human health. The present study attempts to unravel the efficacy and potential mechanisms of paeoniflorin (PF), a naturally sourced active ingredient, for the management of UC. By establishing a DSS (dextran sulphate sodium)-induced experimental rat model of UC, this study found that PF was effective in ameliorating UC symptoms, inhibiting oxidative stress, inflammation and apoptosis, and repairing colonic epithelial damage. In addition, metabolomics revealed that PF may alleviate UC by primarily improving linoleic acid metabolism. Mechanistically, PF inhibited the CDC42/JNK signaling pathway by targeting CDC42. In particular, HuProtTM20K proteomics, molecular docking and MST revealed that PF is a novel CDC42 inhibitor. In LPS-treated Caco-2 cells, PF similarly inhibited oxidative stress, inflammation, and apoptosis and down-regulated the CDC42/JNK signaling pathway. Overall, PF inhibits oxidative stress, inflammation and apoptosis and repairs colonic epithelial damage through modulation of serum metabolites and inhibition of the CDC42/JNK signaling pathway, leading to alleviation of UC.
Intestinal barrier disruption and oxidative stress are the major pathological features during the ulcerative colitis (UC). The present research aimed to explore the amelioration property of fucoidan of Stichopus chloronotus (FucSc) against dextran sulfate sodium (DSS) resulted UC. The findings from our study suggest that treating with Fuc-Sc improved the integrity of the Caco-2 monolayer through raising its TEER value, reducing LDH release, promoting the tight junction proteins (TJs) in Caco-2 cells, and shielding the cells from decreases of these proteins caused by H2O2. Besides, Fuc-Sc activated Nrf2/HO-1 pathway to facilitate the antioxidant activities of Caco-2 cells under oxidative stress through elevating the SOD and GSH, and reducing LDH and MDA. Furthermore, oral administration of Fuc-Sc attenuated DSS resulted body weights decrease, DAI score increase, colon length decrease, and structural damage of colon tissue. Fuc-Sc also promoted the barrier function and suppressed oxidative injury via activation of Nrf2/HO-1 signal path. Collectively, this research provided the theoretical foundation for fucoidan as a promising functional food for colitis.
Curcumin (CUR) is a natural polyphenol that holds promise for treating ulcerative colitis (UC), yet oral administration of CUR exhibits limited bioavailability and existing formulations for oral delivery of CUR often suffer from unsatisfactory loading capacity. This study presents hydroxyethyl starch-curcumin microspheres (HC-MSs) with excellent CUR loading capacity (54.52 %), and the HC-MSs can further encapsulate anti-inflammatory drugs dexamethasone (DEX) to obtain a combination formulation (DHC-MSs) with high DEX loading capacity (19.91 %), for combination therapy of UC. The microspheres were successfully engineered, retaining the anti-oxidative and anti-inflammatory activities of parental CUR and demonstrating excellent biocompatibility and controlled release properties, notably triggered by α-amylase, facilitating targeted drug delivery to inflamed sites. In a mouse UC model induced by dextran sulfate sodium, the microspheres effectively accumulated in inflamed colons and both HC-MSs and DHC-MSs exhibited superior therapeutic efficacy in alleviating UC symptoms compared to free DEX. Moreover, mechanistic exploration uncovered the multifaceted therapeutic mechanisms of these formulations, encompassing anti-inflammatory actions, mitigation of spleen enlargement, and modulation of gut microbiota composition. These findings underscore the potential of HC-MSs and DHC-MSs as promising formulations for UC, with implications for advancing treatment modalities for various inflammatory bowel disorders.
BACKGROUND Amauroderma rugosum (AR) is a medicinal mushroom commonly used to treat inflammation, gastric disorders, epilepsy, and cancers due to its remarkable anti-inflammatory and anti-oxidative properties. This study was designed to evaluate the pharmacological effects of AR and its underlying mechanism of action against ulcerative colitis (UC) in vitro and in vivo. METHODS A UC mouse model was established by administration of dextran sulfate sodium (DSS). AR extract was administered intragastrically to mice for 7 days. At the end of the experiment, histopathology, macrophage phenotype, oxidative stress, and inflammatory status were examined in vivo. Furthermore, RAW 264.7, THP-1, and Caco-2 cells were used to elucidate the mechanism of action of AR in vitro. RESULTS AR extract (0.5-2 mg/mL) significantly suppressed lipopolysaccharide (LPS) and interferon-gamma (IFN-γ)-induced M1 macrophage (pro-inflammatory) polarization in both RAW 264.7 and THP-1 cells. LPS-induced pro-inflammatory mediators (nitric oxide, TNF-α, IL-1β, MCP-1, and IL-6) were reduced by AR extract in a concentration-dependent manner. Similarly, AR extract downregulated MAPK signaling activity in LPS-stimulated RAW 264.7 cells. AR extract elicited a concentration-dependent increase in the mRNA expression of M2 (anti-inflammatory) phenotype markers (CD206, Arg-1, Fizz-1, and Ym-1) in RAW 264.7 cells. Moreover, AR extract suppressed DSS-induced ROS generation and mitochondrial dysfunction in Caco-2 cells. The in vivo experiment revealed that AR extract (200 mg/kg) increased colon length compared to the DSS-treated group. In addition, disease activity index, spleen ratio, body weight, oxidative stress, and colonic inflammation were markedly improved by AR treatment in DSS-induced UC mice. Finally, AR suppressed M1 and promoted M2 macrophage polarization in UC mice. CONCLUSION The AR extract protected against DSS-induced UC by regulating macrophage polarization and suppressing oxidative stress. These valuable findings suggest that adequate intake of AR can prevent and/or treat UC.
BACKGROUND Epimedium polysaccharide (EPS) is a bioactive compound derived from the traditional Chinese herb Epimedium brevicornum. The objective of this study was to investigate the protective effects of EPS on ulcerative colitis (UC) and to elucidate the underlying mechanisms involved. RESULTS The findings showed that EPS treatment mitigated UC symptoms, including weight loss, anal bleeding, elevated disease activity index (DAI), and colon shortening. Hematoxylin and eosin (H&E) and Alcian blue-periodic acid-Schiff (AB-PAS) staining demonstrated that EPS alleviated histopathological damage and improved the integrity of the colonic mucosa. Mechanistically, EPS was found to substantially decrease inflammation by inhibiting the Toll-like receptor 4/nuclear factor-κB (TLR4/NF-κB) signaling pathway and to alleviate oxidative stress through modulation of the Kelch-like ECH-associated protein 1/nuclear factor erythroid-derived 2-like 2 (Keap1/Nrf2) pathway. Notably, EPS failed to exert protective effects against dextran sulfate sodium (DSS)-induced UC in Nrf2-knockout (Nrf2-/-) mice. Additionally, Western blotting and immunohistochemical analysis demonstrated that EPS facilitated autophagy via the adenosine monophosphate-dependent protein kinase/mammalian target of rapamycin (AMPK/mTOR) pathway. In vitro experiments revealed that EPS effectively suppressed lipopolysaccharide (LPS)-mediated cellular damage and oxidative stress by regulating Keap1/Nrf2 pathway. Transcriptomic analysis of LPS-treated Caco-2 cells following EPS treatment revealed a significant up-regulation of Nrf2 expression. CONCLUSION In conclusion, the findings of this study suggest that EPS exerts protective effects against DSS-induced UC through the inhibition of the TLR4/NF-κB signaling pathway, regulation of the Keap1/Nrf2 pathway, and promotion of autophagy via the AMPK/mTOR pathway. Consequently, EPS may represent a potential therapeutic target for the treatment of UC. © 2024 Society of Chemical Industry.
BACKGROUND Ulcerative colitis (UC) is a chronic inflammatory bowel disease marked by intestinal barrier dysfunction, oxidative stress, and inflammation. Biochanin A (BCA) is a natural flavonoid found in various plants, known for its anti-inflammatory, antioxidant, and anticancer properties, while its therapeutic role in UC and potential mechanism remains unexplored. PURPOSE To explores the therapeutic potential of BCA in alleviating UC, focusing on its effects on ferroptosis and the JAK2/STAT3 signaling pathway. METHODS The BCA's therapeutic effects on Dextran sulfate sodium (DSS)-induced colitis model in C57BL/6J mice was investigated. Subsequently, a comprehensive range of techniques was performed to investigate the impact of BCA on intestinal barrier integrity, oxidative stress, inflammation. Besides, the RNA sequencing was performed to explore the potential mechanism. The role of ferroptosis inhibition in BCA's effects in vitro and in vivo was explored by co-treating with the ferroptosis activator Erastin. RESULTS Treatment of colitis mice with BCA significantly improved DAI scores and histopathological damage scores, reduced oxidative stress, enhanced intestinal barrier function, and suppress inflammatory responses. RNA sequencing result found that BCA could lead to the inhibition of ferroptosis in mice colon tissue. Moreover, erastin co-treatment negated BCA's effects in vitro and vivo. Mechanistically, BCA exerts these effects by suppressing the JAK2/STAT3 pathway, which plays a pivotal role in ferroptosis and inflammation. Molecular docking studies further confirm the direct binding of BCA to both GPX4 and STAT3. CONCLUSION These results establish BCA as a promising natural compound for UC treatment, offering a novel therapeutic strategy by specifically targeting ferroptosis and its associated molecular pathways, thereby addressing key gaps in current UC management and advancing potential clinical applications.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized primarily by immune dysregulation. Its pathogenesis involves multiple factors, including dysregulation of T-cell subsets, hypersecretion of pro-inflammatory cytokines, imbalance in the gut microbiota, and disruption of the intestinal barrier. Among T-cell subsets, abnormal activation of Th1 and Th17 cells, in conjunction with Treg dysfunction, significantly amplifies local pro-inflammatory signals. Pro-inflammatory cytokines, such as TNF-α, IL-6, and IL-17, exacerbate apoptosis and disrupt tight junctions (TJs) in intestinal epithelial cells (IECs), thereby creating favorable conditions for invasion by pathogenic bacteria and their metabolites. Intestinal microecological imbalance not only leads to significant alterations in the structure of the bacterial flora but also involves abnormal fluctuations in its metabolites that directly regulate intestinal immune homeostasis, a factor closely associated with the severity of inflammation and prognosis of ulcerative colitis. Recent studies have demonstrated that in the treatment of UC, traditional Chinese medicine (TCM) achieves a multi-target, multi-pathway integrated intervention by regulating immune cell differentiation, balancing inflammatory factor levels, repairing the intestinal epithelial barrier, and remodeling the structure of the bacterial flora. This article reviews the pathogenic mechanisms underlying immune dysregulation in UC and the advances in research on TCM’s role in immune regulation, anti-inflammatory repair, and flora modulation, encompassing the mechanisms of action of individual active ingredients and classic TCM compound formulas. Although some studies have preliminarily confirmed TCM’s potential to modulate immunity and repair the intestinal barrier, breakthroughs in mechanism analysis, herb standardization, and large-scale validation remain forthcoming. It is anticipated that the unique advantages of TCM will be translated into a more precise therapeutic strategy for UC through modern molecular and systems biology approaches.
Background Ulcerative colitis (UC) is a debilitating inflammatory condition with growing global prevalence. While immune dysregulation is a known hallmark, the specific molecular drivers and their link to fibrosis remain incompletely characterized. To address this, we conducted a study combining bioinformatic analyses of public datasets with experimental validation to identify and validate key biomarker candidates involved in UC pathogenesis. Methods Three publicly available ulcerative colitis gene expression datasets (GSE38713, GSE87466, GSE119600) were retrieved from the Gene Expression Omnibus (GEO). Immune cell infiltration was evaluated using ssGSEA, with significant cell types identified by Wilcoxon test and LASSO regression. DEGs were screened and analyzed using GO, KEGG, and PPI networks. Hub genes were identified using cytoHubba and validated via ROC curves. RT-qPCR, WB, and IHC validated findings in UC rat models and clinical samples. Results The differentially expressed genes (DEGs) were evaluated using ten distinct algorithms, resulting in the identification of eight common DEGs following an intersection analysis. 4 hub genes were further identified through validation using the GSE119600 dataset, namely Cluster of Differentiation 274 (CD274), Matrix Metallopeptidase 1 (MMP1), neutrophil cytosolic factor 2 (NCF2), Plasminogen Activator Urokinase (PLAU). Notably, NCF2 demonstrated the highest specificity and sensitivity for diagnosing ulcerative colitis (UC), suggesting its potential utility as a diagnostic biomarker. Additionally, a distinct immune cell type exhibited significant differences between UC patients and healthy controls (HC). Correlation analyses utilizing bioinformatics techniques revealed that the hub genes CD274, MMP1, NCF2, and PLAU were positively associated with macrophage infiltration, highlighting their potential role in the immune response in UC. Conclusion CD274, MMP1, NCF2, PLAU can serve as hub genes associated with UC. Among these, NCF2 stands out as a particularly promising target for further research into the underlying mechanisms of UC. Additionally, NCF2 may play a role in the development and progression of UC by modulating macrophage infiltration.
Ulcerative colitis (UC) is a chronic inflammatory disease driven by immune dysregulation. PANoptosis, a novel form of programmed cell death, has been implicated in inflammatory diseases, but its specific role in UC remains unclear. This study aimed to identify PANoptosis‐related genes (PRGs) that may contribute to immune dysregulation in UC.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease marked by immune dysregulation, microbiota imbalance, and intestinal barrier damage. Unconjugated bilirubin (UCB) shows promise in treating UC due to its anti-inflammatory properties but is limited by poor solubility and potential toxicity. This study developed a chitosan-based controlled-release microsphere (CBMS) treatment to overcome these issues. CBMS utilizes the mucoadhesive properties of chitosan to achieve targeted, controlled UCB release in the colon, enhancing its stability and bioavailability. In a DSS-induced UC mouse model, CBMS alleviated clinical symptoms, reduced colon shortening, and improved histological outcomes, including reduced inflammation and enhanced mucosal repair. The mechanism involves CBMS retention in the intestinal lumen, UCB inactivation of digestive proteases, and restoration of microbiota balance, suppressing pro-inflammatory pathways. CBMS offers a promising new therapeutic strategy for UC and insights into polysaccharide-based drug delivery systems.
Ulcerative colitis (UC) is a chronic inflammatory disease primarily mediated by overactivated CD4+ T cells. Previous studies have suggested that natural killer (NK) cells may exert immunoregulatory effects by lysing autologous overactivated CD4+ T cells1-4. However, the precise regulatory and effector mechanisms of NK cells in UC remain unclear. Colon biopsy samples were collected from 6 newly diagnosed UC patients with active disease and 6 healthy volunteers. Using single-cell RNA sequencing, we identified NK and CD4+ T cell populations and analyzed their differentially expressed genes and associated enriched pathways. Flow cytometry was employed to detect the expression of NK cell surface receptors. Multiplex immunofluorescence was used to examine the expression and tissue distribution of NK and CD4+ T cells. Single-cell transcriptomic analysis revealed that KLRC1, the gene encoding the inhibitory receptor NKG2A, was highly expressed in NK cells from the intestinal tissue of active UC patients. Flow cytometry further confirmed a significant upregulation of NKG2A surface expression on NK cells derived from patient intestinal tissues. NKG2A is a transmembrane protein that, upon ligand binding, activates inhibitory signaling pathways within NK cells, thereby reducing their cytotoxic activity and impairing their ability to lyse target cells. These findings suggest that the capacity of intestinal NK cells to lyse activated CD4+ T cells may be suppressed in UC. Further analysis showed an increased abundance of CD4+ T cells in active UC intestinal tissues compared to healthy controls. Differentially expressed genes in these CD4+ T cells were significantly enriched in pathways related to cell proliferation, differentiation, and immune activation. Consistent with this, multiplex immunofluorescence demonstrated a marked infiltration of CD4+ T cells in patient tissues, with spatial co-localization observed between NK and CD4+ T cells. In the intestinal tissue of active ulcerative colitis (UC) patients, upregulation of the inhibitory receptor NKG2A on NK cells compromises their cytotoxicity against activated CD4+ T cells. This impairment facilitates the accumulation of pathogenic CD4+ T cells within the local immune microenvironment, thereby exacerbating intestinal inflammation. Our integrated analysis, combining single-cell RNA sequencing, flow cytometry, and multiplex immunofluorescence, elucidates a possible mechanism through which NK cell dysfunction contributes to immune dysregulation in UC. References: 1. Mora-Bitria L, Asquith B. Germline natural killer cell receptors modulating the T cell response. Front Immunol. 2024;15:1477991. 2. Wu X. Innate Lymphocytes in Inflammatory Arthritis. Front Immunol. 2020;11:565275. 3. Yang Y, Day J, Souza-Fonseca Guimaraes F, Wicks IP, Louis C. Natural killer cells in inflammatory autoimmune diseases. Clin Transl Immunology. 2021;10(2):e1250. 4. Zhao ZB, Lu FT, Ma HD, et al. Liver-resident NK cells suppress autoimmune cholangitis and limit the proliferation of CD4+ T cells. Cell Mol Immunol. 2020;17(2):178-189. Conflict of interest: Dr. Zhang, Yingzhi: No conflict of interest Guo, Hong: No conflict of interest
Ulcerative colitis (UC) involves immune dysregulation, barrier dysfunction, and dysbiosis, driving chronic inflammation and pain. Current treatments show limited efficacy and high toxicity. This study develops an engineered nanozyme, CO&MnOx@Hs (CMHs), synthesized via in-situ manganese oxide (MnOx) generation on halloysite nanotubes (Hs) with controlled encapsulation of the carbon monoxide (CO)-releasing molecule CORM-401 for gas therapy. CMHs selectively accumulate at inflamed UC sites, where MnOx scavenges reactive oxygen species (ROS) while CO exerts anti-inflammatory effects. These combined actions restore immune homeostasis, repair intestinal barrier, modulate gut microbiota, and alleviate inflammation-associated pain. In murine ulcerative colitis, CMHs outperform conventional treatments, demonstrating superior therapeutic efficacy. Mechanistic studies reveal that CMHs activate Nrf2/HO-1 for antioxidant effects while modulating PI3K-Akt and HIF-1α/LDHA pathways to promote M2 macrophage polarization and suppress NF-κB/TNF signaling. CMHs also fortify the intestinal barrier by mitigating bacterial invasion and ROS-induced damage while activating focal adhesion and ECM-receptor interaction. 16S ribosomal RNA sequencing further confirms CMHs' ability to remodel gut microbiota, reinforcing their immunomodulatory potential. Importantly, CMHs relieve chronic pain by reducing inflammation, inhibiting SP secretion and TACR1 expression, and suppressing TRPV1 channel activation and Ca2+ influx. These findings establish CMHs as a multi-targeted and highly effective therapeutic strategy for UC.
Ulcerative colitis (UC) is a heterogeneous autoimmune condition. PANoptosis, a new form of programmed cell death, plays a role in inflammatory diseases. This study aimed to identify differentially expressed PANoptosis-related genes (PRGs) involved in immune dysregulation in UC. Three key PRGs-BIRC3, MAGED1, and PSME2 were found using weighted gene co-expression network analysis (WGCNA) and machine learning. Immune infiltration analysis revealed that these key PRGs were associated with neutrophils, CD8+ T cells, activated CD4 T cells, and NK cells. Moreover, these key PRGs were significantly enriched in pathways related to inflammatory bowel disease, the IL-17 signaling pathway, and NOD-like receptor signaling pathway. The expression levels of the key PRGs were validated in various datasets, animal models, and UC intestinal tissue samples. Our findings confirmed the involvement of PANoptosis in UC and predict hub genes and immune characteristics, providing new insights for further investigations into UC pathogenic mechanisms and therapeutic strategies.
Ulcerative colitis (UC) is a chronic or recurrent inflammatory disease of the large intestine. Although the causes of UC are insufficiently understood, a complex interaction of several factors, including genetic factors, environmental factors, and gut microbiota, influences the onset of UC. The pathophysiology of UC involves intestinal barrier dysfunction, abnormal immune responses, and dysregulation of cytokines. Cytokine-targeted therapies have been approved for the treatment of UC, with several targeted therapies being currently available. The induction response rates range from 47.8 % to 73 %, and we often experience difficult-to-treat cases. In this review, we outlined the abnormal immune response and cytokine regulation underlying the complex pathology of UC. Moreover, we summarized the mode of action and the effects at the cellular and genetic levels of targeted therapies. A deeper understanding of the pathophysiology of UC and the effects of treatment is essential for advancing personalized medicine, which remains a key, challenging goal in the future management of UC.
Innate and adaptive immunity are intricately linked to the pathogenesis of ulcerative colitis (UC), with dysregulation of the Treg/Th17 balance and M2/M1 macrophage polarization identified as critical factors. Artesunate (ARS) has previously been shown to alleviate UC by inhibiting endoplasmic reticulum stress (ERS). To further investigate the regulatory effects of ARS on immune dysregulation associated with colitis and the role of ERS in this process, an experimental colitis model was established using dextran sulfate sodium (DSS). Flow cytometry was employed to assess changes in the Th17/Treg cell ratio in the spleen and macrophage polarization in the intestine, while RT-qPCR was used to quantify the transcription levels of relevant genes in colonic tissues. ARS treatment significantly mitigated DSS-induced pathological damage, reduced the proportion of CD4+Th17 cells, and downregulated the mRNA expression of IL-17A, IL-17F, and RORγt, while concurrently increasing the proportion of CD4+Treg cells and upregulating TGF-β expression. Additionally, ARS restored the DSS-induced decline in the M2/M1 macrophage ratio and enhanced the transcription of Arg-1 and IL-10, while suppressing the expression of pro-inflammatory markers, including iNOS, IL-1β, IL-6, and TNF-α. Notably, co-treatment with 4-phenylbutyric acid (4-PBA, ERS inhibitor) augmented the immunoregulatory effects of ARS, whereas 2-deoxy-D-glucose (2-DG, ERS agonist) co-treatment counteracted its protective activity against UC. These findings suggest that ERS plays a crucial role in mediating the therapeutic effects of ARS on UC, particularly by modulating Th17/Treg balance and macrophage polarization. This study provides further insights into the mechanistic basis of ARS in UC treatment offering a potential avenue for therapeutic intervention.
Histological healing is increasingly recognized as a sensitive marker of disease remission in ulcerative colitis (UC). However, the dynamics of mucosal T lymphocytes and proinflammatory cytokines during healing remain incompletely understood. In this paired, within-subject observational study (retrospective analysis of paired biopsies), colonic biopsy sets from 20 adult UC patients were analyzed during active inflammation and at a subsequent time point of histologic healing. Immunohistochemistry was performed for CD3, CD4, CD8, and IL-6. Lymphocyte densities were quantified in intraepithelial and lamina propria compartments, while IL-6 expression was scored semi-quantitatively. Histological activity was assessed using the Geboes score. Intraepithelial CD4+ T cells significantly decreased during histologic healing (mean 6.8 → 3.75 cells/100 epithelial cells, p < 0.05), whereas lamina propria CD4+ cells remained variably persistent, suggesting ongoing immune regulation. Intraepithelial CD8+ cells increased during remission, indicating a potential reparative or surveillance role. IL-6 expression markedly declined in epithelial and stromal compartments during healing, reflecting resolution of mucosal inflammation. Correlation analyses revealed enhanced coordination between CD4+ and CD8+ cells in the healing phase, consistent with immune homeostasis. Histologic healing in UC involves compartment-specific shifts in T lymphocyte populations and a marked reduction in IL-6 expression, reflecting coordinated immune regulation beyond clinical remission. These findings highlight the potential of combined cellular and cytokine biomarkers to monitor mucosal healing and guide immunomodulatory therapies.
Introduction and aim. Ulcerative colitis (UC) is a chronic inflammatory bowel disease (IBD) characterized by immune dysregulation and mucosal inflammation. Current UC biomarkers lack specificity, underscoring the need for novel diagnostic tools. Dipeptidyl peptidase-4 (DPP-4), a serine protease implicated in immune modulation and inflammation, and interleukin-7 (IL-7), a cytokine linked to mucosal immune dysregulation, may serve as dual biomarkers. This study aimed to evaluate the diagnostic utility of serum levels of DPP-4, C-reactive protein (CRP), and IL-7 to differentiate UC patients with UC from healthy individuals. Material and methods. This research conducted a case-control study involving 130 individuals, 65 diagnosed with UC and 65 apparently healthy individuals serving as the control group. Blood samples were obtained to measure DPP-4, IL-7, insulin and C-reactive protein levels. Results. The study demonstrated a significantly higher level of inflammatory markers compared to the healthy controls with a significantly higher CRP (23.38±17.76 vs. 2.38±0.89 mg/dL, p<0.001) and IL-7 concentrations (62.39±19.7 vs. 22.86±4.73 ng/L, p<0.001). and lower level of DPP-4 activity (1.33±0.19 vs. 2.37±0.35 U/L, p<0.001). ROC curve analysis revealed the excellent diagnostic performance of DPP-4 and IL-7 in identifying UC. Conclusion. Reduced serum DPP-4 levels and elevated levels of inflammatory markers (CRP and IL-7) highlight their utility as dual biomarkers for the diagnosis and monitoring of UC disease. DPP-4 expression is inversely correlated with inflammation. These biomarkers demonstrate diagnostic potential for UC; however, longitudinal studies are needed to assess their role in monitoring disease progression and response to treatment.
Dysregulated T-cell-mediated immune responses are a hallmark of inflammatory bowel diseases (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC). MicroRNAs (miRNAs) regulate various biological processes and play a significant role in the pathophysiology of numerous diseases. In this study, we aim to clarify the relationship between dysregulated immune response and altered miRNA signatures in patients with IBD. Our goal is to identify differentially expressed miRNAs that could potentially serve as diagnostic markers to differentiate between CD and UC. To quantify circulating miRNAs, we employed small RNA sequencing. To describe immune dysregulation, we determined the levels of circulating T-cell-related cytokines and the distribution of T-cell subpopulations in both circulation and in tissue samples. Our analysis revealed that 14 miRNAs exhibited significant expression differences between IBD patients and control subjects. These miRNAs may also implicate pathways associated with colitis-related colorectal carcinogenesis, suggesting their value in early risk assessment. Furthermore, we found that five miRNAs demonstrated a strong ability to discriminate between CD and UC patients. Additionally, levels of IL-22 and IFN-γ were significantly elevated in individuals with IBD. Notably, miRNA levels showed strong correlations with cytokine levels and T-cell subset distribution in both blood and tissue samples, exhibiting disease-specific patterns. In conclusion, we identified differentially expressed miRNAs in IBD patient groups, and a subset of these miRNAs might exhibit diagnostic potential to distinguish between CD and UC. Analyzing miRNAs in the blood of IBD patients may provide valuable insights into the underlying immune dysfunction.
Background Inflammatory bowel disease (IBD) presents unpredictable therapeutic responses and complex immune dysregulation. Current precision medicine approaches lack robust molecular tools integrating transcriptomic signatures with immune dynamics for personalized treatment guidance. Methods We performed multi-omics analyses of GEO datasets using machine learning algorithms (LASSO/Random Forest) to derive a four-gene signature. Validation employed ten algorithms and nomogram construction. Immune infiltration (CIBERSORT/ssGSEA), single-cell RNA sequencing, and DSS-colitis models characterized immune dynamics, cellular specificity, and therapeutic response modulation. Results We identified 536 differentially expressed genes significantly enriched in IL-17 signaling, TNF signaling, and cytokine-cytokine receptor interactions. WGCNA revealed six co-expression modules with disease-specific correlations: turquoise module strongly correlated with Crohn’s disease (r=0.6, P=4×10-20) and purple module with ulcerative colitis (r=0.55, P=1×10-16). The four-gene signature (CDC14A, PDK2, CHAD, UGT2A3) demonstrated exceptional diagnostic performance across ten validation algorithms (AUC range: 0.86-0.97), with the integrated nomogram achieving superior accuracy (AUC=0.952) compared to individual genes (CDC14A: 0.934, PDK2: 0.913, CHAD: 0.893, UGT2A3: 0.797). Consensus clustering stratified patients into two distinct molecular subtypes: Cluster 1 exhibited elevated M1 macrophages, activated dendritic cells, and neutrophils with enhanced glycolysis and mTORC1 signaling, while Cluster 2 showed higher signature gene expression, enhanced oxidative phosphorylation, and enrichment in regulatory immune populations including Tregs and M2 macrophages. Single-cell RNA sequencing revealed cell-type-specific expression patterns: PDK2 demonstrated widespread expression across epithelial cycling cells and stem cells, UGT2A3 showed preferential epithelial localization, and CDC14A exhibited selective enrichment in innate lymphoid cells. Nomogram-based risk stratification effectively predicted biologic treatment responses across multiple therapeutic classes using four independent treatment datasets (GSE16879, GSE92415, GSE73661, GSE206285): low-risk patients demonstrated superior response rates to golimumab (63.3%), infliximab (54.8%), and vedolizumab (29% vs. 15% in high-risk group). Connectivity Map analysis identified MS.275 as the top therapeutic enhancer, with experimental validation in DSS-induced colitis confirming synergistic anti-inflammatory effects with TNF-α inhibitors, improving disease activity indices and restoring signature gene expression patterns. Conclusion This mechanistically grounded four-gene signature enables precise IBD patient stratification across distinct immunological subtypes and predicts biologic responses, providing validated molecular tools for precision immunotherapy and personalized treatment optimization.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by oxidative stress, immune dysregulation, and compromised intestinal barrier integrity. Current therapeutic agents are frequently limited by safety concerns. To address this clinical challenge, we pioneered the development of an innovative nanotherapeutic system derived from the medicinal plant Atractylodes macrocephala via hydrothermal synthesis, which integrates antioxidant, anti-inflammatory, and barrier-restorative functionalities. Comprehensive characterization demonstrated that A. macrocephala-derived carbon dots (AM-CDs) possess a uniform particle size (∼5.0 nm), abundant surface hydrophilic groups, and exhibit potent antioxidant activity by scavenging over 95% of hydroxyl radicals (•OH) and superoxide anions (•O2-). AM-CDs confer therapeutic benefits via a tripartite mechanism: potent antioxidant activity, characterized by the direct elimination of excessive intestinal reactive oxygen species (ROS), thereby disrupting the oxidative stress cascade; anti-inflammatory modulation, evidenced by the significant downregulation of key pro-inflammatory cytokines, including TNF-α, IL-6, and IL-1β; and barrier reinforcement, demonstrated by enhanced secretion of mucin in the colonic mucus layer, restoration of intestinal epithelial tight junction proteins such as ZO-1 and occludin, and reduced infiltration of M1 macrophages and neutrophils. Mechanistic investigations revealed that these therapeutic benefits are mediated through coordinated regulation of critical signaling pathways, including PI3K-Akt, Jak-STAT, TGF-β, and MAPK, which synergistically orchestrate anti-inflammatory responses and barrier restoration. In conclusion, this study introduces an interdisciplinary approach termed "natural medicine-nanotechnology-multitarget modulation," which presents a multifunctional platform based on plant-derived carbon dots for the treatment of UC. The enhanced efficacy of AM-CDs, surpassing that of conventional 5-aminosalicylic acid (5-ASA) treatments, along with their favorable biosafety profile and potential for clinical translation, offers an innovative therapeutic strategy for the precise management of IBD.
Ulcerative colitis (UC) is a chronic, non-specific inflammatory bowel disease characterized by inflammation and injury of the colonic mucosa, exhibiting an increasing global incidence. Although research into UC pathogenesis is ongoing, the precise mechanisms remain to be fully elucidated. Studies indicate that UC development results from a complex interplay of factors, including genetic predisposition, environmental exposures, gut microbial dysbiosis, and immune dysregulation. Specifically, UC pathogenesis involves aberrant immune responses triggered by interactions between the host and gut microbiota. A complex, dynamic relationship exists between the microbial community and the host immune system throughout UC pathogenesis. Accumulating evidence suggests that changes in microbiota composition significantly impact gut immunity. This review will examine the intricate balance between the gut microbiota and mucosal immunity in UC progression and discuss potential therapeutic applications, providing a reference for further clinical treatment of this patient population.
Ulcerative colitis (UC), a chronic inflammatory bowel disease driven by gut dysbiosis, immune dysregulation, and oxidative stress, lacks universally effective therapies. Fucoidan (FCD), a sulfated polysaccharide derived from brown algae, has emerged as a multifaceted therapeutic candidate due to its anti-inflammatory, antioxidant, and immunomodulatory properties. This review synthesizes FCD’s mechanisms in UC pathogenesis, emphasizing its suppression of NF-κB and MAPK signaling pathways to reduce proinflammatory cytokines (e.g., IL-6, TNF-α) and regulate TLR-mediated macrophage polarization. FCD enhances intestinal barrier integrity via upregulation of tight junction proteins (Claudin-1, ZO-1) and mucin MUC2 expression, while remodeling gut microbial ecology through enrichment of SCFAs-producing bacteria (e.g., Ruminococcaceae) and suppression of pathogens (Escherichia coli, Candida albicans). Preclinical studies highlight LMWF as a superior candidate, demonstrating enhanced bioavailability and efficacy in mitigating DSS-induced colitis. Despite its promise, challenges persist in structural heterogeneity (source- and extraction-dependent), scalable production of LMWF, and insufficient pharmacokinetic data. Emerging strategies—including nanoparticle-based delivery systems and structural modifications (cross-linking, covalent bonding)—aim to overcome bioavailability limitations. This review underscores FCD’s potential as a functional food or adjuvant therapy for UC, while advocating for rigorous clinical validation to bridge translational gaps, Enrichment of SCFAs-producing taxa and suppression of pathobionts (Escherichia coli, Candida albicans), mediated through prebiotic fermentation. Suppression of NF-κB activation via IκBα stabilization and inhibition of p65 nuclear translocation, and downregulation of MAPK phosphorylation (ERK1/2, JNK, p38), reducing proinflammatory cytokines (IL-6, TNF-α, IL-1β). FCD can be used as a potential treatment for UC.
Ulcerative colitis (UC) is manifested by excessive oxidative stress and immune dysregulation in the colonic microenvironment. To address these pathological features, we developed a microfluidics-engineered oral delivery system comprising methacrylated hyaluronic acid (HAMA) hydrogel microspheres encapsulating polydopamine-coated selenium nanoparticles (CS-Se@PDA). The uniform microspheres featured a microfluidics-enabled structure that enabled stable CS-Se@PDA nanoparticles anchoring via electrostatic and covalent interactions. The PDA coating enhanced the stability, mucosal adhesion, and scavenging of reactive oxygen species (ROS) of the nanoparticles. At the same time, the HAMA shell provided pH-responsive protection and CD44-mediated targeting to inflamed colonic tissues. In vitro studies demonstrated excellent biocompatibility, effective ROS neutralization, and macrophage polarization toward the anti-inflammatory M2 phenotype. In a dextran sulfate sodium-induced colitis mouse model, oral administration of these microspheres significantly alleviated clinical symptoms, including ∼25 % mitigation of weight loss, increased colon length from 4.78 ± 0.3 cm to 6.83 ± 0.25 cm, and reduced histological damage. Furthermore, the treatment restored tight junction protein expression to approximately 60 % of normal levels for ZO-1 and about 55 % for Occludin, indicating substantial epithelial barrier repair, and effectively suppressed pro-inflammatory cytokines such as TNF-α and IL-6. Overall, this microfluidics-enabled, colon-targeted delivery system with integrated antioxidative and immunomodulatory functions offers a promising strategy for the non-invasive treatment of UC and other inflammation-associated gastrointestinal disorders.
Dietary content and eating behavior in ulcerative colitis: a narrative review and future perspective
Ulcerative colitis (UC) has experienced a steady increase in global incidence and prevalence recently. Current research into UC pathogenesis focuses on the complex interplay of genetic and environmental factors with the immune system and gut microbiome, leading to disruption of the intestinal barrier. Normally, the microbiome, intestinal epithelium, and immune system interact to maintain intestinal homeostasis. However, when this equilibrium is disturbed, a harmful cycle of dysbiosis, immune dysregulation, and inflammation emerges, resulting in intestinal barrier dysfunction and UC progression. Among various risk factors, diet significantly influences epithelial barrier integrity and architectural stability through both direct and indirect mechanisms, shaping the entire UC continuum from pre-clinical prevention to active phase treatment and remission maintenance. This review provides insights into the impact of dietary content and eating behaviors on UC, focusing on specific food, food groups, nutrients, and intermittent fasting, while providing a detailed explanation of why the gut microbiota may mediate the sustained effects of diet across all stages of UC. Additionally, it addresses the limitations of current studies, explores underexamined areas in UC dietary research and proposes potential directions for future research and expansion. Not applicable.
The global prevalence of ulcerative colitis (UC) and Crohn’s disease (CD) is increasing, placing greater burdens on national health systems. The pathophysiology of diarrhea, the commonest debilitating symptom in UC and CD patients, has been studied more extensively in UC, where it reflects defective colonic Na+ absorption combined with changes in colonic Cl- and K+ transport which greatly reduce colonic water absorption. Dysfunctional ion transport in patients with UC is accompanied by abnormalities in tight junctional protein distribution and function, which cause the inflamed colonic epithelium to become ‘leakier’. Progress in understanding how abnormal colonic ion transport in UC might be influenced pharmacologically has been hampered by the low availability of clinical material. To counter this, various animal models of acute colitis have been developed, but differ in the way mucosal inflammation is induced. Identifying models that closely mimic human UC in terms of pathology and ion transport abnormalities remains challenging. However, the introduction of human colonic epithelial organoids (colonoids) has added a new and exciting dimension to research in this area. Here, we review current knowledge about abnormal colonic ion transport and barrier function in experimental and human colitis as well as the use and potential of human colonoids to better understand the pathophysiology of UC, which may ultimately lead to novel approaches to the treatment of diarrhea in this disease.
Background Sophocarpine, a quinoline alkaloid derived from Sophora alopecuroides L., is known for its anti-inflammatory effects. These effects are achieved by modulating both nuclear factor-κB (NF-κB) pathway and node-like receptors pyrin domain containing 3 (NLRP3) inflammasome. However, whether sophocarpine could alleviate colonic inflammation requires further exploration. Objectives The present work focused on investigating the potential of sophocarpine for treating colonic epithelial barrier dysfunction in ulcerative colitis. Materials and Methods An inflammatory model was initially developed using human colorectal adenocarcinoma cells (Caco-2) induced by lipopolysaccharide (LPS) and tumor necrosis factor-α (TNF-α), which was used for investigating how sophocarpine affected inflammation-mediated colonic epithelial barrier function and monitoring levels of inflammatory responses. Besides, the colonic epithelial barrier integrity was evaluated through measuring transepithelial/transendothelial electrical resistance (TEER). Lastly, we conducted Western blotting for assessing zonula occludens-1 (ZO-1), claudin-1, p65, p-p65, IκBα, p-IκBα, MLC, p-MLC, and myosin light chain kinase (MLCK) protein levels. Besides, the beneficial effect of sophocarpine was also evaluated in a mouse mode of ulcerative colitis. Results Upon LPS stimulation, Caco-2 cells exhibited enhanced TNF-α and interleukin (IL)-1β levels, along with reduced IL-4 and IL-10 levels, decreased TEER values, increased fluorescein isothiocyanate (FITC)-dextran concentrations, and suppressed ZO-1 and claudin-1 protein levels. In contrast, sophocarpine treatment at varying concentrations attenuated the detrimental effects of LPS induction. Notably, sophocarpine could reverse TNF-α-induced colonic epithelial barrier dysfunction through significantly decreasing p65, IκBα, and MLC protein phosphorylation levels within LPS-treated Caco-2 cells. Sophocarpine administration also mitigated inflammatory damages within the ulcerative colitis mouse model. Conclusion According to these findings, sophocarpine prevents inflammatory damage in the colonic epithelial barrier by targeting the NF-κB/MLCK/MLC signaling pathway, indicating a novel intervention strategy to ameliorate ulcerative colitis.
No abstract available
The specific pathogenesis of UC is still unclear, but it has been clear that defects in intestinal barrier function play an important role in it. There is a temporary lack of specific drugs for clinical treatment. Astragaloside IV (AS-IV) is one of the main active ingredients extracted from Astragalus root and is a common Chinese herbal medicine for the treatment of gastrointestinal diseases. This study aimed to determine whether AS-IV has therapeutic value for DSS or LPS-induced intestinal epithelial barrier dysfunction in vivo and in vitro and its potential molecular mechanisms. The intestinal tissues from UC patients and colitis mice were collected, intestinal inflammation was observed by colonoscopy, and mucosal barrier function was measured by immunofluorescence staining. PI3K/AKT signaling pathway activator YS-49 and inhibitor LY-29 were administered to colitic mice to uncover the effect of this pathway on gut mucosal barrier modulation. Then, network pharmacology was used to screen Astragaloside IV (AS-IV), a core active component of the traditional Chinese medicine Astragalus membranaceus. The potential of AS-IV for intestinal barrier function repairment and UC treatment through blockade of the PI3K/AKT pathway was further confirmed by histopathological staining, FITC-dextran, transmission electron microscopy, ELISA, immunofluorescence, qRT-PCR, and western blotting. Finally, 16 S rRNA sequencing was performed to uncover whether AS-IV can ameliorate UC by regulating gut microbiota homeostasis. Mucosal barrier function was significantly damaged in UC patients and murine colitis, and the activated PI3K/AKT signaling pathway was extensively involved. Both in vivo and vitro showed that the AS-IV-treated group significantly relieved inflammation and improved intestinal epithelial permeability by inhibiting the activation of the PI3K/AKT signaling pathway. In addition, microbiome data found that gut microbiota participates in AS-IV–mediated intestinal barrier recovery as well. Our study highlights that AS-IV exerts a protective effect on the integrality of the mucosal barrier in UC based on the PI3K/AKT pathway, and AS-IV may serve as a novel AKT inhibitor to provide a potential therapy for UC.
Disruption of intestinal epithelial barrier is the major pathological characteristics of ulcerative colitis (UC). Palmatine (PAL) is a natural isoquinoline alkaloid derived from various traditional Chinese herbal medicines. The present study reported that PAL exerted anti-UC effects via protecting against intestinal epithelial cell injury and alleviating intestinal barrier dysfunction. In dextran sulfate sodium (DSS)-induced mice UC model, PAL alleviated symptoms like weight loss, diarrhea, rectal bleeding, colon shortening, and colon damage. In particular, PAL reduced intestinal permeability and FITC-dextran leakage, prevented the loss of goblet cells, increased expressions of mucins, tight junction (TJ) and adherens junction (AJ) proteins. In HCoEpiC cells, PAL promoted cell proliferation, inhibited apoptosis, improved cell barrier function by reducing the penetration of FITC-dextran across the cell barrier and increasing transepithelial electrical resistance. By using the Cellular Thermal Shift Assay (CETSA) and liquid chromatography-tandem mass spectrometry (LC-MS/MS) proteomics technology, we identified Enolase 3 (ENO3) as the direct molecular target of PAL. CETSA, DARTS, and molecular docking confirmed PAL binds ENO3 and upregulates its expression. The protective effects of PAL on intestinal inflammation and barrier dysfunction were abolished when co-treated with ENOblock (an ENO3 inhibitor) or ENO3 knockdown by small interfering RNA, confirming that PAL alleviates UC by targeting ENO3. Mechanistically, Seahorse assays and ATP detection confirmed that PAL inhibits intestinal epithelial cell glycolysis to alleviate UC symptoms. In conclusion, our findings identify PAL as a novel phytochemical that displays anti-UC efficacy via targeting ENO3, endorsing its potential utility as a therapy for treatment of UC.
BACKGROUND Oxymatrine (OMT), an alkaloid isolated from Sophora flavescens Ait., is effective in treating ulcerative colitis (UC). However, its molecular mechanism of action remains unclear. PURPOSE This research aimed to assess the therapeutic effects of OMT on chronic UC and to elucidate the underlying mechanisms. METHODS The therapeutic effects of the water extract of the root of Sophora flavescens Ait. (WSF) and OMT were evaluated using a chronic UC mouse model. Proteomic analysis was conducted to elucidate the underlying mechanisms. Apoptosis models of HCT116 and Caco-2 cells, induced by TNF-α and IFN-γ were employed to assess the impact of OMT and its in vivo metabolite, matrine (MAT), on intestinal epithelial barrier (IEB) dysfunction. Cellular thermal shift assay (CETSA), drug affinity responsive target stability (DARTS), and microscale thermophoresis (MST) were used to evaluate the direct binding affinity of OMT to its targets. The target protein was knocked down via lentiviral transfection to further investigate the effects of OMT and MAT. RESULTS WSF and OMT alleviated chronic UC by inhibiting inflammation and improving IEB function. Proteomic analysis revealed that desmoglein-2 (Dsg2) was significantly upregulated. In an intestinal epithelial cell apoptosis model, OMT and MAT reduced Dsg2 cleavage, thereby enhancing cell adhesion and improving IEB function. OMT stabilized Dsg2 by directly binding to it. The therapeutic effects of OMT and MAT were diminished when Dsg2 was knocked down. Additionally, OMT and MAT inhibited caspase-8 activity, which was responsible for Dsg2 cleavage. CONCLUSIONS Dsg2 was identified as a target of OMT, contributing to its therapeutic benefits in UC. OMT therapy effectively inhibited Dsg2 cleavage by directly binding to it and suppressing caspase-8 activity, thereby enhancing IEB function.
Ulcerative colitis (UC) is a chronic inflammatory disorder characterized by an impaired intestinal epithelial barrier. The complex etiology of UC includes genetic, environmental, immune and microbial factors. It has recently been proposed that dysregulated ketogenesis may play a role in the development of UC; however, the precise mechanism by which this occurs remains unclear. In this study, mice were treated with dextran sulfate sodium to induce UC. UC mice exhibited intestinal epithelial barrier dysfunction characterized by loss of tight junctions in intestinal epithelial cells (IECs) and an imbalance in the Th17/Treg ratio in the peripheral blood. A significant decrease in the ketogenic rate-limiting enzyme HMGCS2 was observed in the IECs of UC mice, which was responsible for the decrease of β-hydroxybutyric acid production. Notably, UC mice treated with artesunate (ART) showed increased HMGCS2 and ketogenesis, as well as restored Th17/Treg and recovered tight junction protein expression. These factors contributed to intestinal epithelial barrier repair and alleviated colitis. The addition of an AMPK inhibitor or mTOR activator effectively reversed the effects of ART on ketogenesis, thereby preventing subsequent restoration of the intestinal barrier. These findings were confirmed in vitro in DSS-treated colonocytes. In conclusion, ART facilitated intestinal epithelial barrier repair in UC by stimulating HMGCS2-dependent ketogenesis in IECs through the AMPK/mTOR signaling pathway.
Background Intestinal epithelial barrier dysfunction is intricately linked to the pathogenesis of ulcerative colitis (UC). Dietary interventions that bolster intestinal epithelial barrier function can effectively thwart UC onset. Our prior research revealed that p-Hydroxy benzaldehyde (HD), a phenolic compound from Nostoc commune (an edible cyanobacterium), markedly upregulated the expression of E-cadherin, a pivotal protein in intestinal mucosa, thereby mitigating mucosal damage in mice afflicted with dextran sulfate sodium (DSS)-induced colitis. Nevertheless, the precise molecular mechanisms underpinning HD’s ameliorative effects on intestinal epithelial barrier dysfunction remain elusive. Methods Dextran sodium sulfate (DSS)-induced colitis mouse model was established, and the successful establishment of the model was determined by evaluating the changes in body weight, disease activity index (DAI), colonic histopathology, and white blood cell count. Transmission electron microscopy (TEM) observed the ultrastructural changes of intestinal villi. The levels of inflammatory factors ( IFN-γ IL-13 ) and intestinal permeability indicators (FITC-Dextran, DAO, ET, and D-LA ) were detected by Enzyme-linked immunosorbent assay (ELISA). Western blotting (WB) and immunohistochemistry (IHC) were used to detect the expression of intestinal barrier integrity-related factors such as tight junction protein TJs (ZO-1, occludin) and adhesion junction protein AJs (E-cadherin). Furthermore, WB, Pull-down assay, drug affinity reaction target stability (DARTS) assay, molecular docking and molecular dynamics (MD) simulation were used to determine the potential target and molecular mechanism of HD. Results HD intervention significantly alleviated the symptoms of colitis mice, inhibited the weight loss and colon shortening, reduced DAI score and colon pathological score, maintained the ultrastructure of intestinal villi in colon tissue, and significantly reduced the inflammatory factors IFN-γ, IL-13 and the number of white blood cells in colon tissue of colitis mice. HD could also reduce the levels of FITC-Dextran, DAO, ET, and D-LA and increase the expression of ZO-1, occludin, and E-cadherin in the colonic tissues of colitis mice, thereby maintaining the impaired intestinal barrier function caused by colitis. Mechanically, HD augmented the expression of hepatocyte nuclear factor 1β (HNF-1β) and DRA. Adeno-associated virus (AAV)-HNF-1β shRNA or Lentivirus-mediated HNF-1β knockdown effectively abolished HD-induced intestinal barrier protection, as well as the promotion of solute carrier family 26 member 3 (SLC26A3) expression levels. SLC26A3 siRNA effectively reversed the inhibition of intestinal permeability by HD. Pull-down assay, DARTS analysis, molecular docking, and MD results showed high binding strength, interaction efficiency and remarkable stability between HNF-1β and HD. Conclusion This study elucidates HD’s role in forestalling intestinal epithelial barrier disruption under colitis conditions. Mechanistic investigations revealed that HD fortifies TJs and AJs expression via the HNF-1β/SLC26A3 pathway, thus preserving the lower intestinal epithelial barrier’s integrity in UC.
Ulcerative colitis (UC) is a chronic relapsing inflammatory bowel disease characterized by persistent mucosal inflammation of the colon and rectum. Although the exact etiology of UC remains incompletely understood, accumulating evidence suggests that intestinal barrier dysfunction plays a central role in disease initiation, progression, and recurrence. The intestinal barrier is a complex system composed of the epithelial layer, tight junction proteins, mucus layer, immune components, and gut microbiota, which together maintain mucosal homeostasis and protect against luminal pathogens and antigens. In UC, impairment of epithelial integrity, altered tight junctions, goblet cell depletion, mucus layer defects, microbial dysbiosis, and exaggerated immune activation contribute to increased intestinal permeability and sustained inflammation. Recent studies have highlighted multiple mechanisms underlying barrier dysfunction in UC, including inflammatory cytokine-mediated signaling, oxidative stress, mitochondrial injury, and dysregulated cell death pathways. Moreover, restoration of barrier integrity has emerged as an important therapeutic goal. Conventional anti-inflammatory agents, biologics, small-molecule compounds, microbiota-based therapies, and several emerging approaches may exert beneficial effects at least partly through improving barrier function. In this review, we summarize the structural and functional components of the intestinal barrier, discuss the major mechanisms of barrier dysfunction in UC, and highlight current and potential therapeutic strategies targeting barrier restoration. A better understanding of intestinal barrier impairment may provide new insights into the pathogenesis of UC and facilitate the development of more effective and personalized treatment approaches.
Ulcerative colitis (UC) is characterized by intestinal barrier dysfunction and chronic inflammation, yet its underlying mechanisms remain incompletely understood. This study investigates the role of Six-transmembrane epithelial antigen of the prostate 4 (STEAP4), a metalloreductase linked to redox regulation, in UC pathogenesis. Using clinical samples from IBD patients, a dextran sulfate sodium (DSS)-induced murine colitis model, and lipopolysaccharide (LPS)-treated intestinal epithelial cells (NCM460 and HT-29), we demonstrated that STEAP4 expression was significantly upregulated in inflamed mucosa across human, murine, and in vitro models. H&E staining, and Western blot analyses verified the successful modeling of DSS-induced colitis mice. STEAP4 knockdown via siRNA restored tight junction protein claudin-1 expression (p < 0.05; n=3), increased TEER value (p < 0.001; n=3), decreased the permeability of FITC-D (p < 0.01, p < 0.001; n=3) and suppressed LPS-induced pro-inflammatory cytokines (TNF-α, IL-6) (p < 0.05; n=3) by attenuating NF-κB phosphorylation (p65, IκBα) (p < 0.05, p < 0.01, p < 0.001; n=3). These findings position STEAP4 as a critical regulator of mucosal inflammation, bridging redox homeostasis, epithelial barrier function, and NF-κB-driven immune responses. Our study highlights STEAP4 as a potential therapeutic target for restoring intestinal homeostasis in UC, warranting further exploration of its molecular interactions and translational applications.
Macrophage polarization is critically involved in the initiation and progression of ulcerative colitis (UC); however, whether microvesicles (MVs) released from macrophages with distinct polarization states exert different effects on the intestinal epithelial barrier and endoplasmic reticulum (ER) stress remains unclear. Here, MVs were isolated from M0, M1, and M2 macrophages and evaluated in a dextran sulfate sodium (DSS)-induced mouse colitis model and an inflammatory cytokine-stimulated NCM460 epithelial cell model. M2 macrophage-derived MVs (M2-MVs) mitigated body-weight loss, disease activity, colon shortening, and histopathological injury and partially restored Claudin-1, Occludin, ZO-1, and MUC2 expression. In contrast, M1 macrophage-derived MVs (M1-MVs) tended to aggravate inflammation and barrier disruption. Mechanistically, M2-MVs reduced IL-1β, TNF-α, and IL-6, increased IL-10, and inhibited GRP78, PERK/eIF2α phosphorylation, CHOP, and cleaved caspase-3. Consistent effects were observed in vitro, where M2-MVs restored barrier proteins and reduced ER stress and apoptosis. Moreover, the ER-stress inhibitor 4-phenylbutyric acid attenuated the detrimental effects of M1-MVs, supporting ER stress as an important downstream mechanism. By systematically comparing MVs from M0, M1, and M2 macrophages in parallel, this study reveals a polarization-dependent, bidirectional pattern of macrophage–epithelial communication in experimental colitis and provides preclinical evidence supporting M2-MVs as candidate cell-free effectors for intestinal mucosal repair.
The intestinal epithelial barrier, among other compartments such as the mucosal immune system, contributes to the maintenance of intestinal homeostasis. Therefore, any disturbance within the epithelial layer could lead to intestinal permeability and promote mucosal inflammation. Considering that disintegration of the intestinal epithelial barrier is a key element in the etiology of ulcerative colitis, further assessment of barrier integrity could contribute to a better understanding of the role of epithelial barrier defects in ulcerative colitis (UC), one major form of chronic inflammatory bowel disease. Herein, we employ fast, non-destructive, and label-free non-linear methods, namely coherent anti-Stokes Raman scattering (CARS), second harmonic generation (SHG), two-photon excited fluorescence (TPEF), and two-photon fluorescence lifetime imaging (2P-FLIM), to assess the morpho-chemical contributions leading to the dysfunction of the epithelial barrier. For the first time, the formation of epithelial barrier gaps was directly visualized, without sophisticated data analysis procedures, by the 3D analysis of the colonic mucosa from severely inflamed UC patients. The results were compared with histopathological and immunofluorescence images and validated using transmission electron microscopy (TEM) to indicate structural alterations of the apical junction complex as the underlying cause for the formation of the epithelial barrier gaps. Our findings suggest the potential advantage of non-linear multimodal imaging is to give precise, detailed, and direct visualization of the epithelial barrier in the gastrointestinal tract, which can be combined with a fiber probe for future endomicroscopy measurements during real-time in vivo imaging.
Benign anorectal disorders and ulcerative colitis (UC) are typically managed as separate clinical conditions, despite growing recognition of overlapping pathophysiological features. Constipation, hemorrhoidal disease, anal fistula and colonic mucosal inflammation may converge on partially shared molecular pathways involving microbial dysbiosis, altered microbial metabolite generation, epithelial barrier impairment, immune activation, stromal remodeling and dysregulated tissue repair, although the strength of mechanistic evidence varies substantially among these conditions. This review synthesizes advances from the past decade to propose a translational molecular medicine framework for investigating potential molecular connections among anatomically distinct anorectal and colonic disorders, without assuming shared causal origins. Clinical and pathological associations between disordered defecation, hemorrhoidal vascular remodeling, fistula persistence and UC are contextualized alongside current insights into gut and anorectal microbiota dysbiosis, short-chain fatty acid signaling, bile acid metabolism, tryptophan metabolite activity, gas-producing microbial communities, mucus biology, tight junction function, innate and adaptive immune responses, and fibro-inflammatory repair processes. Integrating microbiome profiling, metabolomics, transcriptomics, single-cell and spatial analyses with causal inference provides a cross-disease framework for resolving convergent molecular states associated with recurrence, healing and therapeutic response. By moving beyond disease-by-disease description, this strategy may uncover biomarkers and actionable pathways otherwise overlooked, supporting mechanism-informed prevention, perioperative optimization and individualized intervention across anorectal disorders and inflammatory bowel disease (IBD).
No abstract available
No abstract available
Periodontitis and ulcerative colitis (UC) are inflammatory diseases linked through the “gum-gut” axis. Fusobacterium nucleatum, an important periodontitis-associated pathobiont and gastrointestinal opportunist, may mediate their comorbidity. This study investigated the role of F. nucleatum in UC using dextran sulfate sodium-induced UC and F. nucleatum-induced periodontitis models. F. nucleatum exacerbated inflammatory alveolar bone loss and intestinal barrier dysfunction, accelerating UC severity. Integrated 16S rRNA gene sequence and LC-MS metabolomics revealed ferroptosis activation, characterized by elevated Fe2+ and malondialdehyde, glutathione depletion, dysregulated GPX4, FTH1, and ACSL4 expression, reduced mitochondrial membrane potential, and reactive oxygen species aggregation in the mouse colon and colonic epithelial cell CCD841. Administration of ferroptosis inhibitor Ferrostatin-1 attenuated UC by restoring intestinal permeability, preserving mucin layers, and enhancing tight junction proteins ZO-1 and CLDN-1. These findings establish F. nucleatum as a key mediator of periodontitis-UC comorbidity through ferroptosis-mediated gut barrier disruption, providing mechanistic insights into microbial-driven inflammatory cross-talk.
Background: Ulcerative colitis (UC), characterized by chronic intestinal inflammation, epithelial barrier dysfunction, and immune imbalance demands novel ameliorative strategies beyond conventional approaches. Methods: In this study, the probiotic properties of Lactobacillus paracasei L21 (L. paracasei L21) and its ability to ameliorate colitis were evaluated using an in vitro lipopolysaccharide (LPS)-induced intestinal crypt epithelial cell (IEC-6) model and an in vivo dextran sulfate sodium (DSS)-induced UC mouse model. Results: In vitro, L. paracasei L21 decreased levels of pro-inflammatory cytokines (TNF-α, IL-1β, IL-8) while increasing anti-inflammatory IL-10 levels (p < 0.05) in LPS-induced IEC-6 cells, significantly enhancing the expression of tight junction proteins (ZO-1, occludin, claudin-1), thereby restoring the intestinal barrier. In vivo, both viable L. paracasei L21 and its heat-inactivated postbiotic (H-L21) mitigated weight loss, colon shortening, and disease activity indices, concurrently reducing serum LPS and proinflammatory mediators. Interventions inhibited NF-κB signaling while activating HIF1α/AhR pathways, increasing IL-22 and mucin MUC2 to restore goblet cell populations. Gut microbiota analysis showed that both interventions increased the abundance of beneficial gut bacteria (Lactobacillus, Dubococcus, and Akkermansia) and improved faecal propanoic acid and butyric acid levels. H-L21 uniquely exerted an anti-inflammatory effect, marked by the regulation of Dubosiella, while L. paracasei L21 marked by the Akkermansia. Conclusions: These results highlight the potential of L. paracasei L21 as a candidate for the development of both probiotic and postbiotic formulations. It is expected to provide a theoretical basis for the management of UC and to drive the development of the next generation of UC therapies.
BACKGROUND Coptisine is a bioactive isoquinoline alkaloid derived from Coptis Chinensis, exhibiting significant pharmacological potential. Emerging evidence suggests its therapeutic efficacy in gastrointestinal disorders through modulating inflammation and maintaining gut homeostasis. PURPOSE The study aimed to elucidate the molecular mechanisms underlying coptisine mediated restoration of intestinal barrier integrity in ulcerative colitis (UC) and TNF-α challenged intestinal organoids. METHODS A murine UC model was established by dextran sulfate sodium (DSS) induction to evaluate coptisine's therapeutic effects on colonic inflammation and mucosal barrier dysfunction. Complementary in vitro investigations were conducted using TNF-α-challenged HT-29 cells and intestinal organoids derived from wild-type mice to assess epithelial barrier repair capabilities. Additionally, we utilized an integrated experimental approach incorporating cellular thermal shift assay, luciferase reporter assays to explore the influence of coptisine on AhR activation. Lastly, specific AhR dependency of coptisine on barrier protective effects were further validated through three independent model systems: shAhR-transfected HT-29 cells, AhR KO murine intestinal organoids, and AhR KO mice subjected to DSS challenge. RESULTS Coptisine administration significantly attenuated colitis severity in DSS-treated mice, evidenced by reduced histopathological scores, decreased colonic inflammation, and enhanced gut barrier integrity through upregulation of tight junction proteins (TJ proteins). In a barrier dysfunction model of TNF-α stimulation in HT-29 cells and intestinal organoids, coptisine treatment effectively normalized the expression levels of TJ proteins. Mechanistically, coptisine exhibited potent AhR activation through increased nuclear translocation and transcriptional regulation of CYP1A1. Coptisine dose-dependently inhibited reactive oxygen species (ROS) production and NF-κB activation in TNF-α treated HT-29 cells. Crucially, AhR knockdown or knockout completely abolished coptisine's inhibitory effects on NF-κB activation and the protective efficacy in barrier function, confirming pathway dependency. CONCLUSION Coptisine ameliorates intestinal barrier dysfunction and improves UC related symptom in an AhR-dependent manner. This mechanistic insight positions coptisine as a promising phytochemical candidate for UC therapy.
Ulcerative colitis (UC), a chronic idiopathic inflammatory bowel disease affecting the colonic mucosa, has seen a rising global incidence and poses a growing public health challenge. The clinical presentation typically includes recurrent abdominal pain, hematochezia, weight loss and structural damage to the colonic epithelium, substantially impacting patients' quality of life. Recent research has underscored the role of intestinal barrier dysfunction as a fundamental driver of persistent inflammation and disease progression in UC. Intestinal epithelial cells (IECs) form a monolayer through tight intercellular junctions and constitute the primary defense against luminal pathogens. Dysregulation of programmed cell death pathways in IECs such as apoptosis, necroptosis, pyroptosis, ferroptosis and autophagy-related cell death compromises epithelial integrity and exacerbates inflammation. The present review systematically examines how these death pathways contribute to UC pathogenesis, highlighting the molecular mechanisms through which natural bioactive compounds and nanoparticle-based drug delivery systems modulate them. Key signaling targets include the NF-κB pathway, MAPK cascade, NLR family pyrin domain containing 3 inflammasome and autophagy-related networks. By integrating advances in target identification, structure-activity relationship optimization and mechanistic insights, the present review provides a comprehensive framework for understanding UC and facilitates the development of innovative therapeutic approaches aimed at restoring barrier function and regulating epithelial cell death.
No abstract available
Spermidine (SPD), a microbiota‑derived polyamine, exerts potent anti‑inflammatory effects in colitis. This study investigated how SPD mitigates dextran sulfate sodium (DSS)-induced ferroptosis and explored the association between gut microbiota composition and polyamine metabolites in patients with ulcerative colitis (UC). DSS‑induced UC models were established in mice and HT‑29 cells, followed by SPD treatment. RNA sequencing was used to profile transcriptomic changes in HT‑29 cells, and the effects of SPD on NCOA4 and Ferritin were evaluated both in vivo and in vitro. NCOA4 silencing was performed to clarify its role in SPD‑mediated protection against ferroptosis. Fecal polyamines and gut microbiota profiles from UC patients and healthy controls were analyzed using UHPLC‑MS/MS and 16S rRNA sequencing. SPD significantly alleviated DSS‑induced colitis. Gene set enrichment analysis (GSEA) of differentially expressed genes in HT‑29 cells highlighted iron‑metabolism pathways as prominently affected. SPD mitigated DSS‑induced ferroptosis in vitro and in vivo, likely by limiting NCOA4‑dependent ferritin turnover and maintaining iron balance. In UC patients, disturbances in fecal polyamine levels corresponded closely with shifts in gut microbial composition, with 27 genera showing significant correlations with polyamine metabolites. Together, these findings position SPD as a modulator of ferroptosis via the NCOA4-ferritin axis and point to a potential therapeutic avenue. In UC, disrupted polyamine metabolites are closely linked to microbial alterations, implicating microbe-polyamine interactions in disease pathogenesis.
Background Ulcerative colitis (UC) is a chronic, relapsing inflammatory bowel disease characterized by continuous mucosal inflammation of the colon and rectum. The global prevalence of UC has been rising steadily, and accumulating evidence suggests a potential association between proton pump inhibitor (PPIs) use and UC development. Nevertheless, the precise role of PPIs in the pathogenesis and clinical course of UC remains unclear. Methods The C57BL/6J mice were administered saline, omeprazole (OME) and dextran sulfate sodium to establish control, PPIs-treated and UC models, respectively. The fecal samples were subjected to high-throughput sequencing of the V3-V4 hypervariable regions of the 16S rRNA gene. Taxonomic annotation was performed using Mothur software to evaluate microbial diversity and abundance. Principal coordinate analysis, linear discriminant analysis effect size, and functional enrichment analyses were also conducted. Results Alpha and beta diversity analyses showed that the richness and diversity of the gut microbiota in the PPI and UC groups were significantly lower than those in the control group (p < 0.05). At the family and genus levels, the UC group was dominated by Bacteroides, while the PPIs group exhibited enrichment of Eisenbergiella and Prevotella. Furthermore, functional enrichment analysis demonstrated that the gut microbiota in the PPI group was predominantly enriched in functions related to cell wall and membrane structure biogenesis, whereas the UC group was enriched in energy metabolism. Conclusion Long-term PPI exposure profoundly alters the gut microbiota, characterized by reduced microbial diversity and enrichment of pro-inflammatory taxa. These findings highlight the contribution of PPIs to gut microbiota dysbiosis and UC pathogenesis, emphasizing the need for further research on microbiota–immunity interactions and for the development of targeted strategies to mitigate PPI-related adverse effects.
No abstract available
Ulcerative colitis (UC) is a kind of inflammatory bowel condition characterized by inflammation within the mucous membrane, rectal bleeding, diarrhea, and pain experienced in the abdominal region. Existing medications for UC have limited treatment efficacy and primarily focus on symptom relief. Limonium bicolor (LB), an aquatic traditional Chinese medicine (TCM), exerts multi-targeted therapeutic effects with few side effects and is used to treat anemia and hemostasis. Nevertheless, the impact of LB on UC and its mechanism of action remain unclear. Therefore, the objective of this study was to investigate the anti-inflammatory effects and mechanism of action of ethanol extract of LB (LBE) in lipopolysaccharide-induced RAW 264.7 macrophages and dextran sulfate sodium (DSS)-induced UC. The results showed that LBE suppressed the secretion of cytokines in LPS-stimulated RAW 264.7 cells in a dose-dependent manner. LBE had protective effects against DSS-induced colitis in mice, decreased the disease activity index (DAI) score, alleviated symptoms, increased colon length, and improved histological characteristics, thus having protective effects against DSS-induced colitis in mice. In addition, it reversed disturbances in the abundance of proteobacteria and probiotics such as Lactobacillus and Blautia in mice with DSS-induced UC. Based on the results of network pharmacology analysis, we identified four main compounds in LBE that are associated with five inflammatory genes (Ptgs2, Plg, Ppar-γ, F2, and Gpr35). These results improve comprehension of the biological activity and functionality of LB and may facilitate the development of LB-based compounds for the treatment of UC.
This research aimed to delineate the pharmacological mechanisms of 7-Hydroxycoumarin (7-HC) on ulcerative colitis (UC) employing network pharmacology and experimental validation. To investigate the therapeutic effects of 7-HC on UC, a UC mouse model was established through the unrestricted intake of 3.0% dextran sulfate sodium (DSS) in their drinking water. Subsequently, we predicted the core targets and signaling pathways of 7-HC for the treatment of UC using the network pharmacology approach. Finally, the insights gained from network pharmacology were further validated by molecular docking, molecular dynamics simulation as well as in vivo experiments. Administering 7-HC orally to mice with UC led to a marked improvement in colitis indicators. Furthermore, 7-HC significantly lowered the levels of inflammatory cytokines (TNF-α, IL-1β) in the colon and modulated oxidative stress markers (MPO, SOD). Subsequent studies identified 2 core targets (AKT1 and EGFR) in the colon of UC mice that were inhibited by 7-HC. Network pharmacology and experimental validation showed that 7-HC can reduce the expression of MAPK pathway markers P38, JNK, ERK, and their phosphorylation; 7-HC can also ameliorate UC by regulating the gut microbiome. 7-HC demonstrates considerable efficacy in alleviating UC in mice, primarily through substantial diminution of tissue inflammation and oxidative stress. This is the first time that 7-HC has been found to treat UC by inhibiting the MAPK pathway and modulating the gut microbiota, providing a fresh perspective on the pharmacological mechanisms through which 7-HC operates in the management of UC.
To explore the correlation between gut microbiota dysbiosis and the pathogenesis of ulcerative colitis (UC), and to provide an evidence-based basis for clinical diagnosis and treatment. Randomized controlled trials (RCTs) were included through a systematic search of the PubMed, Medline, Web of Science, Cochrane Library, and EMBASE databases. The Cochrane Risk of Bias Tool (RoB 2) was used to evaluate the quality of the literature. RevMan 5.3 software was employed to conduct a Meta-analysis, and the pooled effect size (OR/RR) and 95% confidence interval (CI) were calculated. The primary outcome measures included the associations between gut microbial diversity, changes in the abundance of specific microbial groups and the onset of UC. A total of 6 literatures were included, involving 171 study subjects (100 cases in the fecal microbiota transplantation (FMT) group and 71 cases in the control group), all of which were randomized controlled trials. There was no significant difference in the clinical response between the FMT group (ulcerative colitis patients receiving fecal microbiota transplantation intervention) and the control group (ulcerative colitis patients receiving conventional treatment or placebo) (RD = 0.17, 95% CI [-0.05-0.40], P = 0.14); the clinical remission in the FMT group was significantly better than that in the control group (OR = 2.20, 95% CI [1.05–4.59], P = 0.04); the changes in the microbiota composition in the FMT group were significantly higher than those in the control group (MD = 0.20, 95% CI [0.11–0.28], P < 0.001); there was no significant difference in the occurrence of adverse events between the FMT group and the control group (RD=-0.00, 95% CI [-0.15-0.14], P = 0.98); there was no significant difference in endoscopic remission between the FMT group and the control group (OR = 1.53, 95% CI [0.57–4.11], P = 0.40). This exploratory meta-analysis suggested that gut microbiota dysbiosis may be associated with the onset of UC, manifested as reduced diversity, imbalanced microbiota structure, and changes in the abundance of specific microbial groups. However, given the limited number of included studies, these findings are hypothesis-generating and require validation in larger, well‑powered trials. Further exploration of the potential value of microbiota intervention in the treatment of UC is needed.
Purpose Dihydromyricetin (DMY) is known for its wide range of pharmacological effects and has been approved as a dietary supplement. This study aimed to investigate the therapeutic effects of DMY on dextran sulfate sodium (DSS)-induced disruption of intestinal homeostasis in mice and to explore the underlying molecular mechanisms. Methods To establish a model of colitis, mice were treated with a 3% DSS solution, followed by gavage administration of DMY for therapeutic intervention. Techniques such as histomorphology, RT-qPCR, 16S rRNA sequencing, and Western blot analysis were used. Results DMY alleviated several physiological symptoms in colitis mice, including a reduction in the disease activity index (DAI) and spleen index, as well as decreases in the numbers of white blood cells, lymphocytes, and monocytes. Additionally, DMY helped repair the intestinal mucosal barrier function, reshaped the composition of gut microbiota, and regulated intestinal immune responses. These effects collectively contributed to the partial restoration of intestinal homeostasis in colitis mice. Furthermore, experiments with NLRP3−/− mice and pseudo-germ-free mice confirmed that DMY exerts its anti-colitis effects through the gut microbiota-NLRP3 inflammasome axis. Conclusion DMY helps regulate intestinal homeostasis in colitis mice by suppressing the NLRP3 inflammasome via the gut microbiota. Our study provides new evidence supporting DMY as a potential therapeutic agent for colitis.
BACKGROUND The correlation between periodontitis and ulcerative colitis (UC) has drawn widespread attention recently. Fusobacterium nucleatum (F. nucleatum) as a periodontal pathogen also has reservoirs in gut and may play a role in intestinal diseases. However, its role in the pathogenesis of UC is unclear. METHODS Mice were orally given Dextran sulphate sodium solution (DSS) and F. nucleatum to construct experimental models. The survival rate, weight, and disease activity index (DAI) of mice were monitored. Alveolar bone loss, abundance of F. nucleatum in colon, colon length, histopathological assessment and inflammatory cytokines were detected. Apoptosis of intestinal epithelial cells (IECs) were evaluated by TUNEL assay and pro-apoptotic gene Bax. The epithelial barrier function was assessed by tight junction proteins. By 16S rRNA gene sequencing and LC-MS-based methods, the composition of the intestinal microbiota and metabolites in mice were analyzed. RESULTS F. nucleatum facilitated alveolar bone loss and colonized only in infected colon tissue. Mice fed with DSS showed destruction of gut structure, increased expressions of IL-1β and TNF-α, decreased expression of IL-10, higher apoptosis of IECs, microbiota dysbiosis and bile acid dysmetabolism compared to healthy ones. F. nucleatum further aggravated intestinal inflammation and epithelial barrier damage. Probiotics Bifidobacterium and Faecalibacterium decreased, opportunistic pathogens Escherichia-Shigella increased and the differential microorganisms highly associated with inflammatory parameters and metabolites. Meanwhile, level of uric acid involving in the purine metabolism significantly elevated compared to UC mice. CONCLUSION F. nucleatum promotes gut inflammation, epithelial barrier dysfunction, microbiota dysbiosis and dysmetabolism to aggravate UC. This article is protected by copyright. All rights reserved.
This study was designed to first verify the protective capacity of turmeric powder (TP) as a traditional cooking spice against dextran sulfate sodium (DSS)-induced intestinal inflammation and intestine microbiota imbalance. The DSS-induced mice were fed a standard rodent chow supplemented with or without TP (8%) for 37 days. The results indicated that the pathological phenotype, gut barrier disruption, and colon inflammation of DSS-induced mice were significantly improved through supplementation of TP. In addition, 16S rRNA-based microbiota or targeted metabolomics analysis indicated that TP ameliorated intestinal microbiota dysbiosis caused by DSS and particularly enhanced the abundances of probiotics correlated with tryptophan metabolism, such as Lactobacillus and Bifidobacterium, where the cecal tryptophan was metabolized to indole-3-propionic acid and indole-3-acetic acid. Consumption of TP markedly enhanced the expression levels of colonic aromatic hydrocarbon receptors and further increased the expressions of intestinal tight junction proteins and interleukin-22 in the colitis mice. Collectively, these findings manifest the protective actions of dietary TP consumption against ulcerative colitis via restoring the intestinal microbiota disorders, promoting microbial metabolism, and improving intestinal barrier damage.
Ulcerative Colitis (UC) is a typical intractable disease whose number of patients is increasing worldwide, and studies have suggested that the gut microbiota and its metabolites are closely involved in its pathogenesis and severity. However, to date, no study has comprehensively compared the microbiomes or metabolomes of UC patients and healthy controls after considering important confounding factors such as age, gender, race, and other lifestyle factors. Therefore, we conducted this clinical study to compare the compositions and diversity of the gut microbiota and the fecal metabolites between age-, sex-, and race-matched patients with Ulcerative Colitis (UC) and those without. In total, 90 outpatients with UC (UC group) and 90 without a history of gastrointestinal diseases and their family members (without UC group) were recruited. The UC group had a significantly lower abundance of the genus Bifidobacterium, Faecalibacterium, and Lactobacillus than the without UC group. Furthermore, the UC group had a significantly lower alpha-diversity of the gut microbiota than the without UC group. The UC group had a significantly lower level of fecal SCFAs than the without UC group. These results remained significant after adjusting for sex, age, and smoking status. Furthermore, the expression of a group of genes encoded by the gut bacteria that are involved in the biosynthesis of tetrapyrrole was significantly lower in the UC group than in the without UC group. Gut microbiota dysbiosis and low SCFA levels, as well as reduced tetrapyrrole biosynthetic capacity by the gut bacteria, may contribute to the development of UC. Moreover, regardless of the severity, duration, and type of UC, the gut microbiota and its metabolites were in a stable state of dysbiosis in patients with UC.
This study investigated the effects of foxtail millet whole grain flours obtained through different processing methods on alleviating symptoms and gut microbiota dysbiosis in a dextran sulfate sodium (DSS)-induced murine colitis model. Sixty C57BL/6 mice were divided into six groups (n = 10 in each group), including one control group (CTRL) without DSS treatment and five DSS-treated groups receiving one of the following diets: AIN-93M standard diet (93MD), whole grain foxtail millet flour (FM), fermented (F-FM), germinated (G-FM), and fermented-germinated foxtail millet flour (FG-FM). A comparison of the disease activity index (DAI) demonstrated that foxtail millet whole grain-based diets could alleviate the symptoms of enteritis to varying degrees. In addition, 16S rRNA gene sequencing revealed that FG-FM almost completely alleviated DSS-induced dysbiosis. Mice on the FG-FM diet also had the lowest plasma IL-6 levels and claudin2 expression levels in the colon, indicating reduced systemic inflammation and improved gut barrier function. This study suggested that foxtail millet whole grain is an attractive choice for the intervention of IBD and gut microbiota dysbiosis, and its prebiotic properties are highly affected by the processing methods.
To investigate and compare the preventive effects of apple polyphenols extract (APE) with phloretin on dextran sulfate sodium (DSS)‐induced ulcerative colitis (UC), 60 male mice were treated with 125 or 500 mg/(kg bw d) APE or 100 mg/(kg bw d) phloretin, the single‐ingredient of APE, for continuous 3 weeks by intragastric administration, meanwhile, mice were provided with 3% DSS dissolved in drinking water to induce UC during the third week. Both APE and phloretin significantly ameliorated DSS‐induced UC by inhibiting body weight loss, preventing colon shortening and mucosa damage. Except the same mechanisms of the inhibited activation of NF‐κB signaling, decreased hyodeoxycholic acid level and increased abundance of Verrucomicrobia at phylum and Bacteroides and Akkermansia at genus, APE increased β‐muricholic acid level and decreased Bacterodetes abundance, while phloretin decreased Firmicutes abundance. Furthermore, APE treatment showed much lower disease activity index score, less body weight loss and lighter spleen than phloretin. Thus, our study supported the potentiality of APE as a promising dietary intervention for the prevention of experimental UC.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by persistent inflammation of the colon. Recent research has highlighted the significant role of gut microbiota in the pathogenesis and treatment of UC. This review aims to provide a comprehensive overview of the current understanding of the relationship between gut microbiota and UC. We discuss the involvement of gut microbiota in the onset of UC, including the dysbiosis observed in patients and its potential mechanisms. Additionally, the role of extra-intestinal microbiota in UC pathogenesis is explored, which has been less studied but is gaining attention. The influence of gut microbiota on the efficacy of biological immunotherapy for UC is also examined, highlighting how microbial composition can influence treatment outcomes. Furthermore, we review microbiota transplantation, and their potential benefits in UC management. Finally, we consider the combined use of antibiotics and biological agents in UC treatment, discussing their synergistic effects and potential drawbacks. This review underscores the importance of gut microbiota in UC and suggests that targeting microbial communities could offer new avenues for effective treatment.
Ulcerative colitis (UC) is a chronic immune-mediated disorder, whose etiology is not fully understood and for which no effective treatment is available. Recently, research has focused on the dysbiosis of gut microbiome in UC. However, the results so far remain inconsistent and insufficient to understand the microbial component in UC pathogenesis. In this study, we determine specific changes in the gut microbial profile in Polish UC patients compared to healthy subjects for the first time. Using 16S rRNA gene-based analysis we have described the intestinal microbial community in a group of 20 individuals (10 UC patients and 10 controls). Our results after multiple hypothesis testing correction demonstrated substantially lower gut microbiome diversity in UC cases compared to the controls and considerable differences at the phylum level, as well as among 13 bacterial families and 20 bacterial genera ( p < 0.05). UC samples were more abundant in Proteobacteria (8.42%), Actinobacteria (6.89%) and Candidate Division TM7 (2.88%) than those of healthy volunteers (2.57%, 2.29% and 0.012%, respectively). On the other hand, Bacteroidetes and Verrucomicrobia were presented at a lower level in UC relative to the controls (14% and 0% vs 27.97% and 4.47%, respectively). In conclusion, our results show a reduced gut microbial diversity in Polish UC patients, a reduction of taxa with an anti-inflammatory impact and an increased abundance of potentially pathogenic bacteria.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease with a rising incidence globally, whereas existing treatments exhibit significant limitations. Coix seed polysaccharide (CSP), a component of traditional Chinese medicine known for its immunomodulatory and antioxidant properties, has not been thoroughly investigated for its role in UC. In this study, CSP was prepared via water extraction and ethanol precipitation, and its protective effects and mechanisms were evaluated using a dextran sulfate sodium salt (DSS)-induced UC mouse model. The results demonstrated that CSP significantly ameliorated DSS-induced UC symptoms, including weight loss, an elevated Disease Activity Index, colon shortening, increased levels of inflammatory cytokines, and intestinal barrier damage. Moreover, CSP reshaped the DSS-induced gut microbiota dysbiosis by increasing gut microbial diversity and regulating the abundance of specific genera, such as increasing Anaerotruncus. Metabolomic analysis revealed that CSP significantly modulated the levels of 116 metabolites, particularly enhancing the beneficial metabolite 3-hydroxybutyrate. Importantly, the preventive effect of CSP on UC was dependent on the gut microbiota and could be transferred via fecal microbiota transplantation. This study demonstrates that CSP, a microecology-regulating polysaccharide, effectively modulates gut microbiota and alleviates symptoms of UC. These findings support the potential of CSP as a dietary supplement for UC prevention and underscore its value in the development of medicinal foods and functional food applications.
Characterized by elevated reactive oxygen species (ROS) and disrupted gut flora, ulcerative colitis (UC) affects millions of patients worldwide. Probiotic therapy is commonly utilized in clinical practice to modulate intestinal flora and ameliorate colitis symptoms. Nonetheless, oral probiotics encounter challenges such as limited bioactivity, brief retention time, intricate pathological conditions, and singular efficacy. Here we designed plant-derived 18β-glycyrrhetinic acid (18β-GA) prodrug nanomicelles with ROS and inflammation-resolving capabilities, as well as anti-depressant effects, to protect probiotics and amplify their therapeutic effects in alleviating UC and UC-associated depression-like behaviors. Upon oral administration to UC lesion sites, prodrug nanomicelles can be dissociated by excessive ROS and release 18β-GA to attenuate colonic inflammatory responses and oxidative stress, which in turn provided a favorable microenvironment for LGG to repair intestinal barrier integrity and restore the gut microbiota. The synergistic therapeutic effects of STG nanomicelles and LGG alleviated UC-associated depression-like behavior by suppressing the activation of microglia and reducing neuroinflammation. This study introduces a promising strategy for oral nanomedicine with satisfactory therapeutic outcomes for the treatment of inflammatory diseases by integrating naturally derived small-molecule drugs with probiotics.
Targeted drug delivery remains a critical challenge in the treatment of ulcerative colitis, as the side effects of current systemic therapies often outweigh their therapeutic benefits. In this study, we developed a reactive oxygen species (ROS)-responsive nanogel system that releases polymeric chloroquine (PCQ), a macromolecular derivative of hydroxychloroquine (HCQ), for localized treatment of ulcerative colitis. The initial nanogel formulation, measuring 183 nm in size with a surface charge of +13 mV, was synthesized via RAFT polymerization using a thioketal dimethacrylate crosslinker to demonstrate ROS-triggered degradation, physicochemical stability in simulated gastrointestinal fluids, favorable biocompatibility, and preferential accumulation in inflamed colonic tissue. To assess how variations in size and surface charge impact in vivo therapeutic efficacy, additional formulations were synthesized, resulting in a series of nanogels (T1-T4) with hydrodynamic diameters ranging from 180 to 680 nm and surface charges from +13 to +24 mV and tested in a Citrobacter rodentium-induced model of colitis. The nanogels delivered superior therapeutic benefits, including histological recovery, restoration of epithelial architecture, reduced immune cell infiltration, and attenuation of STAT3 activation as compared to the parent drug HCQ. Cytokine and eicosanoid profiling further revealed robust local and partial systemic immunomodulatory effects, with T1 showing the greatest local efficacy but relatively limited systemic eicosanoid suppression. These findings underscore the importance of optimizing nanogel size and surface properties to balance local and systemic therapeutic outcomes. Overall, this inflammation-responsive PCQ nanogel platform represents a promising strategy for targeted ulcerative colitis therapy with potentially no side effects.
Combating reactive oxygen species (ROS) and targeted drug delivery to inflammatory sites are considered effective therapeutic strategies for ulcerative colitis (UC), a refractory chronic inflammatory disease. Herein, a ROS‐responsive thioketal (TK) crosslinked cyclodextrin metal‐organic framework (TCOF) is fabricated, to which a non‐ROS‐sensitive vector, sulfur substituted by carbon chain‐crosslinked cyclodextrin metal‐organic framework (CCOF) is parallelly designed as ROS negative reference. Dexamethasone (DEX) loaded in TCOF (TCD) and CCOF (CCD) are investigated to demonstrate the advantages of precision medicine for UC. After the ROS‐induced collapse of nanoparticles, TCD selectively triggered the release of DEX. Moreover, TCD effectively protected cells from oxidative stress damage and reduced inflammation levels in vitro. Remarkably, the TK group of TCD is oxidatively broken by consuming ROS at the inflammatory site, exposing the thiol group to mucosal adhesion, which enhances the retention of TCD at colons. In vivo studies of UC treatment reveals that oral administration of TCD demonstrated excellent inflammation‐targeting properties, remarkably attenuated oxidative stress, and ameliorated both acute and chronic colitis compared to CCD. Furthermore, TCD exhibits an excellent safety profile in mice. These results instill confidence in advancing targeted drug delivery and precision therapy for UC.
Ulcerative colitis (UC) is presently considered a multifactorial pathology, which may lead to persistent inflammatory action of the gastrointestinal tract (GIT) because of an improperly managed immunological reactivity to the intestinal microbiota found in the GIT. The immune response to common commensal microbes plays an essential role in intestinal inflammation related to UC synbiotics, and it is an important element in the optimal therapy of UC. Therefore, synbiotics, i.e., a mixture of prebiotics and probiotics, may help control the diseased state. Synbiotics alleviate the inflammation of the colon by lowering the reactive oxygen species (ROS) and improving the level of antioxidant enzymes such as catalase (CAT), glutathione peroxidase (GPX), and superoxide dismutase (SOD). Prebiotic supplementation is not a common practice at the moment, despite numerous research findings proving that the benefits of both probiotics and prebiotics encourage their continued existence and positioning in the GIT, with positive effects on human health by managing the inflammatory response. However, the fact that there have been fewer studies on the treatment of UC with different probiotics coupled with selected prebiotics, i.e., synbiotics, and the outcomes of these studies have been very favorable. This evidence-based study explores the possible role of ROS, SOD, and synbiotics in managing the UC. The proposed review also focuses on the role of alteration of gut microbiota, antioxidant defense in the gastrointestinal tract, and the management of UC. Thus, the current article emphasizes oxidative stress signaling in the GI tract, oxidative stress-based pathomechanisms in UC patients, and UC therapies inhibiting oxidative stress’ effects.
In the pathogenesis of ulcerative colitis, inflammatory responses, mucosal injury, and gut dysbiosis form a mutually reinforcing network that perpetuates disease progression. Current clinical interventions can rarely modulate these pathological modules simultaneously, underscoring the urgent need for more effective therapeutic strategies. Here, we report a dual-functional nanotherapy that couples aryl hydrocarbon receptor (AhR) activation with on-site reactive oxygen species (ROS) scavenging. An amphiphilic copolymer, HA-TK-LA (HTL), was synthesized by grafting lipoic acid (LA) to hyaluronic acid (HA) via a ROS-cleavable thioketal (TK) linker. The copolymer self-assembles into ~130-nm nanoparticles that encapsulate the natural AhR ligand indole-3-acetic acid (IAA) with a high loading efficiency of 73%. The resulting IAA@HTL nanoparticles exhibit ROS/glutathione-triggered drug release and are actively taken up by inflamed intestinal epithelial cells and M1 macrophages through CD44-mediated endocytosis, leading to suppressed epithelial apoptosis and macrophage repolarization toward an anti-inflammatory phenotype. In dextran sulfate sodium-induced murine colitis, IAA@HTL specifically accumulates in the inflamed colon and markedly alleviates disease activity. Mechanistically, IAA and LA released from the nanoparticles synergistically activate aryl hydrocarbon receptor/cytochrome P450 family 1 subfamily A member 1 and nuclear factor erythroid 2-related factor 2/heme oxygenase-1 signaling, skew macrophages toward an anti-inflammatory state, dampen proinflammatory cytokine release, and reinforce the mucosal barrier by up-regulating tight-junction proteins and interleukin-22 secretion. As inflammation subsides and mucosal integrity is restored, the gut microbiota gradually returns to homeostasis. Collectively, this study establishes a ROS-scavenging and AhR-activating nanodelivery system that achieves a “one-stone-three-birds” outcome—attenuating inflammation, repairing mucosa, and rebalancing microbiota—providing new experimental evidence and theoretical support for ulcerative colitis therapy.
Background Reactive oxygen species (ROS) overproduction and excessive hypoxia play pivotal roles in the initiation and progression of ulcerative colitis (UC). Synergistic ROS scavenging and generating O_2 could be a promising strategy for UC treatment. Methods Ceria nanozymes (PEG-CNPs) are fabricated using a modified reverse micelle method. We investigate hypoxia attenuating and ROS scavenging of PEG-CNPs in intestinal epithelial cells and RAW 264.7 macrophages and their effects on pro-inflammatory macrophages activation. Subsequently, we investigate the biodistribution, pharmacokinetic properties and long-term toxicity of PEG-CNPs in mice. PEG-CNPs are administered intravenously to mice with 2,4,6-trinitrobenzenesulfonic acid-induced colitis to test their colonic tissue targeting and assess their anti-inflammatory activity and mucosal healing properties in UC. Results PEG-CNPs exhibit multi-enzymatic activity that can scavenge ROS and generate O_2, promote intestinal epithelial cell healing and inhibit pro-inflammatory macrophage activation, and have good biocompatibility. After intravenous administration of PEG-CNPs to colitis mice, they can enrich at the site of colonic inflammation, and reduce hypoxia-induced factor-1α expression in intestinal epithelial cells by scavenging ROS to generate O_2, thus further promoting disrupted intestinal mucosal barrier restoration. Meanwhile, PEG-CNPs can effectively scavenge ROS in impaired colon tissues and relieve colonic macrophage hypoxia to suppress the pro-inflammatory macrophages activation, thereby preventing UC occurrence and development. Conclusion This study has provided a paradigm to utilize metallic nanozymes, and suggests that further materials engineering investigations could yield a facile method based on the pathological characteristics of UC for clinically managing UC. Graphical Abstract
Ulcerative colitis (UC) is a chronic inflammatory condition that imposes a huge healthcare burden globally. The inflamed colon is marked by an abundance of positively charged proteins, increased reactive oxygen species (ROS), a disrupted intestinal barrier, and an imbalanced gut microbiome. Leveraging these features, we designed a negatively charged ROS-responsive nanocarrier using diselenide-bond-modified carboxymethyl cellulose (CMC) for the targeted delivery of curcumin, a natural ROS-scavenging antioxidant, to treat UC. The design rationale encompasses three key aspects: (1) the biocompatible and biodegradable CMC matrix stabilizes curcumin during digestion; (2) the diselenide bonds enable redox-triggered curcumin release at inflammatory sites, ensuring precise therapeutic action; and (3) the negative charge of the nanoparticles enhances interactions with positively charged proteins in inflamed colon tissues, improving site-specific accumulation. Experimental validation confirmed these design principles, demonstrating that the resulting nanoparticles effectively preserve curcumin during digestion and enable the ROS-responsive release of curcumin at inflamed sites. Additionally, these nanoparticles interact effectively with folic acid receptors (positively charged proteins) that are overexpressed on oxidatively stressed cell membranes, leading to specific accumulation in colitis tissue. Subsequently, the nanoparticles scavenge excessive ROS, restore intestinal barrier function, and modulate the gut microbiota. These synergistic actions collectively contribute to significant mitigation of colitis symptoms in both preventive and therapeutic regimens, suggesting a promising alternative therapeutic approach for UC.
Ulcerative colitis (UC) is an inflammatory disease with a complex pathogenic mechanism. Mounting evidence suggests that UC pathogenesis is linked to excessive production of reactive oxygen species (ROS) and cellular DNA damage. Recent studies have shown that bone mesenchymal stem cells (BMSCs) mainly exert their therapeutic effects through paracrine exosomes, and oxygen concentration is extremely important to BMSCs and exosomes. The main objective of this study was to determine whether exosomes from BMSCs under hypoxic conditions (HP-Exos) exhibit a greater therapeutic effect on UC compared to exosomes under normoxic conditions (Exos) and to resolve the mechanism of HP-Exos. We observed that hypoxia enhances the activity and migration of BMSCs and inhibits BMSC apoptosis without changing their morphological characteristics. Furthermore, HP-Exos significantly relieved UC symptoms and pathological damage. In order to further understand the mechanism of HP-Exos in UC, findings from in vivo experiments demonstrated that HP-Exos reduces ROS production, DNA damage and apoptosis in intestinal epithelial cells. As hypoxia-inducible factor 1α (HIF-1α) plays an important role in hypoxia, we knocked down HIF-1α in BMSCs. HIF-1α knockout reversed the effects of hypoxia on the activity, migration and apoptosis of BMSCs. Moreover, inhibition of HIF-1α expression also reversed the regulation of UC by HP-Exos. Therefore, we conclude that HP-Exos regulates ROS accumulation, DNA damage and immune homeostasis in intestinal epithelial cells via HIF-1α.
As one of the most challenging inflammatory diseases, the incidence of ulcerative colitis (UC) is increasing year by year, but the existing therapeutic drugs are not effective and lack of targeting. Nanomaterials are expected to become promising delivery system due to their good targeting effects. Here, we designed a nanomaterial sensitive to reactive oxygen species, which can be used to treat IBD, especially UC. It is a self-assembled polyether micelle that can be oxidized at the inflammation site where the concentration of reactive oxygen increases, and effectively release the encapsulated budesonide (Bud). Experiments have proved that for DSS-induced colitis, the synthetic drug-loaded nanoparticles have excellent therapeutic effects, can effectively repair intestinal barrier, and significantly improve the damaged colon tissue. At the same time, it has a beneficial regulatory effect on inflammatory factors. Molecular mechanism studies have shown that it achieves its therapeutic effects by activating the peroxisome proliferators-activated receptors-γ (PPAR-γ) pathway and inhibiting the nuclear factor (NF)-κB pathway. This study proves that oral nano-micelles have an important impact on improving the efficacy of UC treatment drugs and have far-reaching significance for the targeted treatment of gastrointestinal diseases.
No abstract available
No abstract available
Ulcerative colitis (UC) is a chronic idiopathic inflammatory disorder of the large intestine. Fructus mume (FM), a natural food with nutritive and pharmaceutical value, has demonstrated therapeutic efficacy against UC. In this study, we investigated the protective effects and mechanisms of FM against UC. We induced UC in rats with 4% (v/v) acetic acid (AA), orally administered 0.7 or 0.325 g/kg FM and 0.3 g/kg sulfasalazine (SASP) for 7 days, and explored the responses the drugs elicited in the rats. We assessed the general conditions of the rats by the disease active index. We evaluated colon tissue damage macroscopically and by Hematoxylin & Eosin, Alcian Blue–periodic acid–Schiff, and Masson's staining, and explored the potential mechanisms of FM on inflammation, oxidative stress, and neuropeptides by measuring TNF-α, IL-6, IL-8, IL-10, MMP9, CXCR-1, SOD, GSH-px, MDA, ROS, SIRT3, SP, VIP, ghrelin, and 5-HT. FM treatment significantly attenuated colon damage and submucosal fibrosis compared with the model. It lowered serum proinflammatory TNF-α, IL-8, and colonic MMP9 and CXCR-1, and raised serum anti-inflammatory IL-10 levels. FM upregulated the antioxidant enzymes SOD, GSH-px, and SITR3 protein but inhibited ROS and MDA production. It downregulated colonic SP, VIP, ghrelin, and 5-HT. The beneficial effects of FM might be dose dependent. Around 0.7 g/kg FM and SASP displayed similar efficacy for treating AA-induced colitis in rats. Our results provide empirical evidence that FM protects against AA-induced UC in rats via anti-inflammatory and antioxidant mechanisms, and regulates neuropeptides; thus, FM may be a promising, safe, and efficacious alternative therapy for UC, if its efficacy can be confirmed in human trials.
ABSTRACT Ulcerative colitis (UC) is a chronic and easy-to-relapse intestinal disease characterized by colon inflammation and microbial dysbiosis. Candida albicans is the most common fungal resident in the human gut. Overgrowth of C. albicans has been linked to the aggravation of UC. Previously, we demonstrated that miR-32-5p was the most differentially expressed microRNA in DSS-induced colitis model supplemented with C. albicans and might be a potential target in the treatment of Candida colitis. However, the underlying pathogenic and therapeutic mechanisms remain unclear. Here, we firstly used the ITS technique to analyse intestinal mycobiota. The miR-32-5p adenovirus in company with extracted Candida cell wall β-glucan were then employed to monitor the impacts of miR-32-5p and fungal β-glucan on the severity of Candida colitis. Subsequently, gene silencing together with inhibitors of reactive oxygen species (ROS) and apoptosis was used to survey the modulation of miR-32-5p on macrophage polarization. According to these results, C. albicans became the dominant intestinal fungal species in Candida colitis model. Candida β-glucan could instruct miR-32-5p expression to affect the severity of Candida colitis in a concentration-dependent manner. Interestingly, high fungal β-glucan with pro-inflammatory effects hindered further increases in gut inflammation. Further analysis showed that overexpression of miR-32-5p could effectively inhibit inflammation and apoptosis and enhance phagocytosis and ROS production through Dectin-1 signalling in macrophages. A panel of representative gene expressions verified the polarization of the M2-like phenotype induced by miR-32-5p. Mechanistically, our results reveal the therapeutic potential of miR-32-5p in the amelioration of Candida colitis.
Ulcerative colitis (UC) is characterized by chronic inflammatory processes of the intestinal tract of unknown origin. Current treatments lack understanding on how to effectively alleviate oxidative stress, relieve inflammation, as well as modulate gut microbiota for maintaining intestinal homeostasis synchronously. In this study, a novel drug delivery system based on a metal polyphenol network (MPN) was constructed via metal coordination between epigallocatechin gallate (EGCG) and Fe3+. Curcumin (Cur), an active polyphenolic compound, with distinguished anti-inflammatory activity was assembled and encapsulated into MPN to generate Cur-MPN. The obtained Cur-MPN could serve as a robust reactive oxygen species modulator by efficiently scavenging superoxide radical (O2•-) as well as hydroxyl radical (·OH). By hitchhiking yeast microcapsule (YM), Cur-MPN was then encapsulated into YM to obtain CM@YM. Our findings demonstrated that CM@YM was able to protect Cur-MPN to withstand the harsh gastrointestinal environment and enhance the targeting and retention abilities of the inflamed colon. When administered orally, CM@YM could alleviate DSS-induced colitis with protective and therapeutic effects by scavenging ROS, reducing pro-inflammatory cytokines, and regulating the polarization of macrophages to M1, thus restoring barrier function and maintaining intestinal homeostasis. Importantly, CM@YM also modulated the gut microbiome to a favorable state by improving bacterial diversity and transforming the compositional structure to an anti-inflammatory phenotype as well as increasing the content of short-chain fatty acids (SCFA) (such as acetic acid, propionic acid, and butyric acid). Collectively, with excellent biocompatibility, our findings indicate that synergistically regulating intestinal microenvironment will be a promising approach for UC.
Ulcerative colitis (UC) is a chronic or relapsing inflammatory disease with limited therapeutic outcomes. Pterostilbene (PSB) is a polyphenol-based anti-oxidant, which has received extensive interest for their intrinsic anti-inflammatory and anti-oxidative activities. This work aims to develop a reactive oxygen species (ROS)-responsive, folic acid (FA)-functionalized nanoparticle (NP) for efficient PSB delivery to treat UC. The resulting PSB@NP-FA had a nano-scaled diameter of 231 nm and a spherical shape. With ROS-responsive release and ROS-scavenging properties, PSB@NP could effectively scavenge H2O2, thereby protecting cells from H2O2-induced oxidative damage. After FA modification, the resulting PSB@NP-FA could be internalized by RAW 264.7 and Colon-26 cells efficiently and preferentially localized to the inflamed colon. In dextran sulfate sodium (DSS)-induced colitis models, PSB@NP-FA showed a prominent ROS-scavenging capacity and anti-inflammatory activity, therefore relieving murine colitis effectively. Mechanism results suggested that PSB@NP-FA ameliorated colitis by regulating dendritic cells (DCs), promoting macrophage polarization, and regulating T cells infiltration. Both innate and adaptive immunity were involved. More importantly, the combination of the PSB and dexamethasone (DEX) enhanced the therapeutic efficacy of colitis. This nanocarrier with ROS-responsive and ROS-scavenging represents an alternative therapeutic approach to UC. It can also be used as an enhancer for classic anti-inflammatory drugs.
No abstract available
No abstract available
No abstract available
Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), accompanied by intense inflammation, oxidative stress, and intestinal microbiota dysbiosis. Current treatments using chemotherapeutic drugs or immunosuppressants have limited effectiveness and side effects. Therefore, the development of safe, effective, and multi-targeting therapies for IBD is of great importance. Momordica charantia exhibits antioxidant, anti-inflammatory, and intestinal microbiota-regulating properties, suggesting that Momordica charantia-derived extracellular vesicles (MCEVs) have the potential for UC management. We extracted MCEVs using differential centrifugation and density gradient centrifugation. The results showed that MCEVs possessed high purity, even particle size, and excellent stability. In vitro, MCEVs were shown to inhibit macrophage inflammatory responses, scavenge reactive oxygen species (ROS), and protect cells from oxidative damage. Transcriptomics analysis revealed that MCEVs may alleviate mitochondria-dependent apoptosis by safeguarding the integrity of the mitochondrial structure and regulating the expression of apoptosis-related proteins. Furthermore, all components of MCEVs contributed to their pharmacological activity. In vivo, MCEVs had better retention in the inflamed colon and significantly alleviated UC through a comprehensive renovation of the intestinal microenvironment. These findings suggested that MCEVs own considerable potential as natural nanotherapeutics for UC treatment.
Colitis-associated cancer (CAC) is a subtype of colon cancer that is driven by chronic inflammation and is prevalent in chronic ulcerative colitis patients. The development of CAC is associated with the inflammation-dysplasia-carcinoma pathway which is significantly different than adenoma-carcinoma pathway of sporadic colon cancer (CRC). Matrix Metalloproteinase 9 (MMP9) is a zinc-dependent endopeptidase against extracellular matrix (ECM) proteins expressed in the gastrointestinal tract during inflammation. We have previously shown that MMP9 plays a tumor suppressor role in CAC via “MMP9-Notch1-ARF-p53 axis” pathway. The aim of this study is to determine the role of MMP9 in maintaining genomic stability in CAC. Homozygous transgenic mice with constitutive-expression of MMP9 in the colonic epithelium (TgM9) with their wild-type littermates (WT) and stably transfected HCT116 cells with/without MMP9 were used for in vivo and in vitro experiments, respectively. As ‘proof of concept’ model, nanoparticles (NPs) loaded with MMP9 siRNA were used to examine the effect of MMP9 silencing in the colonic epithelium. In CAC, colonic epithelium of TgM9 mice exhibited lower amounts of reactive oxygen species (ROS), less DNA damage, and increased expression of mismatch repair genes compared to WTs. Our study showed that MMP9 expression correlates with the reduced ROS levels, decreased DNA damage, and upregulated mismatch repair pathway. This suggests that MMP9 expression is a natural biological way to suppress CAC by limiting ROS accumulation and DNA damage in the colon. Therefore, MMP9 inhibition could be deleterious for CAC patient.
Recurrent and intractable colitis is very distressing for patients. Natural dietary fibers and polysaccharides have shown great potential in the prevention and management of Inflammatory bowel disease. This study aimed to investigate the ameliorative effects of arabinoxylan (AX), derived from barley bran, on dextran sulfate sodium induced ulcerative colitis in murine models, while also elucidating its underlying mechanisms. Additionally, the combined therapeutic effects of AX and 5-Aminosalicylic acid (5-ASA) were evaluated. The results indicated that AX significantly improved colonic inflammation, including restored body weight, colon length, reduced disease activity index (DAI) scores, and histopathological scores. AX intervention significantly reduced colonic inflammation and oxidative stress levels, while enhancing the expression of tight junction proteins. Furthermore, AX exhibited excellent performance in restoring intestinal mucus barrier function, by up-regulated the expression of MUC-2 and proteins associated with goblet cell secretion. Notably, AX selectively enriched beneficial bacterial species, such as Ligilactobacillus, while significantly reducing the abundance of Escherichia-Shigella, improving microbiota composition, and increasing short-chain fatty acids (SCFAs) levels in the colon. Moreover, the combination therapy of AX and 5-ASA compensated for the limitations of 5-ASA monotherapy, particularly in promoting intestinal mucosal barrier repair and enhancing SCFAs production, thereby mitigating colitis symptoms through multiple mechanisms.
Background Ulcerative colitis (UC), a recurrent chronic colon inflammation, presents substantial therapeutic challenges due to the frequent adverse effects associated with conventional pharmacological treatments. These limitations underscore the critical need for developing alternative dietary interventions with improved safety profiles. The present study investigated the therapeutic potential of Enteromorpha prolifera soluble dietary fiber microparticles (EDFM) in UC management, focusing on restoring mucosal barrier integrity and modulating gut microbiota homeostasis. Methods EDFM was fabricated through aqueous extraction of E. prolifera soluble dietary fiber via boiling followed by spray-drying. A mouse UC model was induced by dextran sulfate sodium (DSS). The severity of UC was evaluated through daily disease activity index (DAI) scoring; quantification of pro-inflammatory cytokines (TNF-α, IL-1β) via ELISA; histopathological analysis of colon sections with H&E staining; immunofluorescence detection of tight junction proteins (ZO-1, occludin); and 16S rRNA sequencing for gut microbiota. Results EDFM treatment significantly reduced the expression of pro-inflammatory cytokines (TNF-α and IL-1β), enhanced the expression of tight junction proteins (ZO-1 and occludin), and stimulated mucin (MUC2) production. Additionally, EDFM promoted the proliferation of beneficial probiotics (Alloprevotella, Lachnospiraceae_NK4A136_group, and Ruminococcaceae_UCG-014), while inhibiting pathogenic bacteria (Escherichia-Shigella, Parabacteroides, Rikenellaceae_RC9_gut_group, Odoribacter, and [Ruminococcus]_torques_group). Conclusion EDFM supplementation significantly ameliorates UC through dual modulation of gut microbiota and intestinal barrier integrity, indicating its potential as a functional food ingredient for UC prevention and treatment.
Ulcerative colitis (UC) is characterized by a chronic and protracted course and often leads to a poor prognosis. Patients with this condition often experience postoperative complications, further complicating the management of their condition. Tetrastigma hemsleyanum polysaccharide (THP) has demonstrated considerable potential as a treatment for inflammatory bowel disease. However, its underlying mechanism in the treatment of UC remains unclear. This study systematically and comprehensively investigated the effects of THP on dextran sulfate-induced UC mice and illustrated its specific mechanism of action. The colon and spleen in UC mice were restored after THP treatment. The levels of key markers, such as secretory immunoglobulin A, β-defensin, and mucin-2 were increased, collagen deposition and epithelial cell apoptosis were decreased. Notably, THP administration led to increased levels of Ki67 and tight junction proteins in colon tissue and reduced colon tissue permeability. THP contributed to the restored balance of intestinal flora. Furthermore, THP downregulated the expressions of the proinflammatory cytokines interleukin (IL)-6, tumor necrosis factor (TNF)-α, and IL-17 and promoted those of the regulatory factors forkhead box protein P3. It also exerted anti-inflammatory effects by promoting suppressor of cytokine signaling (SOCS1) expression and inhibiting the Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) signaling pathway. Our results demonstrated that THP had an efficacy comparable to that of JAK inhibitor in treating UC. In addition, THP might play a role in UC therapy through modulation of the SOCS1/JAK2/STAT3 signaling pathway and remodeling of the intestinal mucosal barrier.
No abstract available
Damage to the intestinal mucosal barrier play an important role in the pathogenesis of ulcerative colitis (UC). Discovering the key regulators and repairing the disturbed barrier are crucial for preventing and treating UC. Traditional Chinese medicine (TCM) has been proved to be effective on treating UC and has exhibited its role in repairing the intestinal mucosal barrier. We summarized the evidence of TCM against UC by protecting and repairing the physical barrier, chemical barrier, immune barrier, and biological barrier. Mechanisms of increasing intestinal epithelial cells, tight junction proteins, and mucins, promoting intestinal stem cell proliferation, restoring the abundance of the intestinal microbiota, and modulating the innate and adaptive immunity in gut, were all involved in. Some upstream proteins and signaling pathways have been elucidated. Based on the existing problems, we suggested future studies paying attention to patients’ samples and animal models of UC and TCM syndromes, conducting rescue experiments, exploring more upstream regulators, and adopting new technical methods. We hope this review can provide a theoretical basis and novel ideas for clarifying the mechanisms of TCM against UC via repairing the intestinal mucosal barrier.
Brusatol (BR) is an active compounds isolated from Brucea javanica, a Chinese herbal medicine that is famous for its anti-diarrheal effect. We have previously reported that BR mitigated inflammation in murine ulcerative colitis (UC) models. However, BR's role in intestinal mucosal healing, which is recently established as central strategy for the prevention and treatment of UC, remains unknown. In this study, the ameliorative effect of BR on intestinal mucosal damage was investigated in DSS-induced UC mice. BR significantly alleviated colitis symptoms, improved intestinal barrier function by preventing loss of goblet cells and downregulation of mucins and tight junction proteins, as well as maintained proliferative and apoptotic homeostasis in the colonic epithelium of UC mice. Mechanistically, BR enhanced the level and secretion of IL-22, but inhibited IL-22BP, an inhibitory protein of IL-22, in the blood serum and intestinal tissues of UC mice, as well as in MNK3 cells which is an effective cell model for studying ILC3s. Additionally, BR elevated the expressions of receptors for IL-22 (IL-10R2 and IL-22R1), and activated its downstream STAT3 signaling pathway. Furthermore, the involvement of IL-22 was further investigated by using recombinant IL-22 (rIL-22) and IL-22 antibody (anti-IL-22). BR demonstrated comparable effects with rIL-22 on alleviating intestinal inflammation and repairing intestinal mucosal injury. Treatment with anti-IL-22 abrogated the mucosal protective effects of BR. The present findings shed novel insights into the role of BR in intestinal mucosal healing via activating IL-22/STAT3 signaling pathway in UC.
Using Atractylenolide-1 (AT-1) is a confident strategy for the treatment of ulcerative colitis (UC) due to its natural origin and notable pharmacological activity. The study investigated the therapeutic effect of AT-1 in dextran sodium sulfate (DSS)-induced mice and Caco-2 cells while also exploring the underlying molecular mechanisms. In this study, AT-1 treatment could reduce weight loss and colon shortening and significantly reduce disease activity index (DAI), spleen index, and histopathological scores in UC mice. And AT-1 was observed to restore cell necrosis and monolayer damage and restored F-actin-mediated tight junction (TJ) protein redistribution to alleviate mucosal injury in UC mice and Caco-2 cells. Moreover, AT-1 regulated alanine, aspartic acid, and glutamate metabolism; increased the content of related metabolites; and promoted cell proliferation to restore damaged mucous membranes in UC mice. The results of molecular docking and molecular dynamics simulation showed that the binding of AT-1 to RhoA had a stable conformation, and it was speculated that RhoA was the main target of AT-1. Further investigations revealed that the interference of RhoA disrupted the regulatory pathway of AT-1. Thus, AT-1 could inhibit the reduction of TJ proteins, alter DSS-mediated cytoskeletal migration, promote amino acid metabolism, and subsequently reduce the permeability of the colon epithelium, thereby restoring mucosal barrier dysfunction features.
This study is to investigate the effect of SPS on the UC model. An animal model of UC induced by DSS was developed using C57BL/6 mice. The body weight was recorded every day, and the symptoms related to UC were detected. H&E staining, AB-PAS staining and PSR staining were used to evaluate the histopathological changes of the colon. Inflammation and mucosal barrier indicators were detected by qRT-PCR, and the 16 S rRNA sequence was used to detect the intestinal flora. SPS can significantly prevent and treat DSS-induced ulcerative colitis in animals. SPS significantly improved clinical symptoms, alleviated pathological damage, inhibited the infiltration of intestinal inflammatory cells. SPS treatment can protect goblet cells, enhance the expression of tight junction proteins and mucins, inhibit the expression of antimicrobial peptides, thereby improving intestinal barrier integrity. The prevention and treatment mechanism of SPS may be related to the inhibition of STAT3/NF-κB signaling pathway to regulate intestinal barrier function. In particular, SPS also significantly adjusted the structure of intestinal flora, significantly increasing the abundance of Akkermansia and Limosilactobacillus and inhibiting the abundance of Bacteroides. Overall, SPS has a significant therapeutic effect on ulcerative colitis mice, and is expected to play its value effectively in clinical treatment.
BACKGROUND Ulcerative colitis (UC) is a chronic inflammatory bowel disease closely linked to intestinal mucosal microcirculatory dysfunction. Sweroside (SOS), a natural iridoid glycoside derived from plants such as Swertia mussotii, Swertia pseudochinensis, and Lonicera japonica, exhibits anti-inflammatory properties. Yet, its therapeutic potential and mechanisms in UC remain unexplored. This study aimed to investigate the effects of SOS on dextran sulfate sodium (DSS)-induced UC and its underlying mechanisms. METHODS A DSS-induced UC mouse model was established to evaluate the efficacy of SOS. Inflammatory cytokine levels, intestinal barrier function (assessed via MUC2 immunofluorescence, FITC-dextran permeability, and tight junction protein analysis), and mucosal microcirculation (measured by Laser Speckle Contrast Imaging) were examined. Angiogenesis and endothelial cell (EC) damage were analyzed using ELISA, immunohistochemistry, and transmission electron microscopy. Transcriptomics and molecular docking were utilized to investigate SOS-mediated pathways, with subsequent validation by qRT-PCR, western blot, and immunofluorescence. Additionally, a cellular injury model was generated by treating human umbilical vein endothelial cells (HUVECs) with DSS. Cellular inflammatory and angiogenesis-related factors were quantified via ELISA, while migration and angiogenesis capabilities of HUVECs were assessed through scratch and tube-forming assays. The expression of the VEGF and Hippo pathway-related proteins was determined by western blot. RESULTS SOS significantly ameliorated UC symptoms, reducing weight loss, diarrhea, and DAI scores while suppressing inflammatory infiltration and cytokine release. SOS enhanced intestinal barrier integrity via tight junction upregulation and improved microcirculation by attenuating EC injury and angiogenesis. Mechanistically, SOS regulated the VEGF and Hippo pathways, a key regulator of angiogenesis, as confirmed by transcriptomics and molecular docking. In vitro, SOS protected HUVECs from DSS-induced inflammation and angiogenesis, confirming the improvement of mucosal microcirculation by modulating VEGF and Hippo pathways. CONCLUSIONS SOS ameliorates DSS-induced UC by impacting the VEGF and Hippo pathways, thereby suppressing ECs' angiogenesis, restoring mucosal microcirculation, and mitigating intestinal inflammation. These findings highlight SOS as a promising therapeutic candidate for UC.
BACKGROUND In Ayurveda, Aegle marmelos fruit is described for its utility in alleviating gastrointestinal disorders due to its astringent, digestive, and stomachic properties. PURPOSE Here the aim was to explore the mechanism involved in the protective effect of A. marmelos against ulcerative colitis (UC) in murine model. The study also compared the anti-colitis efficacy of two distinct fruit morphotypes of A. marmelos available in India (oblate-spheroid, Lucknow; pyriform, Bengaluru). Further, it explored the role of the more effective one in modulating the gut microbiota in mice. STUDY DESIGN Aqueous, ethanolic and hydroalcoholic extracts of A. marmelos fruit were analyzed for efficacy against dextran sulfate sodium (DSS)-induced UC in mice at 200 mg/kg BW oral dose. METHODS The most efficacious extract was subjected to dose-dependent (100-500 mg/kg BW) analysis. Its best dose was analyzed in terms of restoration of cytokine levels, tight junction proteins, intestinal permeability, myeloperoxidase activity, transcript abundance of key genes and modulation of gut microbiota through NGS-based 16S rRNA analysis. RESULTS The aqueous extract of Lucknow fruit at 300 mg/kg BW (AM) ameliorated colitis symptoms in DSS-induced mice. It elevated relative abundance of Lactobacillus and Blautia but decreased that of Escherichia-Shigella, Clostridium sensu stricto 1 and Romboutsia in the gut microbiota. AM downregulated Tlr4 transcripts, upregulated Muc2 and Slc6a4 transcripts, ZO-1 protein and goblet cells in colon showing barrier protective properties against colon damage and inflammatory response. Moreover, it was found to be safe up to 3000 mg/kg BW. CONCLUSION This study has elucidated the potential of A. marmelos treatment in UC by modulation of gut microbiome and provided strong scientific evidence to validate its use in traditional medicine.
Ulcerative colitis (UC) is a complex, refractory inflammatory bowel disease characterized impared intestinal mucosal barrier and imbalanced M1/M2 macrophage polarization mediating its progression. Formononetin (FN), a bioactive isoflavone with established anti-inflammatory and immunomodulatory properties, shows promise in mitigating UC, yet its therapeutic and underlying mechanisms remain unclear. In this study, colitis was induced in mice by administering 2.5% (w/v) dextran sulfate sodium (DSS) solution for 7 days. Oral (25, 50, and 100 mg/kg) FN for 10 days significantly ameliorated colitis symptoms in a dose-dependent manner, by mitigating body weight loss, reducing disease activity index (DAI), colonic weight, and colonic weight index, while enhancing survival rates and colonic length. Histological analysis revealed FN remarkably suppressed inflammatory damage in colonic tissues. Furthermore, FN modulated the expression of pro- and anti-inflammatory cytokines and enhanced antioxidant capacity. Notably, FN treatment significantly enhanced the expression of tight junction (TJ) proteins (claudin-1, ZO-1, occludin) at both protein and mRNA levels in the colon tissues, suggesting improved intestinal barrier function. Crucially, FN inhibited macrophage infiltration in colonic tissues and rebalanced M1/M2 macrophage polarization. While, macrophage depletion largely abrogated FN's protective effects against colitis, indicating a crucial role for macrophages in mediating FN's therapeutic response. Overall, FN effectively alleviated colitis primarily via modulating inflammatory cytokine expression, enhancing antioxidant capacity, upregulating TJs proteins expression, and remodeling M1/M2 macrophage polarization equilibrium. These findings suggest that FN could be the next candidate to unlocking UC's treatment challenge.
Ulcerative colitis (UC) is a persistent inflammatory condition marked by the destruction of the intestinal mucosal barrier, infiltration of inflammatory cells, and ulceration. M1/M2 macrophage polarization plays an imperative function in the regulation of inflammation through the nuclear factor-kappa B (NFκB) signaling pathway and modulating microRNA-155 (miR-155). Recent studies have highlighted the anti-ulcerogenic and colo-protective properties of sodium-glucose co-transporter-2 (SGLT2) inhibitors. However, the potential protective and therapeutic effects of ertugliflozin (Ertu), an SGLT2 inhibitor, in UC have not yet been clarified. Therefore, the present research sought to investigate the potential role of Ertu in mitigating acetic acid (AA)-induced UC in rats. Forty-two adult Wistar rats were allocated into seven groups: control, Ertu (10 mg/kg), AA, AA+ Ertu (1, 5, and 10 mg/kg), and AA+ sulfasalazine (Sulfa) (100 mg/kg); all received oral treatments daily for 7 days. Pre-treatment with Ertu mitigated histopathological alterations and enhanced macroscopic assessments. Ertu suppressed the expression of NF-κB p65 and miRNA-155, promoting macrophage polarization towards M2 phenotype, as witnessed by increased expression of CD206, Fizz-1, Ym-1, and Arg-1, along with elevated IL-10 protein content. It reduced the expression of CD86 and MCP-1, besides the levels of TNF-α, IL-1β and iNOS. Moreover, Ertu improved intestinal epithelial integrity by upregulating tight junction proteins, comprising claudin-1, occludin and ZO-1. Ertu also demonstrated anti-apoptotic effects by reducing BAX meanwhile increasing BCL2. Notably, Ertu (10 mg/kg) exhibited therapeutic effects comparable to the standard treatment, Sulfa, underscoring its potential as a distinctive and valuable option for UC management.
The utilization of traditional Chinese medicine (TCM) for disease treatment dates back thousands of years. Atractylodis rhizoma (AR) is recognized as a premier TCM and has effective therapeutic properties for gastrointestinal disorders. Nonetheless, the underlying mechanisms by which the ethanolic extract of Atractylodis rhizoma (EEAR) addresses ulcerative colitis (UC) remain ambiguous. This study aimed to clarify the potential molecular mechanisms by which EEAR ameliorated dextran sodium sulfate (DSS)-induced UC in mouse models and Caco-2 cells. EEAR exhibited significant therapeutic effects in UC mice, including decreasing symptoms and reducing inflammation. It also upregulated the expressions of tight junction (TJ) proteins, which enhanced UC intestinal mucosal barrier protection. In addition, EEAR inhibited the expressions of matrix metalloprotein (MMP)-2/9 proteins and inactivated the RhoA/ROCK (Rho-associated kinase)/MLC (myosin light chain) pathway in UC mice. Consistent with the results of in vivo experiments, EEAR significantly increased cell viability and improved the barrier disruption in DSS-induced Caco-2 cells. EEAR increased the expressions of TJ proteins, regulated F-actin cytoskeletal remodeling, and inhibited the expressions of MMP-2/9 proteins and the RhoA/ROCK/MLC pathway. EEAR significantly decreased intestinal pathological injury. Its potential mechanism was related to its inhibition of the RhoA/ROCK/MLC pathway, decreased activation of MMP-2/9, and increased expressions of TJ proteins, thereby regulating cytoskeleton remodeling.
Intestinal barrier dysfunction characterized by the functional loss of the intestinal epithelium's tight junction (TJ) barrier is a key factor in the pathogenesis of ulcerative colitis (UC). Although rapamycin, an mTOR (mechanistic target of rapamycin) inhibitor, has shown promise in inducing clinical remission and mucosal healing in inflammatory bowel disease, its underlying mechanism remains elusive. Thus, this study investigated the role of the mTOR pathway in regulating the intestinal barrier. To investigate the molecular mechanism regulating the intestinal barrier, specific intestinal epithelial phenazine biosynthesis-like domain-containing protein (PBLD)-deficient (PBLDIEC-/-) mice and control wild-type (WT) mice were intraperitoneally injected with rapamycin or MHY1485. To determine the relevance of the findings for UC, we analyzed transcriptome data and single-cell expression profiles from public databases and intestinal mucosal tissues obtained from patients with active UC or colon cancer. We observed that mTOR activation in the intestinal epithelium of patients with active UC. Moreover, in vivo, rapamycin markedly increased the expressions of PBLD and TJ proteins and reduced intestinal inflammation in mice with dextran sulfate sodium-induced enteritis. However, the therapeutic efficacy of rapamycin was notably reduced in PBLDIEC-/- mice. In vitro, rapamycin influenced PBLD expression by modulating the nuclear transcription of transcription factor EB (TFEB). Angiomotin (AMOT) could directly bind to PBLD, and rapamycin could not effectively increase the expression of TJ proteins after the knockdown of PBLD or AMOT. In summary, the administration of rapamycin is a potential treatment for UC, and targeting the mTOR/PBLD/AMOT axis is a potential novel approach for UC treatment.
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by persistent mucosal inflammation in the colon, leading to substantial morbidity. Current therapies are often limited by side effects and relapse, emphasizing the need for safer, multi-target alternatives. This study investigated the protective effects and underlying mechanisms of lobetyolin (LBT), a natural polyacetylene glycoside, in a dextran sulfate sodium (DSS)-induced colitis mouse model. Male BALB/c mice were randomly divided into four groups: Control, DSS, and DSS treated with low (10 mg/kg) or high (50 mg/kg) doses of LBT. Clinical parameters were assessed using the disease activity index (DAI), histopathological staining, and biochemical assays. Inflammatory and oxidative stress markers were quantified by ELISA, tight junction proteins were analyzed by Western blotting and immunohistochemistry, gut microbiota composition was determined by 16S rRNA sequencing, and short-chain fatty acids (SCFAs) were measured by GC–MS. In addition, non-targeted metabolomics was performed using UHPLC–MS/MS. LBT treatment significantly alleviated DSS-induced colitis by improving body weight, colon length, and histological structure. It reduced TNF-α, IL-6, and IL-1β levels, restored antioxidant capacity (SOD, CAT, GSH), and enhanced epithelial barrier integrity (Occludin, Claudin-1, ZO-1). Moreover, LBT normalized gut microbial composition, increased SCFA production, and regulated amino sugar and nucleotide sugar metabolism. Collectively, these findings demonstrate that LBT exerts multi-target protective effects against UC by modulating inflammation, oxidative stress, epithelial barrier function, gut microbiota, and metabolic pathways.
No abstract available
Ulcerative colitis (UC) is an idiopathic, relapsing, and etiologically complicated chronic inflammatory bowel disease. Despite substantial progress in the management of UC, the outcomes of mucosal barrier repair are unsatisfactory. In this study, phillygenin (PHI) treatment alleviated the symptoms of chronic colitis in mice, including body weight loss, severe disease activity index scores, colon shortening, splenomegaly, oxidative stress, and inflammatory response. In particular, PHI treatment ameliorated the tight junction proteins (TJs) reduction, fibrosis, apoptosis, and intestinal stem cell activity, indicating that PHI exerted beneficial effects on the intestinal mucosal barrier in mice with chronic colitis. In the NCM460 cells damage model, dextran sulfate sodium triggered the sequential induction of TJs reduction, fibrosis, and apoptosis. Takeda G protein-coupled receptor-5 (TGR5) dysfunction mediated NCM460 cell injury. Moreover, PHI treatment enhanced TJs and suppressed fibrosis and apoptosis to maintain NCM460 cell function, depending on TGR5 activation. PHI promoted TGR5 activation and elevated intracellular cyclic adenosine monophosphate levels in HEK 293T cells transfected with TGR5 expression plasmids. Cellular thermal shift assay and molecular docking studies confirmed that PHI directly binds to TGR5, indicating that PHI is an agonist of TGR5. The process of PERK-eIF2α pathway-mediated endoplasmic reticulum Ca2+ release was involved in NCM460 cell injury as well, which was associated with TGR5 dysfunction. When NCM460 cells were pretreated with PHI, the PERK-eIF2α pathway and elevated Ca2+ levels were blocked. In conclusion, our study demonstrated a novel mechanism that PHI inhibited the PERK-eIF2α-Ca2+ pathway through TGR5 activation to against DSS-induced TJs reduction, fibrosis, and apoptosis.
Ulcerative colitis (UC), an incurable and recurrent inflammatory bowel disease, presents a significant threat to health and highlights the need for novel therapeutic strategies. Oleanolic acid 28-O-β-D-glucopyranoside (OAG) is a naturally occurring pentacyclic triterpenoid found in ginseng. In this study, we demonstrated that OAG exhibited remarkable anti-UC activity in LPS-induced Caco-2 cells and DSS-induced model mice. First, OAG alleviated the symptoms of UC by mitigating weight loss, reducing the DAI score, and increasing colon length. Second, the inflammatory response was inhibited after OAG intervention, evidenced decreases in the spleen coefficient, cytokine levels, and inflammatory cell infiltration in colon tissue. Thirdly, OAG also enhanced intestinal epithelial barrier function, as evidenced by elevated TEER values, increased expression of tight junction proteins, diminished bacterial translocation, and maintained intact ultrastructure of colonic mucosal cells. Notably, compared with 5-aminosalicylic acid, OAG demonstrated superior efficacy in enhancing mucosal barrier function. Fourth, OAG increased microbial diversity, promoted the abundance of beneficial bacteria, reduced the abundance of harmful bacteria, and rebalanced the gut microbiome. Finally, the PI3K-AKT and MAPK signaling pathways were identified as crucial mechanisms underlying the therapeutic effects of OAG against UC through multi-omics. In summary, we identified OAG as a novel therapeutic agent against UC, demonstrating anti-inflammatory, barrier-preserving, and gut microbiota-modulating effects, highlighting its promising potential as a candidate UC drug.
Introduction Akkermansia muciniphila (A. muciniphila), known as a next-generation probiotic, has been widely recognized for its beneficial effects in various metabolic diseases. While there is not much research whether live or pasteurized A. muciniphila has different effects on intestinal health. Methods In the present study, a strain of A. muciniphila was isolated from healthy individuals, with the live and pasteurized A. muciniphila named Timepie001 and Timepie001+, respectively. They were administered to dextran sulfate sodium-induced ulcerative colitis mice to investigate their influences on the host intestinal health. Results and conclusion The results showed that prophylactic supplementation with live and pasteurized A. muciniphila alleviates ulcerative colitis symptoms by retarding weight loss, preserving intestinal tissue structure, modulating inflammatory cytokines (TNF-α, IL-1β), and enhance the colonic mucosal barrier by upregulating the expression of tight junction protein Claudin-1. Interestingly, pasteurized A. muciniphila has a better effect compared with live A. muciniphila. Moreover, pasteurized A. muciniphila can regulates the gut microbiome to maintain intestinal homeostasis. This provides theoretical support for the widespread application of postbiotics in the food industry.
Ulcerative colitis (UC) is a chronic, relapsing, and nonspecific inflammatory bowel disease (IBD). Phillygenin (PHI), a natural bioactive ingredient, isolated from Forsythiae Fructus, exhibits anti-inflammatory, anti-oxidative, and hepatoprotective activities. However, few reports provide direct evidence on the efficacy of PHI in improving colitis mice. The present study elucidated that the symptoms of DSS-induced colitis mice were alleviated after PHI administration, including body weight loss, the disease activity index, colon length shortening, colonic pathological damage, splenomegaly, and hepatomegaly. PHI treatment improved the intestinal mucosal barrier by protecting goblet cells, promoting gene expressions of Clca1, Slc26a3, and Aqp8, increasing tight junction proteins (TJs), and reducing epithelial cell apoptosis. In addition, the levels of oxidative stress (MPO, SOD, and MDA) and inflammatory cytokines (TNF-α, IL-1β, IL-6, and IL-10) were reversed by PHI in colitis mice. According to transcriptome and network pharmacology analysis, inflammatory pathway might be an important mechanism for PHI to improve colitis. Western blotting displayed that the PHI inhibited the activation of tyrosine kinase Src mediated by TLR4, and then reduced the phosphorylation of downstream proteins p38, JNK, and NF-κB in colitis mice. In summary, our results suggested that PHI might be an appropriate and effective drug candidate to protect colitis.
Periodontitis is a chronic inflammatory disease, having significant impact on systemic conditions. Ulcerative colitis (UC) is a chronic relapsing inflammatory disorder of the intestines. Studies have suggested a potential association between periodontitis and UC. This study aims to elucidate the influence of periodontitis on the progression of UC and to uncover the potential mechanistic pathways involved. A total of 20 male C57BL/6J mice were randomly assigned to four groups: Sham, Periodontitis (P), UC, and Periodontitis + UC (P-UC). A chronic UC model was induced by alternating oral administration of 1% and 0.5% Dextran Sulfate Sodium Salt (DSS) solution, while periodontitis was induced by ligatures. Disease severity was accessed using Disease Activity Index (DAI), histopathology, and intestinal permeability assays. Gut microbiota and periodontal microbiota was analyzed using 16S rRNA sequencing. Tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6) were measured by quantitative PCR (qPCR) to evaluate the systemic inflammation burden. Zonula occludens-1 (ZO-1) and occludin in intestinal tissues were assessed using qPCR and immunohistochemistry. Correlation analyses were performed between periodontal destruction indices and markers. A chronic UC model closely resembling clinical conditions was successfully established. The P-UC group exhibited earlier and more pronounced body weight loss than the UC group. Colonic inflammation was exacerbated, with significantly elevated TNF-α and IL-6 expression (P < 0.05). In the P-UC group, intestinal barrier disruption was evident with reduced occludin protein levels (P < 0.01) and increased intestinal permeability (P < 0.05), indicated by serum diamine oxidase (DAO). Both the P-UC and UC groups exhibited notable dysbiosis of the gut microbiota, with the P-UC group showing significantly higher abundance of UC-associated bacteria, such as Muribaculum and Allobaculum (P < 0.05), compared to the UC group. A trend toward reduced abundance of the gut-protective bacterium Akkermansia was also observed (P = 0.06). Pearson correlation analysis confirmed the association between periodontitis and intestinal inflammation, suggesting that intestinal barrier dysfunction and gut microbiota dysbiosis may be key mediators in periodontitis-induced UC exacerbation. Periodontitis may exacerbate UC by increasing harmful gut bacteria, reducing beneficial bacteria, and promoting the secretion of pro-inflammatory cytokines, thereby disrupting the intestinal barrier and worsening UC severity.
ABSTRACT Dietary phytochemicals possess anti‐inflammatory and antioxidant properties that may modulate disease activity in ulcerative colitis (UC). This study examined the association between the Dietary Phytochemical Index (DPI) and disease activity, biomarkers, gut microbiota, and psychological health in UC patients. In this cross‐sectional study of 350 UC patients, dietary intake was assessed using a validated FFQ to calculate the DPI. Participants were stratified into DPI quartiles. Disease activity was measured via the Mayo score. Biomarkers (FCP, CRP, IL‐6, ESR, homocysteine, zonulin), gut microbiota diversity, Firmicutes/Bacteroidetes ratio, and SCFA levels were analyzed. Psychological status and quality of life were evaluated using validated questionnaires (PHQ‐9, GAD‐7, PSQI, FSS, SIBDQ, IBD Disability Index). Participants with higher DPI scores showed significantly lower levels of FCP, CRP, IL‐6, ESR, homocysteine, and zonulin (all p < 0.001). Gut microbial richness (Shannon index) and the F/B ratio increased with higher DPI quartiles (all p < 0.001), indicating reduced inflammation (all p < 0.001). In terms of SCFAs, butyrate levels were significantly higher in Q4 (94.83 μmol/g) compared to Q1 (68.30 μmol/g, p < 0.001). In healthy adults, fecal butyrate concentrations typically range between 60 and 100 μmol/g; thus, the observed increase in Q4 reflects a clinically meaningful improvement. Q4 participants reported significantly better sleep quality, lower depression and anxiety scores, reduced fatigue and disability, and higher quality of life (all p < 0.001). The Mayo score, reflecting clinical disease activity, was significantly lower in Q4 (4.90 ± 0.83) compared to Q1 (6.18 ± 1.95, p < 0.001). Higher DPI adherence was associated with lower disease activity and improved clinical outcomes, though causal relationships cannot be inferred due to the cross‐sectional design.
Background: Depression and anxiety are common in UC patients due to gut microbiota dysbiosis and increased proinflammatory markers. Butyrate, a short‐chain fatty acid, participates in the regulation of gut microbiota and inflammation and has neuroprotective effects in neurodegenerative disease. Therefore, we assessed the effects of sodium butyrate supplementation on the disease severity, inflammation, and psychological factors in active UC patients.
The study aimed to investigate the potential of low dose chitooligosaccharide (COS) in ameliorating dextran sodium sulfate (DSS) induced chronic colitis by regulating microbial dysbiosis and pro-inflammatory responses. Chronic colitis was induced in BALB/c mice by DSS (4% w/v, 3 cycles of 5 days) administration. The mice were divided into four groups: vehicle, DSS, DSS + mesalamine and DSS+COS. COS and mesalamine were administered orally, daily once, from day 1 to day 30 at a dose of 20 mg/kg and 50 mg/kg respectively. The disease activity index (DAI), colon length, histopathological score, microbial composition, and pro-inflammatory cytokine expression were evaluated. COS (20 mg/kg, COSLow) administration reduced the disease activity index, and colon shortening, caused by DSS significantly. Furthermore, COSLow restored the altered microbiome in the gut and inhibited the elevated pro-inflammatory cytokines (IL-1 and IL-6) in the colon against DSS-induced chronic colitis in mice. Moreover, COSLow treatment improved the probiotic microflora thereby restoring the gut homeostasis. In conclusion, this is the first study where microbial dysbiosis and pro-inflammatory responses were modulated by chronic COSLow treatment against DSS-induced chronic colitis in Balb/c mice. Therefore, COS supplementation at a relatively low dose could be efficacious for chronic inflammatory bowel disease.
Ulcerative colitis (UC) is a prevalent inflammatory bowel disease (IBD) posing a significant health threat. This study explored the protective effects of D-tagatose against DSS-induced colitis in mice and its underlying mechanisms using H&E staining, AB-PAS staining, immunofluorescence, immunohistochemistry, ELISA, qPCR, western blotting, and other assays. D-Tagatose improved colitis by increasing body weight and colon length, with decreased DAI (disease activity index) and histopathological scores. The results showed that D-tagatose inhibited the secretion of myeloperoxidase (MPO), inflammatory enzymes (iNOS and COX-2) and pro-inflammatory cytokines (TNF-α, IL-1β and IL-6) as well as increased the content of anti-inflammatory cytokines (IL-10) in vitro. In addition, D-tagatose enhanced the expression of tight junction proteins (ZO-1 and Occludin) and mucin (MUC-2). Furthermore, D-tagatose was able to modulate the gut microbiota dysbiosis caused by DSS-induced UC and increased the content of short-chain fatty acids (SCFAs). This study indicated that D-tagatose attenuated DSS-induced UC by modulating inflammatory cytokines, restoring intestinal barrier function, maintaining gut microbiota homeostasis, and enhancing SCFA production. These findings provide D-tagatose as a safe and effective novel functional food strategy for the prevention and treatment of UC.
Ulcerative colitis (UC), a chronic inflammatory bowel disease with limited therapeutic options, necessitates novel treatments targeting its complex pathophysiology. This study identified FHND5032, a novel small-molecule miR-124 inducer, as a potent therapeutic candidate for UC. We found that FHND5032 significantly upregulated miR-124 expression in macrophages, surpassing the clinical-stage comparator ABX464 in vitro and in vivo. Mechanistically, miR-124-5p directly targeted PIK3R2, suppressing the PI3K/Akt pathway and decreasing proinflammatory cytokines while promoting M2 macrophage polarization. In dextran sodium sulfate-induced mouse colitis, FHND5032 markedly reduced the disease activity index, restored colon length, preserved mucosal architecture, and repaired intestinal barrier integrity. Additionally, FHND5032 reversed gut dysbiosis by reducing Proteobacteria and enriching beneficial Firmicutes, outperforming ABX464 in microbiome modulation. Safety assessments confirmed no organ toxicity or biochemical abnormalities. Collectively, FHND5032 exerted multifaceted anticolitis effects by targeting the PIK3R2/PI3K/Akt axis, restoring immune homeostasis, and modulating gut microbiota, positioning it as a promising therapeutic agent for UC.
Introduction Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by colonic mucosal inflammation, compromised intestinal barrier function, and gut microbiota dysbiosis. Current therapies often have significant limitations, including adverse effects, highlighting the need for safer alternatives. Periplaneta americana L. (PA), documented in Shennong's Herbal Classic, possesses anti-inflammatory, tissue-repairing, and immunomodulatory properties. While previous studies demonstrated efficacy of PA in rodent UC models generated using different inducers, the active components within aqueous extracts (PAW) and their comparative effects remain unclear. Materials To address this gap, this study investigated the composition and therapeutic activity of PAW and its sequentially fractionated components based on molecular weight: PAW1 (< 3 kDa), PAW2 (3-10 kDa), and PAW3 (> 10 kDa) using membrane separation. Using a dextran sulfate sodium (DSS)-induced UC model in C57BL/6 mice, we compared the effects of unfractionated PA and its fractions (PAW1, PAW2, PAW3) on UC pathology and intestinal flora. Results Our results demonstrate that PA, PAW1, PAW2, and PAW3 ameliorated key UC-associated pathologic features; notably, the unfractionated PA exhibited superior efficacy compared to its individual fractions. PA treatment significantly mitigated DSS-induced body weight loss, disease activity index scores, and colon shortening. It preserved intestinal mucosal integrity, evidenced by increased goblet cell numbers and elevated expression of tight junction proteins (occludin-1, ZO-1). PA treatment reduced colonic inflammation by significantly downregulating pro-inflammatory mediators (NF-κB-p65, TLR4, MyD88, TNF-α, IL-17A, IFN-γ, MPO, iNOS) and upregulating the anti-inflammatory cytokine IL-10, while IL-4 levels were also modulated. Furthermore, PA treatment attenuated intestinal dysbiosis in UC mice, characterized by an increase in beneficial bacteria (e.g., Psychrobacter) and a decrease in taxa like Actinobacteriota. Conclusion These findings collectively indicate that the aqueous extract of Periplaneta americana L. and its fractions possess significant therapeutic potential for UC treatment, with the unfractionated extract showing the most pronounced benefits via modulating inflammation, restoring barrier function, and rebalancing gut microbiota.
While ulcerative colitis (UC)–associated inflammation primarily occurs in the colon, subclinical terminal ileum inflammation has been previously observed. Given that colonic microbial dysbiosis is common in UC, we profiled the terminal ileum microbiota to determine the extent of gastrointestinal dysbiosis in UC.
Ulcerative colitis (UC) is a chronic inflammatory disorder affecting the colon, with symptomatology influenced by factors including environmental, genomic, microbial, and immunological interactions. Gut microbiota dysbiosis, characterized by bacterial population alterations, contributes to intestinal homeostasis disruption and aberrant immune system activation, thereby exacerbating the inflammatory state. This study assesses the therapeutic efficacy of intraperitoneal (IP) injected flavonoids (apigenin, luteolin, and xanthohumol) in the reduction of inflammatory parameters and the modulation of the gut microbiota in a murine model of ulcerative colitis. Flavonoids interact with gut microbiota by modulating their composition and serving as substrates for the fermentation into other anti-inflammatory bioactive compounds. Our results demonstrate the effectiveness of luteolin and xanthohumol treatment in enhancing the relative abundance of anti-inflammatory microorganisms, thereby attenuating pro-inflammatory species. Moreover, all three flavonoids exhibit efficacy in the reduction of pro-inflammatory cytokine levels, with luteolin strongly demonstrating utility in alleviating associated physical UC symptoms. This suggests that this molecule is a potential alternative or co-therapy to conventional pharmacological interventions, potentially mitigating their adverse effects. A limited impact on microbiota is observed with apigenin, and this is attributed to its solubility constraints via the chosen administration route, resulting in its accumulation in the mesentery.
BACKGROUND & AIMS A high-fat diet has been associated with increased risk of ulcerative colitis (UC). We studied the effects of a low-fat, high-fiber diet (LFD) vs an improved standard American diet (iSAD, included higher quantities of fruits, vegetables, and fiber than a typical SAD). We collected data on quality of life, markers of inflammation, and fecal markers of intestinal dysbiosis in patients with UC. METHODS We analyzed data from a parallel-group, cross-over study of 17 patients with UC in remission or mild disease (with a flare within the last 18 months), from February 25, 2015 through September 11, 2018. Participants were randomly assigned to 2 groups and received a LFD (10% of calories from fat) or an iSAD (35%-40% of calories from fat) for the first 4-week period, followed by a 2-week wash-out period, and then switched to the other diet for 4 weeks. All diets were catered and delivered to patients' homes, and each participant served as her or his own control. Serum and stool samples were collected at baseline and week 4 of each diet and analyzed for markers of inflammation. We performed 16s rRNA sequencing and untargeted and targeted metabolomic analyses on stool samples. The primary outcome was quality of life, which was measured by the short inflammatory bowel disease (IBD) questionnaire at baseline and week 4 of the diets. Secondary outcomes included changes in short-form 36 health survey, partial Mayo score, markers of inflammation, microbiome and metabolome analysis, and adherence to the diet. RESULTS Participants' baseline diets were unhealthier than either study diet. All patients remained in remission throughout the study period. Compared to baseline, the iSAD and LFD each increased quality of life, based on the short IBD questionnaire and short-form 36 health survey scores (baseline short IBD questionnaire score, 4.98; iSAD, 5.55; LFD, 5.77; baseline vs iSAD P=.02; baseline vs LFD P=.001). Serum amyloid A significantly decreased from 7.99 mg/L at baseline to 4.50 mg/L after LFD (P=.02) but did not decrease significantly compared to iSAD (7.20 mg/L; iSAD vs LFD, P=.07). Serum level of C-reactive protein decreased numerically from 3.23 mg/L at baseline to 2.51 mg/L after LFD (P=.07). Relative abundance of Actinobacteria in fecal samples decreased from 13.69% at baseline to 7.82% after LFD (P=.017), whereas relative abundance of Bacteroidetes increased from 14.6% at baseline to 24.02% on LFD (P=.015). Relative abundance of Faecalibacterium prausnitzii was higher after 4 weeks on the LFD (7.20%) compared with iSAD (5.37%; P=.04). Fecal levels of acetate (an anti-inflammatory metabolite) increased from a relative abundance of 40.37 at baseline to 42.52 on the iSAD and 53.98 on the LFD (baseline vs LFD P=.05; iSAD vs LFD, P=.09). Fecal level of tryptophan decreased from a relative abundance of 1.33 at baseline to 1.08 on the iSAD (P=.43) but increased to a relative abundance of 2.27 on the LFD (baseline vs LFD P=.04; iSAD vs LFD P=.08); fecal levels of lauric acid decreased after LFD (baseline, 203.4; iSAD, 381.4; LFD, 29.91; baseline vs LFD P=.04; iSAD vs LFD P=.02). CONCLUSIONS In a cross-over study of patients with UC in remission, we found that a catered, LFD or iSAD were each well tolerated and increased quality of life. However, the LFD decreased markers of inflammation and reduced intestinal dysbiosis in fecal samples. Dietary interventions might therefore benefit patients with UC in remission. ClinicalTrials.gov no: NCT04147598.
PURPOSE Oxidative damage and intestinal flora dysbiosis play important roles in the progression of chronic ulcerative colitis (UC). This study explored the effect and mechanism of molecular hydrogen in chronic UC. MATERIALS AND METHODS Male C57BL/6 mice (19.6 ± 0.4 g, 7 weeks) were randomly divided into 3 groups: normal control (NC) group, UC (Dextran Sulfate Sodium, DSS) group, and hydrogen-rich water (HRW, 0.8 ppm)-treated UC (DSS + HRW) group. Mice in the DSS treatment group were treated with DSS for the following 3 cycles to establish chronic UC model: the first 2 cycles consisted of 2.5% DSS for 5 days, followed by drinking water for 16 days, and a third cycle consisted of 2% DSS for 4 days, followed by drinking water for 10 days. The mice in the DSS + HRW group were administered HRW daily throughout the experiment. RESULTS The mice in the DSS groups developed typical clinical signs of colitis. HRW treatment partially ameliorated colitis symptoms, improved histopathological changes, significantly increased glutathione (GSH) concentration and decreased TNF-α level. Notably, HRW treatment significantly inhibited the growth of Enterococcus faecalis, Clostridium perfringens and Bacteroides fragilis (P < 0.05 vs. DSS group), with the relative abundance that was close to the levels in the NC group. Microarray analysis revealed that 252 genes were significantly modified after HRW treatment compared with those in the DSS treatment alone group, and 17 genes were related to inflammation, including 9 interferon-stimulated genes (ISGs). CONCLUSIONS Hydrogen-rich water partially alleviates inflammation, oxidative stress and intestinal flora dysbiosis in DSS-induced chronic UC mice.
Ulcerative colitis is an inflammatory bowel disease that is mainly related to gut microbiota dysbiosis. Lactobacillus plantarum ZJ316 (ZJ316) has been proved to regulate the gut microbiota in vitro. However, more evidence is needed for the intestinal effects of ZJ316 in vivo. Colitis was induced via dissolved 2.5% DSS in drinking water for 7 days in 8-week-old BALB/c mice, which were then fed with ZJ316 (1 × 108 CFU mL-1) for 35 days. After ZJ316 intervention, the dextran sulfate sodium salt (DSS)-induced colitis symptoms were remarkably alleviated, including recovery of body weight and colon weight and effective inhibition of the expression of pro-inflammatory cytokines. Results based on 16S rRNA gene sequencing indicated that the structure of the gut microbiota in ZJ316 supplementation was markedly altered by upregulating the percentage of Firmicutes while reducing the percentage of Bacteroidetes. Furthermore, the colon contained more short-chain fatty acids (SCFAs) and butyrate-producing genera, such as Faecalibacterium, Agathobacter, and Roseburia. Spearman correlation analysis indicated that SCFAs, especially butyric acid, were positively associated with Faecalibacterium and Agathobacter. Our study suggested that ZJ316 could be used to relieve ulcerative colitis (UC) as dietary therapeutics.
Objectives Ulcerative colitis (UC) is a chronic inflammatory disorder of unknown aetiology. Gut virome dysbiosis is fundamental in UC progression, although its role in the early phases of the disease is far from fully understood. Therefore, we sought to investigate the role of a virome-associated protein encoded by the Orthohepadnavirus genus, the hepatitis B virus X protein (HBx), in UC aetiopathogenesis. Design HBx positivity of UC patient-derived blood and gut mucosa was assessed by RT-PCR and Sanger sequencing and correlated with clinical characteristics by multivariate analysis. Transcriptomics was performed on HBx-overexpressing endoscopic biopsies from healthy donors. C57BL/6 mice underwent intramucosal injections of liposome-conjugated HBx-encoding plasmids or the control, with or without antibiotic treatment. Multidimensional flow cytometry analysis was performed on colonic samples from HBx-treated and control animals. Transepithelial electrical resistance measurement, proliferation assay, chromatin immunoprecipitation assay with sequencing and RNA-sequencing were performed on in vitro models of the gut barrier. HBx-silencing experiments were performed in vitro and in vivo. Results HBx was detected in about 45% of patients with UC and found to induce colonic inflammation in mice, while its silencing reverted the colitis phenotype in vivo. HBx acted as a transcriptional regulator in epithelial cells, provoking barrier leakage and altering both innate and adaptive mucosal immunity ex vivo and in vivo. Conclusion This study described HBx as a contributor to the UC pathogenesis and provides a new perspective on the virome as a target for tailored treatments.
No abstract available
Ulcerative colitis (UC) is a chronic inflammatory bowel disease characterized by epithelial damage, excessive cytokine release, and dysregulated inflammasome activation. Herein, we report the design, synthesis, and multi-targeted biological evaluation of three novel mesalamine–NSAID hybrid derivatives (D1, D3, and D4) as potential therapeutic agents for UC. Structural hybridization was employed to enhance colonic targeting, suppress NLRP3 inflammasome signaling, and reduce systemic toxicity. All compounds were characterized and screened for anti-inflammatory efficacy via qRT-PCR analysis of key inflammasome-related genes (NLRP3, IL1B, IL-18, Caspase-1) in LPS-activated macrophages. Compound D3 exhibited the most potent downregulation profile, supported by molecular docking studies showing favorable interactions with NLRP3 and caspase-1. Antioxidant activity was evaluated using the DPPH assay, with D3 demonstrating the lowest IC50 (19.20 µg/mL). Antimicrobial and brine shrimp lethality assays confirmed the moderate cytotoxicity profiles and pathogen-inhibitory potential of all compounds. Collectively, these results highlight D3 as a dual-action anti-inflammatory and antioxidant agent capable of modulating key immune and redox pathways implicated in UC pathogenesis. The study supports mesalamine–NSAID hybridization as a promising strategy for developing next-generation UC therapeutics with improved efficacy and safety profiles.
Genome-wide association studies in inflammatory bowel disease have identified risk loci in the orosomucoid-like protein 3/ORMDL sphingolipid biosynthesis regulator 3 (ORMDL3) gene to confer susceptibility to ulcerative colitis (UC), but the underlying functional relevance remains unexplored. Here, we found that a subpopulation of the UC patients who had higher disease activity shows enhanced expression of ORMDL3 compared to the patients with lower disease activity and the non-UC controls. We also found that the patients showing high ORMDL3 mRNA expression have elevated interleukin-1β cytokine levels indicating positive correlation. Further, knockdown of ORMDL3 in the human monocyte-derived macrophages resulted in significantly reduced interleukin-1β release. Mechanistically, we report for the first time that ORMDL3 contributes to a mounting inflammatory response via modulating mitochondrial morphology and activation of the NLRP3 inflammasome. Specifically, we observed an increased fragmentation of mitochondria and enhanced contacts with the endoplasmic reticulum (ER) during ORMDL3 over-expression, enabling efficient NLRP3 inflammasome activation. We show that ORMDL3 that was previously known to be localized in the ER also becomes localized to mitochondria-associated membranes and mitochondria during inflammatory conditions. Additionally, ORMDL3 interacts with mitochondrial dynamic regulating protein Fis-1 present in the mitochondria-associated membrane. Accordingly, knockdown of ORMDL3 in a dextran sodium sulfate -induced colitis mouse model showed reduced colitis severity. Taken together, we have uncovered a functional role for ORMDL3 in mounting inflammation during UC pathogenesis by modulating ER-mitochondrial contact and dynamics.
Background: Ulcerative colitis (UC) is a chronic recurrent inflammatory bowel disease (IBD). The conventional drugs for UC may induce severe side effects. Herbal medicine is considered as a complementary and alternative choice for UC. Purpose: This study aims to estimate the effect of natural polyphenol gallic acid (GA) on the NLRP3 inflammasome with dextran sulfate sodium (DSS)-induced colitis in mice. Study design: The body weights and symptoms of BALB/c mice were recorded. Histological evaluation, ELISA, q-PCR, immunohistochemistry, and western blotting were carried out to observe the morphology, cytokine contents, mRNA expressions, and protein expressions, respectively. Lipopolysaccharide (LPS)-induced RAW264.7 macrophage was used to probe GA’s effect on relative protein expression. Results: GA attenuated weight loss (p < 0.05), relieved symptoms, and ameliorated colonic morphological injury (p < 0.05) in mice with colitis induced by DSS. GA also lowered the contents of TNF-α, IL-1β, IL-18, IL-33, and IFN-γ in the serum and colon of mice, which were elevated by DSS, downregulated protein, and mRNA expressions of the NLRP3 pathway in the colon tissue. Furthermore, GA downregulated the expressions of NLRP3 (p < 0.05), iNOS (p < 0.01), COX2 (p < 0.01), and P-p65 (p < 0.05), and suppressed NO release (p < 0.001) in LPS-induced RAW264.7 cells. Conclusion: GA ameliorated DSS-induced UC in mice via inhibiting the NLRP3 inflammasome. These findings furnish evidence for the anti-inflammatory effect of herbal medicines containing GA on UC.
Ulcerative colitis (UC) is characterized by the dysregulation of inflammatory pathways, leading to extensive tissue damage and chronic inflammation. NLRP3 inflammasome promotes inflammatory cytokine maturation and pyroptosis. Meteorin-like protein (Metrnl) has anti-inflammatory effects; however, its specific mechanisms in regulating these pathways remain unclear. This study investigated the effect of Metrnl on UC via regulation of the NLRP3 inflammasome through regulation of its key component, apoptosis-associated speck-like protein containing CARD (ASC). NCM460 and FHC cells were treated with TNF-α to establish a cell validation model. Cells with Metrnl interference or overexpression were intervened with three inflammasome activators (ATP, nigericin, or alum), and a caspase-1 inhibitor (belnacasan). The inflammatory factor levels, ASC mRNA and protein expressions, pyroptosis-related proteins, and inflammasome were detected. Interactions between ASC, Metrnl and inflammasome were determined by protein immunoprecipitation. UC models were constructed using wild-type and Metrnl knockout mice. Histopathological changes and differences in pyroptosis-related protein and inflammasome expressions were examined. Metrnl expression was significantly decreased in colitis, and the inflammatory factors IL-1β and LDH expressions increased at the cellular and animal levels, promoting ASC expression and pyroptosis, and activating the inflammasome. Metrnl interference accelerated inflammation and pyroptosis, which were reversed by Metrnl overexpression. Interactive relationships between Metrnl and ASC were noted. Metrnl may mediate ASC protein expression, and reduce IL-1β expression and pyroptosis in colon epithelial cells through the inhibition of ASC-NLRP3 binding. In vivo studies with DSS-induced colitis models confirmed the significance of these findings. After Metrnl knockout, the colon of normal mice was shorter, and Metrnl-/- UC mice showed more severe colon tissue damage, reduced goblet cells, increased inflammation, and accumulation of pyroptosis protein expression, indicating that Metrnl knockout increases susceptibility to UC. Metrnl interferes with key inflammatory signaling pathways in UC by inhibiting the interaction between ASC and NLRP3, suggesting its potential in UC treatment.
INTRODUCTION Ulcerative Colitis (UC) is driven by disrupted epithelial barrier function and chronic inflammation, yet the interaction between oxidative stress and inflammasome signaling remains unclear. This study investigated whether Nrf2 expression correlates with NLRP3 inflammasome activity in intestinal epithelial cells under inflammatory conditions and whether the natural Nrf2 activator, Sulforaphane (SFN), modulates this axis. METHODS A UC-like inflammatory state was established in Caco-2 cells using a cytokine cocktail (TNF-α, LPS, IFN-γ, IL-1β). Nrf2 was silenced using siRNA, and SFN was administered for activate Nrf2. Gene and protein expression were assessed by qPCR, ELISA, and Western blot. Public bulk and single-cell RNA-seq datasets from UC patients were analyzed to validate clinical relevance. RESULTS Cytokine stimulation significantly reduced Nrf2 expression while upregulating NLRP3, IL-1β, and IL-18 (p < 0.001). Nrf2 knockdown was associated with enhanced inflammasome activation, as evidenced by increased levels of NLRP3, caspase-1, and pro-inflammatory cytokines. Conversely, SFN pretreatment restored Nrf2 expression and markedly suppressed NLRP3 and IL-18 expression (p < 0.01 to p < 0.001). Multiomic analyses of UC patient samples confirmed an inverse expression pattern between Nrf2 and NLRP3 signaling pathways. DISCUSSION These findings indicate that reduced Nrf2 expression is strongly associated with enhanced NLRP3 inflammasome activation in inflamed intestinal epithelial cells. Pharmacologic activation of Nrf2 by SFN correlates with restored redox balance and attenuated inflammation, supporting the Nrf2-NLRP3 axis as a potential therapeutic target warranting further investigation. Limitations include use of a single cell line and lack of in vivo validation. CONCLUSION This study provides correlative evidence for a redox-inflammasome axis in UC pathogenesis and suggests that further investigation of SFN as a candidate therapeutic approach is warranted.
No abstract available
The inflammasomes induce maturation of pro-interleukin-1β (IL-1β) and pro-IL-18. We investigated roles of the NLRP3 inflammasome in the pathogenesis of ulcerative colitis (UC). After induction of oxazolone-induced colitis, a mouse UC model, colonic tissues were assayed for inflammatory mediators. Histological studies were performed on inflamed colonic tissue from mice and UC patients. Histological severity of murine colitis peaked on day 1, accompanied by an increase in the expression of Th2 cytokines including IL-4 and IL-13. Oxazolone treatment stimulated maturation of pro-caspase-1 and pro-IL-1β, while it reduced IL-18 expression. Either exogenous IL-1β or IL-18 ameliorated the colitis with or without reduction in Th2 cytokine expression, respectively. Induction of colitis decreased MUC2 expression, which was reversed by administration of IL-18, but not IL-1β. Compared to wild-type mice, NLRP3−/− mice exhibited higher sensitivity to oxazolone treatment with enhancement of Th2 cytokine expression and reduction of mature IL-1β and IL-18 production; this phenotype was rescued by exogenous IL-1β or IL-18. Immunofluorescent studies revealed positive correlation of NLRP3 expression with disease severity in UC patients, and localization of the inflammasome-associated molecules in macrophages. The NLRP3 inflammasome-derived IL-1β and IL-18 may play a protective role against UC through different mechanisms.
Ulcerative colitis (UC) is a chronic inflammatory disease with unknown aetiology. As a pro-inflammatory cytokine, interleukin-1β (IL-1β) plays a critical, damaging role in UC. Heat shock proteins (HSPs) are important anti-inflammatory factors that maintain intestinal epithelial cells (IECs) homeostasis. Heat shock transcription factor 2 (HSF2) is an important regulator of HSPs. In our previous research, we found that HSF2 is highly expressed in UC, is negatively related to colon inflammation of mice, and inhibits the expression of IL-1β, but the specific mechanism is still unclear. As a product of the NLRP3 inflammasome, the expression of IL-1β is closely related to NLRP3 inflammasome activation. Therefore, we hypothesised that HSF2 affects the secretion of IL-1β by regulating activation of the NLRP3 inflammasome. In this study, hsf-/- DSS model mice showed highest levels of expression of the NLRP3 inflammasome and the secretion of IL-1β. In Caco-2 cells, the levels of expression of the NLRP3 inflammasome and the secretion of IL-1β were inhibited by overexpression of HSF2, and inhibited HSF2 increased activation of the NLRP3 inflammasome and the secretion of IL-1β. These findings indicated that HSF2 might be an important target for inflammatory modulation in UC.
Ulcerative colitis (UC), a chronic inflammatory bowel disease, is driven by dysregulated immune responses and persistent intestinal inflammation. Pyroptosis, a caspase/gasdermin-mediated inflammatory cell death that exacerbates mucosal damage through excessive cytokine release and epithelial barrier disruption. Although pyroptosis is considered to be a key mechanism in the pathogenesis of UC, the systematic assessment of the role of natural products in targeting the pyroptosis pathway remains a critical research gap. The purpose of this review is to investigate the regulatory effects of natural products on pyroptosis in UC and elucidate the mechanisms of action and potential therapeutic effects. Key findings highlight polyphenols (e.g., resveratrol), flavonoids (e.g., Quercetin), and terpenoids as promising agents that inhibit NLRP3 inflammasome activation, suppress gasdermin D cleavage, and restore barrier integrity, thereby reducing pro-inflammatory cytokine release in preclinical UC models. Current evidence shows enhanced efficacy and safety when these compounds are combined with standard therapies, but clinical translation requires overcoming three key barriers: limited human trial data, uncharacterized polypharmacology, and suboptimal pharmacokinetics needing formulation refinement. Future research should prioritize standardized animal-to-human translational models, mechanistic studies on synergistic pathways, and rigorous clinical validation to harness the full potential of natural products in pyroptosis-targeted UC therapies.
This study aimed to investigate the therapeutic potential of scopoletin in ulcerative colitis, with a primary focus on its impact on crucial inflammatory pathways and immune responses. A male mouse model of DSS-induced colitis was employed with six distinct groups: a control group, a group subjected to DSS only, three groups treated with varying scopoletin doses, and the final group treated with dexamethasone. The investigation included an assessment of the effects of scopoletin on colitis symptoms, including alterations in body weight, Disease Activity Index (DAI), and histopathological changes in colonic tissue. Furthermore, this study scrutinized the influence of scopoletin on cytokine production, PPARγ and NF-κB expression, NLRP3 inflammasome, and the composition of intestinal bacteria. Scopoletin treatment yielded noteworthy improvements in DSS-induced colitis in mice, as evidenced by reduced weight loss and colonic shortening (p < 0.05, < 0.01, respectively). It effectively diminished TNF-α, IL-1β, and IL-12 cytokine levels (p < 0.01, p < 0.05), attenuated NLRP3 inflammasome activation and the associated cytokine release (p < 0.05, p < 0.01), and modulated the immune response by elevating PPARγ expression while suppressing NF-κB pathway activation (p < 0.05, p < 0.01). Additionally, scopoletin induced alterations in the gut microbiota composition, augmenting beneficial Lactobacillus and Bifidobacteria while reducing E. coli (p < 0.05). It also enhanced tight junction proteins, signifying an improvement in the intestinal barrier integrity (p < 0.05, < 0.01). Scopoletin is a promising therapeutic agent for managing ulcerative colitis, showing benefits that extend beyond mere anti-inflammatory actions to encompass regulatory effects on gut microbiota and restoration of intestinal integrity.
A contributing factor in the development of ulcerative colitis (UC) and Crohn’s disease (CD) is the disruption of innate and adaptive signaling pathways due to aberrant cytokine production. The cytokine, interleukin (IL)-1β, is highly inflammatory and its production is tightly regulated through transcriptional control and both inflammasome-dependent and inflammasome- independent proteolytic cleavage. In this study, qRT-PCR, immunohistochemistry, immunofluorescence confocal microscopy were used to (1) assess the mRNA expression of NLRP3, IL-1β, CASP1 and ASC in paired biopsies from UC and CD patient, and (2) the colonic localization and spatial relationship of NLRP3 and IL-1β in active and quiescent disease. NLRP3 and IL-1β were found to be upregulated in active UC and CD. During active disease, IL-1β was localized to the infiltrate of lamina propria immune cells, which contrasts with the near-exclusive epithelial cell layer expression during non-inflammatory conditions. In active disease, NLRP3 was consistently expressed within the neutrophils and other immune cells of the lamina propria and absent from the epithelial cell layer. The disparity in spatial localization of IL-1β and NLRP3, observed only in active UC, which is characterized by a neutrophil-dominated lamina propria cell population, implies inflammasome-independent processing of IL-1β. Consistent with other acute inflammatory conditions, these results suggest that blocking both caspase-1 and neutrophil-derived serine proteases may provide an additional therapeutic option for treating active UC.
ABSTRACT Inflammatory bowel disease is a significant health concern not only in humans but also in companion animals and livestock, where it manifests as chronic diarrhoea, abdominal pain, and mucosal injury. Probiotics have gained increasing attention as potential therapeutic agents due to their immunomodulatory effects and ability to restore intestinal homeostasis. This study investigated the therapeutic efficacy of Bacillus coagulans and Lactobacillus acidophilus in an acetic acid–induced ulcerative colitis model in Wistar rats. Forty male rats were randomly assigned to control, colitis, mesalazine, B. coagulans, and L. acidophilus treatment groups. Disease severity was evaluated by macroscopic and histopathological scoring, colon length and weight, pro‐inflammatory cytokine levels (IL‐1β, IL‐17), and inflammasome‐associated gene expression (NLRP3, Caspase‐1, IL‐18, TNF‐α). The results showed that colitis induction significantly increased pro‐inflammatory cytokine expression and histological damage compared with controls. Both probiotics markedly reduced inflammatory markers, improved colon morphology, and attenuated inflammasome activation. Their protective effects were comparable to mesalazine, the standard treatment. These findings suggest that B. coagulans and L. acidophilus can serve as effective adjunct therapies for ulcerative colitis in veterinary practice, with potential translational applications for companion animals and livestock.
DNA sensor pathways can initiate inflammasome, cell death and type I interferon (IFN) signalling in immune-mediated inflammatory diseases (IMIDs); including type I interferonopathies. We investigated the involvement of these pathways in the pathogenesis of ulcerative colitis (UC); by analysing expression of DNA sensor, inflammasome, and type I IFN biomarker genes in colonic mucosal biopsy tissue from control (n=31), inactive UC (n=31), active UC (n=33) and a UC single cell RNA-Seq dataset. The effects of type I IFN (IFN-β), IFN-γ and TNF-α on gene expression, cytokine production and cell death were investigated in human colonic organoids. In organoids treated with cytokines alone, or in combination with NLRP3, caspase or JAK inhibitors, cell death was measured, and supernatants were assayed for IL-1β/IL-18/CXCL10. The expression of DNA sensor pathway genes - PYHIN family members (AIM2, IFI16, MNDA, PYHIN1), as well as ZBP1, cGAS and DDX41 were increased in active UC and expressed in a cell type restricted pattern. Inflammasome genes (CASP1, IL1B, IL18), type I IFN inducers (STING, TBK1, IRF3), IFNB1 and type I IFN biomarker genes (OAS2, IFIT2, MX2) were also increased in active UC. Co-treatment of organoids with IFN-β or IFN-γ and TNFα increased expression of IFI16, ZBP1, CASP1, cGAS and STING, induced cell death and IL-1β/IL-18 secretion. This inflammatory cell death was blocked by the JAK inhibitor tofacitinib but not by inflammasome or caspase inhibitors. Increased type I IFN activity may drive elevated expression of DNA sensor genes and JAK-dependent but inflammasome-independent inflammatory cell death of colonic epithelial cells in UC.
SCOPE The objective of this study was to explore the effects of 10-hydroxy-2-decenoic acid (10-HDA), the major fatty acid in royal jelly, on dextran sodium sulfate (DSS)-induced mice ulcerative colitis (UC) and its potential mechanism of action. METHODS AND RESULTS Forty male C57BL/6 mice were randomly divided into 5 experimental groups: control, DSS, DSS + 25 (or 100) mg/kg/d 10-HDA, and DSS + 200 mg/kg/d mesalazine. UC was induced in mice using 2.5% DSS in drinking water for 7 days. During the induction, these UC mice were orally administrated 10-HDA or mesalazine per day. Meanwhile, LPS/ATP-stimulated THP1 cells were used as a model to test the effects of 10-HDA. 10-HDA reduced DSS-induced pathological damage, ROS accumulation, neutrophil infiltration, and cytokine production in colonic tissue. Compared with the DSS group, the expressions of TXNIP, NLRP3, ASC, Caspase-1, GSDMD, N-GSDMD, IL-1β, and IL-18 in the colon were decreased after administration of 10-HDA. 10-HDA also elevated the barrier integrity and the expressions of ZO-1 and Occludin in colonic epithelium exposed to DSS. In THP1 cells, the inflammasome-mediated pyroptosis induced by LPS/ATP was inhibited by 10-HDA pretreatment. CONCLUSION 10-HDA alleviates DSS-induced colitis by regulating the NLRP3 inflammasome-mediated pyroptotic pathway and enhancing colonic barrier function. This article is protected by copyright. All rights reserved.
No abstract available
No abstract available
Loss of expression of DLG2 has been identified in a number of cancers to contribute to the disease by resulting in increased tumor cell proliferation and poor survival. In light of the previous evidence that DLG2 alters the cell cycle and affects proliferation, combined with indications that DLG2 is involved in NLRP3 inflammasome axis we speculated that DLG2 has an immune function. So far, there is no data that clearly elucidates this role, and this study was designed to investigate DLG2 in inflammatory colon disease and in colon cancer as well as its impact on inflammasome induction. The DLG2 expression levels were established in publicly available inflammation, colon cancer and mouse model datasets. The overexpression and silencing of DLG2 in colon cancer cells were used to determine the effect of DLG2 expression on the activation of the inflammasome and subsequent cytokine release. The expression of DLG2 is repressed in inflammatory colon diseases IBD and Ulcerative colitis as well as colorectal cancer tissue compared to healthy individuals. We subsequently show that induction with inflammatory agents in cell and animal models results in a biphasic alteration of DLG2 with an initial increase followed by an ensuing decrease. DLG2 overexpression leads to a significant increase in expression of IL1B, IκBζ and BAX, components that result in inflammasome formation. DLG2 silencing in THP1 cells resulted in increased release of IL-6 into the microenvironment which once used to treat bystander COLO205 cells resulted in an increase in STAT3 phosphorylation and an increase proliferating cells and more cells in the G2/M phase. Restoration of DLG2 to the colon resulted in reduced AKT and S6 signaling. DLG2 expression is altered in response to inflammation in the gut as well as colon cancer, resulting in altered ability to form inflammasomes. NCT03072641.
BACKGROUND Inflammatory bowel disease (IBD) is a group of intestinal disorders characterised by chronic relapsing inflammation of the small intestine and colon. IBD manifests as either ulcerative colitis or Crohn's disease and increases the risk of developing colorectal cancer. METHODS Here, we have reviewed current treatment regimen for IBD utilising anti-inflammatory drugs, immune system suppressors and antibiotics or a combination of these. However, these therapeutics lead to a number of adverse effects, remission or significant non-responsiveness creating an urgent need to develop potent drugs with novel mechanisms of action for IBD. RESULTS The inflammasome is a multiprotein complex that assembles to a key innate immune system signalling platform and is involved in the pathogenesis of inflammatory and autoimmune diseases. A number of investigations show that the NLRP3 inflammasome recognizes microbial and cell stress components and serve as a platform for caspase-1 activation and pro-inflammatory cytokine IL-1β, IL18 maturation. Although the exact aetiology of IBD is unknown, uncontrolled NLRP3 Inflammasome activation has shown to play a major role in the chronic intestinal inflammation and mature IL-1β and IL18 are consistently associated with increased colitis and colitis associated colorectal cancer development. CONCLUSION In this review, we discuss the experimental NLRP3 inhibitors that have been investigated in IBD experimental models. The potential mechanism of action of these inhibitors such as inhibiting NF-κB activation and decreasing mitochondrial reactive oxygen species are discussed in detail. We further expand the controversial role of NLRP3 in IBD and future issues that might arise from the long term use of NLRP3 inhibitors in IBD therapy.